



Supplement to

Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

1998 *Index* To Volume 58

December 15, 1998
Index Issue
Volume 58 • Number 24
PP. 5891-5936
ISSN 0008-5472 • CNREA 8

Notice to Members of the American Association for Cancer Research (AACR)

Officers for 1998-1999

President: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92093-0660

President-Elect: Daniel D. Von Hoff, Institute for Drug Development, San Antonio, TX 78245

Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483

Annual Dues

The annual dues of active members of the AACR are \$175, \$90 of which may be applied to a subscription to *Cancer Research*. Corresponding members of the Association will be charged an appropriate fee to offset postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to: Member Services, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300; FAX: (215) 440-9313.

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal *Cancer Research* may be ordered from AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Telephone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588]. As long as supplies permit, single copies of *Cancer Research* will be sold at \$30 per copy for regular and Supplement issues, plus \$4 shipping for orders outside the U.S. The annual *Proceedings of the American Association for Cancer Research* is available at \$45 per copy, plus \$6 shipping for orders outside the U.S.

Advertisements in *Cancer Research*

Advertisement insertion orders and copy must be received approximately 5 weeks prior to the date of the issue in which the advertisement is to be published. The journal is mailed approximately 5 days preceding the date of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009 [Telephone: (609) 768-9360; FAX: (609) 753-0064].

Historical Cover Themes

Readers are invited to submit themes (events, persons, institutions) for consideration for the illustrated covers of *Cancer Research*. Correspondence regarding suggested cover themes, or other matters regarding covers, should be addressed to the Cover Editor, AACR Publications Department.

Submission of Manuscripts

Manuscripts should be sent to the attention of: Dr. Carlo M. Croce, Editor-in-Chief, AACR Publications Department, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Telephone: (215) 440-9300. If accepted, they will be listed under one of ten categories in the Table of Contents. Please specify in a covering letter which category applies to your submission: biochemistry and biophysics, carcinogenesis, clinical investigations, endocrinology, epidemiology and prevention, experimental therapeutics, immunology, molecular biology and genetics, tumor biology, and virology. (Final categorization in the Table of Contents is at the discretion of the Editor-in-Chief.) For other submission requirements, consult the "Instructions for Authors" printed in the January 1 issue of the journal and available through the AACR Website at <http://www.aacr.org/caninst.htm>. Reprints of the "Instructions" are available also upon request.

Manuscript Processing Fee

Journal policy requires that a manuscript processing fee of \$75 be assessed for each paper to defray the expenses incurred in the editorial review process. Each manuscript submitted for publication should be accompanied by a check (drawn on a U.S. bank) for \$75 in U. S. currency, payable to AACR, Inc., or credit card information (VISA, Mastercard, or American Express) should be supplied. Note: If an author resubmits a manuscript that our Editors previously found unacceptable for publication, it is journal policy to consider it a new submission, assign it a new manuscript number, and charge the author another \$75 handling fee to cover the cost of review.

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$80 per printed page. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Carlo M. Croce, Editor-in-Chief, at the time of submission, for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Copyright and Copyright Clearance Center

The Copyright Revision Act (PL 94-553), which became effective January 1, 1978, states that the copyright of a work is vested in the author from the moment of creation. Therefore, all authors who wish to publish in *Cancer Research* must formally transfer copyright to the proprietor of the journal, AACR, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U. S. Federal Government are not required to transfer copyright to the American Association for Cancer Research, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to AACR, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

Copies of articles for which AACR, Inc. owns the copyright may be made for personal or internal use, provided that the copier pay the per-copy fee of \$4 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978. Those who wish to photocopy *Cancer Research* articles may report the number of copies they have made, together with the fee code 0008-5472/98 \$04.00, to: Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; (508) 750-8400. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Between June 1978 and August 1983, a fee code appeared on the first page of all articles for which *Cancer Research* owned the copyright. For those issues, it is understood that any articles which did not carry this code are in the public domain.

Cancer Research is abstracted or indexed in *Biological Abstracts*, *Chemical Abstracts*, *Index Medicus*, *MEDLINE*, *Current Contents*, and *Reference Update*. This journal is printed on acid-free paper.

No responsibility is accepted by the Editors, by AACR, Inc., or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Research (ISSN 0008-5472) is published twice a month by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for \$90 annually for members and \$495 for individual nonmembers. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1998 institutional subscription price of \$795 includes a subscription to *Clinical Cancer Research*. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copyright 1998 by the American Association for Cancer Research, Inc. Printed in the U.S.A.



Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

American Association for Cancer Research, Inc.

Publications Staff Managing Editor

Margaret Foti

Assistant Managing Editor

Mary Anne Mennite

Manager, Editorial Services

Heide M. Pusztay

Senior Staff Editor

Kathleen C. Assemaacher

Staff Editors

Ronald M. Vitale

Carolina Miranda

Editorial Associate

Michelle K. Bruni

Staff Assistant

Mary Ellen Pirring

Senior Editorial Assistant

Theresa A. Griffith

Editorial Assistant

Brenda Roberson

Journal Manager,

Cancer Epidemiology,

Biomarkers & Prevention

Michael J. Beveridge

Senior Editorial Assistant,

Cancer Epidemiology,

Biomarkers & Prevention

Cecilia Gallo

Administrative Staff

Executive Director

Margaret Foti

Director of Administration

Adam D. Blistein

Controller

Joan D. Ritchie

Manager, Meetings and Exhibits

Jeffrey M. Ruben

Assistant Director,

Administration

Jenny Anne Horst-Martz

Assistant to the Executive

Director

Ruth E. Fortson

Membership Development

Coordinator

Robin E. Felder

Administrative Assistant

Margaret A. Pickels

Systems Specialist

Lydia I. Rodriguez

Secretary

Malika L. Wright

Editorial Assistant

Diana F. Certo

Office Clerk

James J. Waters

Data Entry Clerk

Robert A. Simms II

Editor-in-Chief

Carlo M. Croce

Associate Editors

Stuart A. Aaronson

David S. Alberts

Carmen J. Allegra

Frederick R. Appelbaum

Leonard H. Augenlicht

Silvia Bacchetti

William M. Baird

Allan Balmain

J. Carl Barrett

Renato Baserga

Stephen B. Baylin

William T. Beck

Nathan A. Berger

Joseph R. Bertino

Diane F. Birt

Mina J. Bissell

Clara D. Bloomfield

Ronald H. Blum

Gianni Bonadonna

Rodrigo Bravo

Paul A. Bunn, Jr.

C. Patrick Burns

Fernando Cabanillas

Bruno Calabretta

Eli Canaani

Robert L. Capizzi

Webster K. Cavenee

Ann F. Chambers

Bruce D. Cheson

Lorraine J. Gudas

F. Peter Guengerich

Sen-iroh Hakomori

Stanley R. Hamilton

Pelayo Correa

Suzanne Cory

William M. Crist

Riccardo Dalla-Favera

Mary B. Daly

Nancy E. Davidson

Benoit de Crombrughe

Albert B. Deisseroth

Luigi M. DeLuca

Eugene R. DeSombre

Vincent T. DeVita, Jr.

T. Michael Dexter

Ralph E. Durand

Alan Eastman

Merrill J. Egorin

Gertrude B. Elion

Leonard C. Erickson

Nelson Fausto

Eric R. Fearon

Andrew P. Feinberg

Olivera J. Finn

Robert A. Floyd

Antonio T. Fojo

Judah Folkman

Kenneth A. Foon

Albert J. Fornace, Jr.

Joseph F. Fraumeni, Jr.

Stephen H. Friend

Zvi Y. Fuks

Minoru Fukuda

Philip Furmanski

Eugene W. Gerner

Eli Glatstein

David W. Golde

Joe W. Gray

J. W. Grisham

Lorraine J. Gudas

F. Peter Guengerich

Sen-iroh Hakomori

Stanley R. Hamilton

Curtis C. Harris

Stephen S. Hecht

Carl-Henrik Heldin

Ingegerd Hellström

Brian E. Henderson

Richard B. Hochberg

Wun Ki Hong

Tasuku Honjo

H. Robert Horvitz

Janet A. Houghton

Kay Huebner

Mark A. Israel

Elaine S. Jaffe

Rakesh K. Jain

Peter A. Jones

Fred F. Kadlubar

Michael B. Kastan

John H. Kersey

Young S. Kim

Kenneth W. Kinzler

Hynda K. Kleinman

Alfred G. Knudson, Jr.

Richard D. Kolodner

Laurence N. Kolonel

Peter H. Krammer

David P. Lane

Edmund C. Lattime

John S. Lazo

Victor A. Levin

Jay A. Levy

Victor Ling

Lance A. Liotta

Martin Lipkin

Marc E. Lippman

Gerald Litwack

Leroy F. Liu

David M. Livingston

Lawrence A. Loeb

Dan L. Longo

Reuben Lotan

David B. Ludlum

Lynn M. Matrisian

W. Gillies McKenna

Beatrice Mintz

James B. Mitchell

Malcolm S. Mitchell

Ruth J. Muschel

Yusuke Nakamura

Susan L. Naylor

Kenneth Nilsson

Susumu Nishimura

Jeffrey A. Norton

Kenneth Olden

Allen I. Oliff

Richard J. O'Reilly

Robert F. Ozols

Michael A. Palladino, Jr.

Takis S. Papas

Luis F. Parada

Drew M. Pardoll

Ramon Parsons

Anthony E. Pegg

Pier Giuseppe Pelicci

Angel Pellicer

Bice Perussia

Lester J. Peters

Gordon L. Phillips

Cecil B. Pickett

Jennifer A. Pietenpol

Yves G. Pommier

Bruce A. J. Ponder

Theresa P. Pretlow

Vito Quaranta

Frank J. Rauscher III

John C. Reed

Richard A. Rifkin

Leslie L. Robison

Igor B. Roninson

Eric K. Rowinsky

Howard I. Scher

Robert T. Schimke

J. Schlessinger

Manfred Schwab

Jerry W. Shay

David Sidransky

Joseph V. Simone

Francis M. Sirotnak

Anna Marie Skalka

Michael B. Sporn

Martha R. Stampfer

Eric J. Stanbridge

Patricia S. Steeg

Glenn Steele, Jr.

Gary S. Stein

Gary D. Stoner

Takashi Sugimura

Saraswati Sukumar

Paul Talalay

Tadatsugu Taniguchi

Steven R. Tannenbaum

Masaaki Terada

Kenneth D. Tew

Donald J. Tindall

Thea D. Tlsty

Jeffrey M. Trent

Giorgio Trinchieri

Takashi Tsuruo

Axel Ullrich

George F. Vande Woude

Peter W. Vaupel

Giancarlo Vecchio

Peter K. Vogt

Daniel D. Von Hoff

Cheryl Walker

Michael D. Waterfield

Lee W. Wattenberg

Ralph R. Weichselbaum

Bengt Westermark

Raymond L. White

Alice S. Whitemore

Max S. Wicha

Wendell Wierenga

Roger Wiseman

Sheldon Wolff

Harald zur Hausen

Cover Editorial Board

Sidney Weinhouse,

Cover Editor

Hugh J. Creech

Clark W. Heath, Jr.

Edwin A. Mirand

Raymond W. Ruddon

Takashi Sugimura

John H. Weisburger

Cancer Research is sponsored by the American Association for Cancer Research, Inc. Accelerated mailing of all AACR journals to AACR members in Japan is supported by a generous grant from the Banyu Pharmaceutical Company, Tsukuba, Japan.

Subscription Information

Cancer Research is published twice a month, one volume per year, by the American Association for Cancer Research (AACR), Inc. Subscriptions include the *Proceedings of the American Association for Cancer Research*, issued in March of each year. Except for members of the AACR, all subscriptions are payable in advance to AACR, Subscription Office, P.O. Box 11806, Birmingham, AL 35202 [Telephone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588], to which all business communications, remittances (in United States currency or its equivalent), and subscription orders should be sent. In Japan, send orders and inquiries to (sole agent): USACO Corporation, Tsutsumi Bldg., 13-12, Shimabashi 1-chome, Minato-ku, Tokyo 105, Japan; Tel: (03) 502-6471. Individuals who are not AACR members may subscribe to Volume 58 (1998) of *Cancer Research* at the rate of \$495 U.S./\$585 foreign. *Cancer Research* is only available to institutions as a combined subscription with *Clinical Cancer Research*. The combined 1998 institutional subscription price of \$795 U.S./\$925 foreign includes \$210 U.S./\$250 foreign for a subscription to *Clinical Cancer Research*. (Foreign subscription cost includes cost of surface mail. For faster delivery, expedited mailing rates are available by contacting the AACR Publications Department.) Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: AACR Member Services, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Nonmember subscribers should send changes of address to: AACR Subscription Office, P.O. Box 11806, Birmingham, AL 35202. Copies of the journal which are undeliverable because of address changes will be destroyed.



Cancer Research

VOLUME 58 • NUMBER 24 • INDEX ISSUE • CNREA 8 • PP. 5891-5936

CONTENTS

INDEX TO VOLUME 58

5891 Author Index

5910 Subject Index

i Contents of Volume 58

xviii Cover Illustrations for Volume 58

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Officers

President, Webster K. Cavenee

President-Elect, Daniel D. Von Hoff

Treasurer, Bayard D. Clarkson

Past President, Donald S. Coffey

Executive Director, Margaret Foti

Board of Directors

Until 1999

Susan P. C. Cole

Eric R. Fearon

Stephen H. Friend

Waun Ki Hong

Until 2000

William T. Beck

O. Michael Colvin

Lynn M. Matrisian

Joseph V. Simone

Until 2001

Karen S. H. Antman

J. Carl Barrett

Tom Curran

Jean Y. J. Wang

AUTHOR INDEX*

Volume 58

A

- Aaltonen, L. A., 2087
Aarden, L. A., 2863
Aaronson, S. A., 4439
Abbruzzese, J. L., 38
Abbruzzese, M. C., 38
Abdel-Mageed, A. B., 2335
Abdel-Malek, Z. A., 47
Abe, H., 609
Abe, J., 3032
Abe, K., 3073
Abe, T., 2456
Abel, K. J., 1338
Abken, H., 1116
Aboagye, E. O., 1063, 1185, 4075
Abraham, C., 1074
Abraham, J. M., 4802
Abraham, R. T., 4375
Abrahamson, J., 2919
Abramian, A., 5656
Achiwa, H., 3761
Ackerman, S. L., 4598
Ács, P., 1423
Adam, A. N., 3409
Adams, G. P., 485
Addeo, R., 871
Adema, G. J., 2509
Adhikari, D., 4292
Adler, G., 3551
Adler-Storh, K., 3142
Aeberhard, P., 5559
Afeworki, M., 1562
Agani, F., 5280
Agarwal, R., 1920
Agnarsson, B. A., 4421
Agrawal, B., 4079, 5151
Agrawal, K. C., 2335
Ågren, U., 342
Agus, D. B., 3009
Ahmad, K., 947
Ahmad, M., 5201
Ahmad, N., 1785
Ahmadian, A., 2449
Ahnen, D. J., 1149
Ahonen, M., 2310
Ahrendt, S. A., 509
Ahuja, N., 5489
Aihara, T., 2524
Aikou, T., 3727
Ain, K. B., 2063
Aizawa, S., 2076
Aizenman, L., 1730
Akagi, Y., 4008
Akai, H., 3028
Akaike, T., 159
Akao, T., 5835
Akao, Y., 3773
Akedo, H., 462
Åkerström, G., 377
Akinaga, S., 3248
Akiyama, T., 5176
Akiyoshi, K., 3385
Akman, S., 2793
Alarcon, R. M., 1779
Albanell, J., 2825
Alberts, D., 1684
Albitar, M., 4552
Albor, A., 2091
Alcalde, R. E., 462
Aldape, K. D., 3819
Alderete, B., 2298
Aldridge, D. R., 2817
Alhava, E., 342
Alimandi, M., 3415
Alitalo, K., 1599
Alitalo, R., 1599
Allan, J. M., 3965
Allegra, C. J., 2606
Allen, C., 896
Allen, E. D., 5221
Allen, P. D., 633
Allen, T. M., 3320
Allende, R., 4654
Allikmets, R., 5337
Alnemri, E. S., 962, 5201
Al-Shamma, H., 4607
Altenschmidt, U., 2661
Altieri, D. C., 1808, 5071
Altorki, N. K., 1034
Altucci, L., 871
Alvarez, R. D., 1893
Alvarez-Gonzalez, R., 5075
Amato, S. F., 241
Amberger, V. R., 149
Ambrosone, C. B., 2107
Ambs, S., 334
Amer, S. M., 3059
Amin, N. S., 5027
Amin, S. G., 4096
Amino, N., 4913
Amundson, S., 1593
Ananthawat-Jonsson, K., 859
Ananth, S., 226
Andersen, J., 2166
Andersen, R. J., 5701
Andersen, T. I., 1004, 2923
Anderson, H. J., 5701
Anderson, L. M., 3590
Anderson, T. A., 2557
Andl, T., 5
Ando, A., 5079
André, P. C., 2857
Andreff, M., 1538
Andrei, G., 2562
Andrulis, I. L., 785
Angeli, A., 3015
Angus, W. G. R., 2366
Anker, P., 4728
Annable, T., 5850
Antalis, T. M., 3719
Anthony, G. M., 2869
Anttila, S., 4997
Anver, M., 5157
Aoki, Y., 4044
Aozasa, K., 1105
Apel, I. J., 5221
Aplan, P. D., 4269
Appella, E., 2433
Aquilina, G., 135
Arab, S., 2801
Arbuck, S. G., 3248
Arcangeli, A., 815
Archer, P. A., 4701
Arden, K. C., 743, 2042, 5027
Arencibia, J. M., 4132
Arends, J. W., 4324
Arioli, I., 5812
Arita, N., 2117
Arizti, P., 4439
Arlett, C., 84
Armier, J., 102
Armin, G., 3423
Arneson, N. C. R., 785
Arnold, A., 2876, 3706
Arnold, L. L., 2557
Arnold, R., 1583
Arosarena, O., 3668
Arrigo, A-P., 5495
Artemov, D., 4075
Arthur, D. C., 55, 4173
Aruga, E., 491
Asada, M., 4923
Asami, K., 5182
Asano, K., 296
Asano, S., 556
Ascara-Wilke, J. E., 3409
Ascherio, A., 442
Ashikari, S., 1099
Ashley, D. M., 302
Asou, H., 3344
Assouline, B., 2298
Atkinson, E. N., 4761
Atkinson, G., 3221
Attardo, G., 3461
Au, J. L-S., 2141, 2777
Augenlicht, L. H., 2869
Augensen, F., 4333
Aukerman, S. L., 933
Aurelio, O. N., 2190
Aust, A. E., 1144
Austin, C. A., 1886
Avanzini, J., 2331
Avet-Loiseau, H., 5640
Avizienyte, E., 2087
Avril, M-F., 4402
Avril, N., 4333
Avvedimento, V. E., 2888
Awasthi, Y. C., 5340
Axenovich, S. A., 3423
Azemar, M., 2661
Azuma, H., 5182
Azzara, M., 3504

B

Baba, T., 5079
Babajko, S., 1670
Babcock, G., 47
Baccala, A. A., 5280
Baccarini, S., 5795
Bachmann, M. F., 4682
Bae, M-H., 348
Bae, S-K., 348
Baer, M. R., 55, 3173
Baffa, R., 4708
Bagella, L., 5049
Bagnasco, L., 3654
Bahua, M., 2298
Baier, D., 5803
Bailey, L. R., 65, 5038
Bajno, L., 3004
Baker, A. H., 2310
Baker, S. M., 1087
Bakker, W. H., 437
Balazs, M., 3555
Balcron, R., 3611
Balderson, T., 1004
Baldini, N., 4127
Baliva, F., 4122
Ballangrud, A., 3009
Ballard, D. W., 3993
Ballenger, C. A., 3765
Band, V., 4782
Bander, N. H., 4055
Bandiera, A., 426
Banerjee, D., 4292
Banoglu, E., 647
Bao, S., 219
Bapat, B., 500
Baptiste, N., 1551
Barbanti-Brodano, G., 3777
Barbarics, E., 276
Barber, M. D., 2359
Barchowsky, A., 717
Bar-Eli, M., 2733
Barfoot, R., 1384
Barkardottir, R., 1004
Barkardottir, R. B., 4421
Barker, A. D., 5590
Barlati, S., 2234
Barna, B. P., 962
Barnas, C., 2057
Barnett, G. H., 962
Baron, E. L., 599
Barone, L., 1332
Barr, F. G., 3542
Barr, L. F., 5537
Barrasso, A. M., 413
Barratt, R. A., 2639
Barrett, J. C., 2500, 2978, 3353, 3579, 5188
Barrett, J. T., 3845
Barrows, J., 4909
Barry, P., 3508
Barsky, S. H., 4851
Bartek, J., 5053
Barth, P., 1583
Barthelmann, M., 711
Bartholomew, J., 3712
Bartram, C. R., 2618
Bartsch, D., 1124, 1583
Bartsch, G., 4640
Bar-Yehuda, S., 3181
Baselga, J., 2825
Baserga, R., 2477, 3353
Bassam, M., 1843
Bassuk, J. A., 5529
Bast, R. C., Jr., 2253
Bastian, B. C., 2170
Basu, A., 1609
Bataille, R., 5640
Batta, A. K., 1684
Bauer, P. I., 614
Baumann, H., 3173
Bavelloni, A., 5057
Bay, J-O., 3480
Baylin, S., 1972
Baylin, S. B., 591, 2063, 4515, 5489
Bea, S., 1762
Beamer, W. G., 3694
Beattie, B., 4333
Beauchamp, R. D., 362, 2323
Beaudry, G. A., 5690
Beaumont, P. O., 947
Bechtel, P. E., 3259, 3264
Bechter, O. E., 4918
Beck, D., 448
Beck, W. T., 5762
Becker, C., 779
Becker, M., 1124
Beckett, M. A., 3215, 5686
Beckman, B. S., 4940
Beckwith, J. B., 5046
Bedi, Asheesh, 882
Bedi, Atul, 882, 4531
Bedi, G. C., 4531

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

- Beekman, A., 1910
 Beer, D. G., 3409
 Beger, H. G., 2703, 4250
 Behan, K. A., 2606
 Behari, N., 3649
 Beijnen, J. H., 2410
 Bekesi, J. G., 2126, 5389
 Bélanger, A., 60
 Belardelli, F., 5795
 Belinsky, M. G., 1332, 2741
 Bell, D. A., 2328, 3603
 Bell, D. W., 1332, 2741
 Beldegrun, A., 956, 2895
 Bello, L., 4654
 Belt, J. A., 4349
 Ben David, Y., 2919
 Bender, C. M., 95, 1245
 Bendik, I., 626
 Benedict, W. F., 1090
 Benhamou, S., 5291
 Benini, S., 4127
 Bennett, W. P., 334, 2533
 Bennicelli, J. L., 3542
 Bennink, J. R., 4688
 Benoit, E., 109
 Benoit, N. E., 717
 Bentley, R. C., 2500
 Berberat, P., 753
 Berchuck, A., 2500
 Berens, M. E., 2020
 Berenson, J., 256
 Berg, D. T., 4173
 Berg, M., 241
 Berger, M. S., 1068
 Berger, N., 823, 4193
 Berger, N. A., 940
 Bergeron, R. J., 3883
 Bergmann, U., 4250
 Berkowitz, R. S., 2328
 Berlinck, R. G. S., 5701
 Berlingieri, M. T., 823
 Bernard, B. F., 437
 Bernard, M., 2680
 Bernhard, E. J., 1754
 Bertario, L., 4799
 Bertelsen, A. H., 5690
 Bertino, J. R., 4292
 Bertolaet, B. L., 2042
 Bertrand, R., 3066
 BeruBe, K., 4543
 Besnard, F., 4577
 Bessho, T., 5196
 Beurdeley-Thomas, A., 5777
 Bezdek, T., 3504
 Bhalla, K. N., 3202, 4561
 Bhattacharya, N., 542
 Bhattacharya-Chatterjee, M., 1217
 Bhaumik, M., 2881
 Bhujwalla, Z. M., 1063, 4075
 Biamonti, G., 5818
 Bianchi, L., 815
 Bibby, M. C., 5263
 Bièche, I., 2081, 2298
 Bielenberg, D. R., 808
 Biesalski, H. K., 2693
 Bignami, M., 135
 Bignell, G. R., 1384
 Bigner, D. D., 302
 Bignon, Y.-J., 1004, 3480
 Billi, A. M., 5057
 Billiar, T. R., 334
 Binaschi, M., 1886
 Binder, R. L., 4314
 Biran, H., 2919
 Bird, C. L., 661
 Birkholtz, G. G., 1376
 Birnbaum, D., 1588
 Bischof, C., 1850
 Bischof, D., 1057
 Bischoff, E. D., 479
 Bishop, W. R., 4947
 Bissery, M. C., 3896
 Bissonnette, M., 1074
 Biswas, T., 3950
 Bittner, M., 5009
 Bizik, J., 1843
 Black, J. D., 3270, 3883
 Black, K. L., 914, 4475
 Black, P. M., 4654
 Blackburn, G. L., 5231
 Blackburn, R. V., 1358
 Blagosklonny, M. V., 3331
 Blakesley, V. A., 3021
 Blalock, J. E., 1217
 Blanco, J., 1544
 Blank, A., 1068
 Blasberg, R., 4333
 Blasberg, R. G., 4185
 Blaser, M. J., 588
 Blasi, F., 1843
 Blazes, M. S., 3254
 Bloch, A., 4282
 Blöchl-Daum, B., 2982
 Block, A. W., 55, 3173
 Bloomfield, C. D., 55, 790, 4173
 Blot, W. J., 588
 Bluestone, J. A., 5301
 Blüggel, M., 5803
 Blum, A., 1583
 Blum, J. L., 3237
 Blumberg, P. M., 1423
 Blumrich, M., 1195
 Boardman, M. L., 142
 Bobola, M. S., 1068
 Bochner, B. S., 5537
 Bockenheimer, J., 2982
 Boghaert, E. R., 2063
 Bögi, K., 1423
 Bogomolny, F., 3193
 Bohlen, P., 3209
 Bohr, V. A., 1400
 Boiko, A. D., 3423
 Bol, S. A. M., 2850
 Boland, C. R., 767, 2724, 5248
 Bold, P., 5803
 Boldogh, I., 3950
 Bolen, J. B., 2331
 Boller, Y. C., 3059
 Bonassi, S., 4117
 Bonifacio, D., 426
 Bonin, A., 5361
 Bonnè, S., 4587
 Bonnotte, B., 5495
 Bontkes, H. J., 1700
 Booker, S., 1405
 Bookstein, R., 2331, 5285
 Boon, T., 743
 Booth, C. L., 3641
 Boothman, D. A., 767, 1876, 3712
 Boral, A. L., 4211
 Borch, R. F., 2568
 Borchard, F., 3942
 Borden, E. C., 2489
 Borens, R., 2489
 Bordignon, C., 2969
 Borg, A., 1004, 1367
 Boritzki, T. J., 3036
 Born, T. L., 2042
 Bornkamm, G.-W., 1616
 Bornmann, W. G., 1876
 Boros, L. G., 3188
 Borresen-Dale, A.-L., 1004, 2923
 Bos, H. M. K., 2863
 Bosaeus, I., 5374
 Bosch, F. X., 5
 Bose, S., 421
 Bosl, G. J., 4260
 Bosland, M. C., 3282
 Bosslet, K., 1195
 Boström, J., 29
 Bostwick, D. G., 389, 759, 2461
 Botta, R., 562
 Bottai, M., 4122
 Bottaro, D. P., 5157
 Botti, G., 4193
 Bouchardy, C., 5291
 Bouck, N. P., 1298, 5551
 Bougnoux, P., 3529
 Boulares, A. H., 4510
 Bourdon, M. A., 3743
 Boutin, C., 840
 Bouvet, M., 2288
 Bova, G. S., 204, 5652
 Bova, R. J., 1773
 Bowden, G. T., 711
 Bowen, C., 3275
 Bowen, D. T., 2029
 Bower, M., 4363
 Bowlin, T., 3461
 Boyd, D., 1135
 Boyd, J., 3193
 Boyd, J. T., 1332
 Boyer, J. C., 3946
 Boyer, R., 5267
 Boyle, M. A., 2003
 Boynton, A. L., 5089
 Bradbury, E. M., 1305
 Brake, P. B., 2366
 Brambilla, C., 3926
 Brambilla, E., 3926
 Brampton, M. H., 4363
 Brandenburg, S., 4155
 Brash, D. E., 1723
 Brastitus, T. A., 1074, 1684
 Bready, J. V., 933
 Breeman, W. A. P., 437
 Brekken, R. A., 1952
 Brem, H., 672, 2784
 Bremond, A., 1451
 Brenner, M., 4577
 Bresciani, F., 871
 Bressac-de Paillerets, B., 1588
 Brevinge, H., 5374
 Briand, P., 4264
 Briffod, M., 2081
 Brigaudeau, C., 5640
 Briley, L. P., 2445
 Brinckerhoff, C. E., 5321
 Britton, R., 5701
 Briviba, K., 4297
 Brix, G., 3598
 Broberg, U., 2568
 Brock, C. S., 4363
 Brock, G. B., 215
 Bröcker, E.-B., 2170
 Brodeur, G. M., 3226, 4238, 4602
 Brodie, A., 3826
 Brodt, P., 3243
 Brögger, A., 4117
 Bronner, C. E., 1087
 Bronson, R. T., 848
 Brooks, A. D., 3391
 Brooks, K. S., 1593
 Brossart, P., 732, 5803
 Brouwer, K. L. R., 3641
 Brouwer, K. R., 3641
 Brown, E., 5850
 Brown, J. M., 1408, 2098
 Brown, J. S., 2003
 Brown, M. R., 5326
 Brown, S. B., 3706
 Bruder, C., 3226
 Brugger, W., 732
 Brunelli, B. T., 71
 Brunet, J.-S., 2919
 Brunner, M., 2982
 Brünner, N., 1843
 Bruno, S., 3654
 Bruyneel, E., 4587
 Bryant, M. S., 4947
 Buard, A., 840
 Bubendorf, L., 2304
 Bucana, C. D., 808, 2288
 Bucci, B., 283
 Buchberg, A. M., 3401
 Büchler, M. W., 753, 3769
 Buchsbaum, D. J., 5738
 Bucht, E., 4113
 Buettner, G. R., 2809
 Bufo, P., 4799
 Bugaj, J. E., 437
 Bulfone-Paus, S., 2707
 Bullerdiek, J., 2278, 4930
 Bunn, P. A., Jr., 910, 1149
 Burgart, L. J., 1713, 3455, 5473
 Burke, L., 2533
 Burnett, A. K., 2029
 Burns, C. P., 2809
 Burns, T. F., 1593
 Burrow, M. E., 4940
 Burrows, S. R., 310
 Burt, R. W., 4909, 5248
 Burtis, W. J., 4113
 Burton, D. W., 4113
 Busby, E. C., 4375
 Bussion, P., 310
 Bustos, V., 5271
 Butash, K. A., 2515
 Butler, A. A., 3021
 Butler, L. H., 1057
 Butterfield, L. H., 5305
 Buttice, G., 5321
 Butzow, R., 892, 2715, 4274
 Buyse, I. M., 4238
 Byers, K. L., 1876
 Bykov, V. J., 2961
 Byrd, J. C., 4173

C

- Cabral, F., 2404
 Cadei, M., 737
 Cai, J., 1444
 Cai, Y., 4771
 Caille, B., 2298
 Cairns, P., 204, 509
 Cajot, J.-F., 2190
 Calabretta, B., 283
 Caldas, C., 4086
 Califano, D., 823, 4745
 Caligiuri, M. A., 55, 790
 Caligo, M. A., 1004
 Calin, G., 3777
 Calkins-Adams, D. P., 3765
 Callery, P. S., 2385, 4864
 Callister, M., 3668

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 58

- Camenisch, G., 5678
 Campbell, I. G., 1707, 2095
 Campbell, S. C., 1298
 Campbell, S. E., 5537
 Campo, E., 1624, 1762
 Cancelas, J. A., 1544
 Cancemi, M., 871
 Candas, B., 60
 Canevari, S., 991, 4146, 4468, 5812
 Cangi, M. G., 1730
 Canman, C. E., 5637
 Cannell, M. B., 1185
 Cannistra, S. A., 4776
 Cao, D., 5418
 Cao, S., 1695, 3270
 Cao, Y., 3362
 Caporaso, N. E., 2533
 Cappetti, B., 5812
 Cappia, S., 3015
 Capranico, G., 1886
 Carbone, M., 4505
 Carboni, J. M., 1111
 Cardesa, A., 1762
 Cardi, G., 2078
 Carethers, J. M., 2724
 Cargile, C. B., 3254
 Carling, T., 377
 Carlisle, A. J., 5326
 Carlomagno, N., 4799
 Carlsen, N. L. T., 448
 Carlton, M. B. L., 1338
 Caron, P., 2727
 Carrasquillo, J. A., 2612
 Carroll, A., 4173
 Carroll, M., 2793
 Carroll, P. R., 3555
 Carron, C. P., 1930
 Carrozzi, L., 4122
 Carter, D., 4805, 5466
 Casamassimi, A., 2888
 Casazza, A. M., 1111
 Casero, R. A., Jr., 2711
 Casorati, G., 4146
 Cass, C. E., 4349
 Cassarà, D., 4468
 Cassidy, J., 5042
 Casslén, B., 3294
 Castaldo, P., 815
 Castelli, C., 2433
 Castonguay, A., 5354
 Castranio, T., 3603
 Catino, J. J., 4947
 Catovsky, D., 1736, 2293, 3488
 Cattoretti, G., 114
 Catzavelos, G. C., 542
 Cavenee, W. K., 2724, 5002
 Cayuela, J.-M., 2298
 Cazorla, M., 1624, 1762
 Ceccotti, S., 135
 Celi, A., 4122
 Celli, G., 5157
 Cerutti, J., 4745
 Cha, A., 3215
 Chabner, B. A., 4211
 Chaganti, R. S. K., 4260
 Chakraborty, M., 1217
 Chakraborty, N. G., 1363, 5305
 Champême, M.-H., 2081
 Chan, R., 5500
 Chandrasekaran, L., 3154
 Chaney, S. G., 3579
 Chang, A. E., 491
 Chang, B. S., 3202
 Chang, C., 1260, 5310
 Chang, C. J., 3905
 Chang, C. L., 2724
 Chang, G.-W., 4445
 Chang, I.-W., 1825
 Chang, J., 3504
 Chanock, S. J., 5842
 Chao, T. L., 2784
 Chao, Y., 985
 Chap, H., 1429
 Chaplin, D. J., 4510
 Chapman, J. D., 3571
 Charpin, C., 1588
 Chasovskikh, S., 3495
 Chatterjee, S. J., 1090
 Chatterjee, S. K., 1217
 Chau, G.-Y., 985
 Chauhan, D. P., 2724
 Chaussade, L., 3926
 Chekmareva, M. A., 4963
 Chen, C.-T., 2141, 2777
 Chen, C.-Y., 328
 Chen, J., 1376, 3307, 3504, 4947
 Chen, J. N., 933
 Chen, J. X., 2070
 Chen, L. B., 71, 4776
 Chen, L.-C., 3677
 Chen, Q., 2217
 Chen, S., 5695
 Chen, S. L., 3561
 Chen, S.-H., 3221
 Chen, S.-K., 328
 Chen, T., 4805
 Chen, T. T.-L., 3237
 Chen, W., 711
 Chen, X., 5061
 Chen, Y., 1965, 2699, 5009
 Chen, Y.-T., 1034
 Chen, Z., 3668, 3950
 Chenevix-Trench, G., 2095
 Cheney, I. W., 2331
 Cheng, A., 3611
 Cheng, A.-J., 4052
 Cheng, J. Q., 2973
 Cheng, L., 389
 Cheng, L. L., 1825
 Cheng, Y.-C., 1909
 Cherng, S.-H., 328
 Cheshire, K., 2784
 Chessa, L., 4923
 Cheung, N.-K. V., 2844
 Cheville, J. C., 389
 Chi, J.-G., 504
 Chiang, J.-M., 3289
 Chiang, S.-Y., 222
 Chiao, P., 38, 1538
 Chiao, P. J., 5656
 Chiappa, S. A., 896
 Chiappetta, G., 4193
 Chiaur, D. S., 1730
 Childs, S., 4160
 Chiles, T. C., 241
 Chilov, D., 5678
 Chilvers, E. R., 5239
 Chinery, R., 2323
 Chishima, T., 4217
 Chiu, J.-H., 985
 Chong, A. S.-F., 2832
 Chopra, D. P., 3466
 Chou, T.-B., 3289
 Chou, Y.-H. W., 3289
 Chow, C. J., 2469
 Chow, W., 2793
 Chow, W.-H., 588
 Choyke, P., 1719
 Chrest, F. J., 4611
 Christensen, C. R. L., 1238
 Christensen, E. R., 3455
 Christian, B., 5151
 Christiani, D. C., 1804
 Christianson, T. A., 5123
 Christodoulou, G., 1789
 Christofori, G., 801
 Chu, E., 1723
 Chu, L., 3555
 Chu, X.-Y., 5137
 Chung, D. C., 3706
 Chung, F.-L., 581, 4096
 Churchill, G. A., 3694
 Churg, A., 4543
 Ciacchini, G., 4122
 Ciaparrone, M., 114, 3448
 Ciborowski, P., 5066
 Ciacchiello, L., 871
 Cimino, L., 1325
 Cinatl, J., 367
 Cinatl, J., Jr., 367
 Ciolino, H. P., 2754, 5707
 Cistulli, C. A., 1993
 Citro, G., 283
 Cittadini, A., 3448
 Claas, A., 863
 Claffey, K. P., 4185
 Clark, S. J., 3508
 Clarke, P., 1469
 Clayman, G. L., 3132, 3142
 Clejan, S., 4940
 Clerico, L., 3654
 Clifford, S. C., 3932
 Clinton, G. M., 5123
 Clinton, S. K., 5231
 Clouse, M. E., 5673
 Cnaan, A., 3226
 Cnubben, N. H. P., 4616
 Coates, M. M., 1013
 Cobbers, J. M. J. L., 29
 Cobo, J. M., 413
 Cocco, L., 5057
 Cochet, O., 1170
 Coetzee, G. A., 585, 1620, 4497
 Coffey, R. J., 2323
 Coffin, D., 1562
 Cohen, D., 276
 Cohen, H. T., 226
 Cohen, I. R., 5447
 Cohen, J., 5731
 Cohen, M. B., 5870
 Cohen, S. M., 2557
 Colby, T. V., 2533
 Colditz, G. A., 442, 667, 5117
 Cole, S. P. C., 5130
 Colella, G., 3654
 Collan, Y., 432
 Colledge, W. H., 1338
 Coller, H. A., 1268, 2857
 Collins, C., 1972, 3677
 Collins, K. I., 5850
 Collins, N., 1384
 Collins, S., 500
 Collins, V. P., 29
 Colnaghi, M. I., 991
 Colombo, B., 3866
 Colombo, M. P., 1225, 4146, 5795, 5812
 Colon, I., 3668
 Colquhoun, I., 4363
 Coluzzi, P., 2793
 Colvin, O. M., 672
 Condeelis, J. S., 2528
 Condorelli, G. L., 562
 Conney, A. H., 2269
 Connors, T. D., 4155
 Conradt, C., 5
 Conti, C. J., 4314
 Cooper, L., 310
 Cooper, P. A., 5263
 Copeland, N. G., 5023
 Copeta, A., 2234
 Corbett, S. A., 3586
 Cordon-Cardo, C., 1291, 2727, 3009
 Corn, P. G., 4515
 Cornelius, J., 47
 Cornell, L. A., 1111
 Corral, T., 1253
 Corry, P. M., 1358
 Corti, A., 3866
 Corvi, C., 570
 Cos, S., 4383
 Costa, M., 2182
 Cote, R. J., 1090
 Coticelli, M. G., 3401
 Coucke, P. A., 5411
 Couillard, S., 60
 Coutts, A. S., 4071
 Covelli, B., 1315
 Covitz, K.-M. Y., 519
 Cowan, J. M., 4782
 Coze, C., 448
 Crawford, B. A. L., 5105
 Crawford, C. R., 4349
 Crawford, H. C., 5206
 Creighton, A. M., 1460
 Crichton, D. N., 1004
 Crissman, H. A., 413
 Cristiano, R. J., 4761
 Cristofalo, V. J., 1
 Critchlow, C. W., 3839
 Croce, C. M., 1609, 3401, 4708, 5032
 Crociani, O., 815
 Crocitto, L., 1620
 Croop, J. M., 276
 Crotty, K., 5361
 Croucher, P. I., 5294
 Crowe, D. L., 142
 Crowe, T. C., 4970
 Crystal, R. G., 4368
 Culig, Z., 4640
 Cullinane, C., 1400
 Cummings, O. W., 34
 Cummins, A. B., 4543
 Cunningham, G. R., 76
 Cunningham, J. M., 1713, 3455, 5473
 Cuny, M., 1004
 Cupp, S. B., III, 5144
 Curiel, D. T., 1893, 2134, 5738
 Curman, D., 5701
 Curmis, F., 3866
 Cuthbert, A. P., 2863, 4572
 Cuthill, S., 767
 Cuvillier, O., 1817
 Czech, J., 1195
 Czubayko, F., 3415

D

- D'Agnano, I., 283
 Dahl, A. R., 1417
 Dahler, A. L., 1646
 Dairkee, S. H., 3677, 5271
 Daish, A., 3909
 Dal Cin, P., 2278
 Dalerba, P., 2969
 Daly, R. J., 1773
 Damjanov, I., 4598
 Daneryd, P., 5374
 Dang, C. V., 4342, 5537
 Danks, M. K., 20, 2646, 3627
 D'Anna, J. A., 413
 Dannull, J., 956
 Dano, K., 1843
 Darbon, J.-M., 1429
 Darley, R. L., 2029
 Darwiche, N., 1435
 Dasaradhi, L., 647
 Daschner, P. J., 5707
 Dashwood, R. H., 1127
 Davey, F. R., 4173
 Davidson, B. L., 3873
 Davidson, N. E., 2515
 Davidson, N. O., 1074
 Davie, J. R., 3004
 Davies, M. A., 5285
 Davies, P., 5701
 Davis, A. S., 5389
 Davis, B. H., 1074
 Davis, E. M., 3561
 Davis, J. D., 2784
 Davis, R. J., 3542
 Davis, T. W., 767
 Davison, A., 276
 Davison, K., 5110
 Day, K. C., 4667
 Day, M. L., 4667
 Day, R., 5344
 Daya-Grosjean, L., 4402
 Dayer, P., 5291
 Dazin, P., 4525
 De, M., 1986
 Deacon, D. D., 5144
 Dean, M., 5337, 5633
 Dean, R., 1850
 Debatin, K.-M., 4453, 5876
 de Bernardi, B., 448
 DeBerry, C. S., 4660
 De Biasio, M. C., 4193
 de Boer, A. J., 2509
 DeBoer, G., 542
 de Boer, J., 89
 De Bruijn, M. L. H., 724
 Dechant, M., 3051
 Decker, J., 4090
 DeClerck, Y. A., 2209
 De Clercq, E., 384, 2562
 de Cock, K. A. J., 724
 Deeds, J., 1515
 Deeley, R. G., 5130
 de Franciscis, V., 823
 Deftos, L. J., 4113
 De Galle, B., 1670
 De Giovanni, C., 1225
 De Giuli, P., 3015
 DeGroff, V. L., 4227
 de Groot, A. J. L., 2850
 de Gruijl, T. D., 1700
 Deininger, M. W. N., 421
 de Jong, M., 437
 de Jonge, R. R., 1986
 Dekker, M., 248
 de Kraker, J., 448
 DelaBarre, L., 5083
 Delabesse, E., 2680
 de la Chapelle, A., 55
 Delahoussaye, Y. M., 2098
 Delannoy, P., 4066
 Delia, D., 4923
 Delius, H., 829
 Dell, J., 4947
 Della Valle, V., 3926
 Dellian, M., 5866
 Delsol, G., 1057
 De Luca, A., 5049
 De Luca, L. M., 1435
 Delumeau, I., 1170
 Demant, P., 4794
 DeMasters, B. K. K., 2020
 Demers, G. W., 2331
 Demers, L. M., 927
 Demetriou, A. A., 4475
 Demidchik, E. P., 198
 Demple, B., 3435
 Denda, A., 3028, 4548
 de Nigris, F., 2888, 4193, 4745
 Denmeade, S. R., 2537
 Denner, L., 76
 de Oliveira, L. M., 2557
 De Petro, G., 2234
 De Pinieux, G., 5777
 Deprest, J., 2278
 DeRemer, S. J., 1688
 Derguini, F., 2007
 Derry, W. B., 1177
 Deryugina, E. I., 3743
 Desai, S. A., 2417
 Desbaillets, I., 5678
 De Smet, C., 743
 Detmar, M., 1599
 Devetten, M., 3538
 Devile, P., 1004
 De Vita, G., 2888
 de Vries, A., 2850
 DeVries, S., 3555
 de Waal, R. M. W., 4880
 de Wind, N., 248
 de Wit, J., 89
 DeYoung, B. R., 237
 Diab, A., 3891
 Diamond, D. J., 2601
 Di Bonito, L., 426
 Dicker, A. J., 1646
 Diehl, V., 1116, 4930
 Dierick, H. A., 3409
 Dierov, J., 4233
 Dietz, A., 5
 DiGiuseppe, J. A., 4611
 Di Lauro, R., 2888
 Dimtchev, A., 3495
 Dinarello, C. A., 2489
 Di Nicola, N., 4040
 Dinney, C. P. N., 808
 Diotel, C., 2541
 DiPalma, C. R., 933
 Di Palma, S., 4721
 Di Pede, F., 4122
 DiResta, G., 4333
 Diwan, B. A., 3590
 Dixon, D. A., 4909
 Dmitrovsky, E., 2727
 Dodge, R., 5546
 Doekhie, F. S., 1700
 Doerr, H. W., 367
 Doggett, N., 1972
 Doherty, J. K., 5123
 Doll, R. J., 4947
 Dolo, V., 4468
 Domagala, W., 2946
 Done, S. J., 785
 Dong, G., 3668
 Dong, S. M., 1140, 3787
 Dong, S.-M., 504
 Dong, Z., 711, 4102
 Donker, I., 89
 Donoho, G., 3441
 Donowitz, M., 2784
 Dontje, B., 4840
 Dooley, L., 3282
 Doroshov, J. H., 2793
 Dosaka-Akita, H., 322
 Dosemeci, M., 2176
 Dotzlaw, H., 1348, 3197
 Double, J. A., 5263
 Douglas, J. T., 5738
 Douglass, E. C., 1387
 Doxsey, S. J., 3974
 Drabkin, H. A., 4701
 Dragani, T. A., 3401
 Draube, A., 4930
 Dreier, T., 3918
 Dreslin, A. J., 3965
 Driever, P. H., 367
 Drijfhout, J.-W., 724
 Driouch, K., 2081
 Driscoll, K., 4543
 Dritschilo, A., 3495
 Drolet-Savoie, P., 1631
 Drougard, C., 4402
 Druck, T., 2946, 3401
 Du, J., 1866
 Dubauskas, Z., 3561
 Dubinett, S. M., 1208
 DuBois, R. N., 362, 5473
 Duffel, M. W., 647
 Duffy, S., 4646
 Duggan-Keen, M. F., 1700
 Dumanski, J. P., 3226
 Dumaz, N., 4402
 Duncan, L. M., 1515
 Dunn, D., 3538
 Dunn, M. D., 1090
 Dunn, S. E., 3353
 Dupont, W. D., 65, 5038
 Durand, R. E., 3547
 Dutrillaux, B., 5777
 Dutschman, G. E., 1909
 Dvorak, H. F., 1278
- E**
- Earnest, D. L., 1684
 Easton, J., 2624
 Ebeling, S. B., 2863
 Ebrahimi, S. A., 4417
 Eckelman, W. C., 2612
 Economou, J. S., 5305
 Eda, H., 1165
 Edelmann, W., 5713
 Eder, I. E., 4640
 Edmiston, K. H., 1524
 Eggermont, A. M. M., 4880
 Eggers, J., 5662
 Egilsson, V., 4421
 Egorin, M. J., 2385
 Eguchi, M., 4923
 Ehleiter, D., 2260
 Ehrenman, K., 4475
 Ehrlich, M., 3353
 Eicher, E. M., 3694
 Eichler, H. G., 2982
 Eid, M. A., 2461
 Eiriksdottir, G., 4421
 Eiseman, J. L., 2385, 4864
 Eisinger, D. P., 5144
 Eisinger, F., 1588
 Eisterer, W., 4918
 El-Deiry, W. S., 1593, 3513, 4531
 Eling, D. J., 1965
 Ellenhorn, J. D. I., 2601
 Ellenson, L. H., 3254
 Ellis, F. H., Jr., 1730
 Ellis, L. M., 2288, 4008
 Ellis, S. L., 5168
 Ellison, E. C., 237
 Ellmore, N., 5157
 El-Naggar, A., 3132
 Elonen, E., 55
 El-Rifai, W., 34
 Eltom, S. E., 2366
 Emmert-Buck, M. R., 5326
 Encell, L. P., 1013
 Endo, S., 1231
 Engelhard, V. H., 5144
 Engelsberg, A., 4090
 Engelward, B. P., 3965
 Engleman, V. W., 1930
 English, N. M., 3736
 Engwall, Y., 1372
 Enomoto, T., 4227
 Ensminger, W. D., 1688
 Entius, M. M., 5267
 Eppeberger, U., 622
 Epstein, A. L., 3051
 Epstein, D. S., 2784
 Epstein, J., 4426
 Erber, R., 5
 Erez-Alon, N., 5447
 Eriksson, E., 4113
 Erion, J. L., 437
 Ernstoff, M. S., 2078
 Esche, C., 380
 Eshhar, Z., 4146
 Eshleman, J. R., 5248
 Eskelinen, M., 342
 Essig, M., 3598
 Esteller, M., 4515
 Eswara, J. R., 4342
 Eto, S., 4138
 Evans, D. B., 38, 5656
 Evans, H., 4363
 Evans, J. W., 2098
 Evans, M. J., 1338
 Eve, B. Y., 808
 Evron, E., 509
 Ewend, M. G., 672
 Eyfjörð, J. E., 859, 1004
- F**
- F.-Ouchi, K., 1165
 Facon, T., 5640
 Faenza, I., 5057
 Faessel, H. M., 3036
 Fahrrenkrug, J., 4845
 Fairchild, C. R., 1111
 Falette, N., 1451
 Falkmer, U. G., 4113
 Fan, C., 2217
 Fan, H., 1650
 Fan, K., 5713
 Fan, Y., 5089
 Fan, Y.-H., 4082
 Fang, B., 2288
 Fang, G., 3202, 4561

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

- Fang, H., 1914
 Fang, X., 2253, 5285
 Fanjul, A. N., 4607
 Fantl, V., 1353
 Faravelli, L., 815
 Farber, R. A., 3946
 Faria, T. N., 2007
 Farina, A. R., 2957
 Farina, K. L., 2528
 Farinosi, R., 1886
 Farr, G. H., Jr., 1713
 Farrell, C. L., 933
 Fausto, N., 5514
 Faux, S. P., 189
 Favre, N., 5495
 Fawcett, J., 3719
 Fay, M. J., 1866
 Featherstone, T., 3986
 Fedele, M., 4193
 Federici, M. G., 3193
 Fehres, O., 3312
 Feigelson, H., 4497
 Feigelson, H. S., 585
 Feigl, P., 1149
 Feinberg, A. P., 1052, 4155
 Felix, K., 1616
 Felley-Bosco, E., 334
 Feng, S., 1509
 Fenical, W., 1111
 Fenning, M. C., 3571
 Fenoglio-Preiser, C., 1149
 Fenton, B. M., 1478
 Fenton, R. G., 3391, 3855
 Feramisco, J. R., 2042
 Ferguson, D. J., 2766
 Fernandes-Alnemri, T., 5201
 Fernández, P. L., 1762
 Fernández, P., 1583
 Ferrans, V. J., 195
 Ferrantini, M., 5795
 Ferrari, A., 1843
 Ferrari, E., 4947
 Ferrone, S., 737, 2149, 2417
 Fiddes, R. J., 1773
 Fidler, I. J., 808
 Field, J. K., 2003
 Fields, A., 2919
 Figdor, C. G., 2509, 4138
 Figg, W. D., 3248
 Figini, M., 991, 4146
 Fijneman, R. J. A., 4794
 Filipski, E., 3896
 Fine, H. A., 3362
 Fink, D., 5731
 Finke, L., 863
 Finlay, H. J., 717
 Finn, O. J., 5066
 Finn, R., 4185, 4333
 Fischer, S. M., 4624
 Fishel, R., 767, 4537, 5023
 Fisher, L. M., 1886
 Fisher, R., 1387
 Fisher, W. E., 237
 Fishman, D., 2919
 Fishman, P., 3181
 Fisk, B., 4790
 Fitzgerald, E. B., 4895
 Flad, T., 732, 5803
 Flath, T. J., 1087
 Flavell, D. J., 5787
 Flavell, S. U., 5787
 Fleischhauer, K., 2969
 Fleisher, A. S., 4802
 Fleishman, A., 256
 Fleming, J. B., 5656
 Fleming, M. V., 2533
 Flick, M. B., 1027
 Flossmann-Kast, B. B. M., 3551
 Floyd, R. A., 4548
 Fodde, R., 5248
 Foe, J. L. T., 3538
 Foidart, J.-M., 5529
 Fojo, T., 3331
 Folkman, J., 3362
 Fong, L. Y. Y., 3401, 5380
 Foon, K. A., 1217
 Foor, J., 237
 Ford, J. M., 599
 Ford, R., 1524
 Fornace, A. J., Jr., 1593
 Foroni, L., 2293
 Fossá, S. D., 2087
 Foty, R. A., 3586
 Fowler, W. C., Jr., 3765
 Frade, R., 2733
 Frampton, M. W., 1268
 France, J., 3660
 Francis, G. M., 3142
 François, E., 3896
 Frank, J., 2693
 Franken, K. L. M. C., 724
 Frankl, H. D., 661
 Franklin, W. A., 4701
 Fransson, L.-A., 1099
 Fraser, I. W., 473
 Fraumeni, J. F., Jr., 588
 Freedman, A. N., 2533
 Freeman, M. R., 1395
 Freije, D., 204
 Freireich, E., 4552
 Frelinger, J. G., 1478
 French, A. J., 1713
 French, F. S., 5718
 Freudenheim, J. L., 2107
 Freudreich, C. H., 1260
 Freund, R., 3264
 Frey, R. S., 4752
 Freyer, J. P., 1305
 Fridman, W. H., 1170
 Friedman, L. S., 1338
 Friend, A. J., 5168
 Friend, S. H., 5701
 Frierson, H. F., Jr., 34
 Friess, H., 38, 753, 3769
 Frigerio, L., 1843
 Fritsch, C., 4297
 Fritz, A., 5432
 Fritz, G., 4410
 Froehlich, R., 5137
 Fromentin, A., 5495
 Frommel, T. O., 2772
 Fu, J. Z., 4292
 Fu, S., 2929
 Fu, X.-Y., 2832
 Fuchs, E. J., 882, 4531
 Fueyo, A., 1624
 Fujieda, S., 794
 Fujimoto, T., 5182
 Fujioka, T., 4255
 Fujita, H., 322
 Fujita, K.-i., 1833
 Fujita, S., 512
 Fujita, T., 4823
 Fujiwara, H., 2426
 Fujiwara, T., 2288, 3499
 Fujiyama, A., 5176
 Fukase, Y., 685
 Fukayama, M., 2053
 Fuks, Z., 2260
 Fukuchi, T., 3526
 Fukuda, K., 42
 Fukuda, M., 1095
 Fukuhara, K., 2838
 Fukui, T., 1021
 Fukumoto, T., 3339
 Fukuse, T., 1108
 Fukushige, S., 4222
 Fukushima, K., 4301
 Fukushima, S., 3806
 Fulco, M., 1325
 Fulda, S., 4453, 5876
 Fung, H., 189
 Fung, K. H. Y., 5019
 Fung, L. K., 672
 Furger, C., 1773
 Furihata, C., 4107
 Furnari, F. B., 2724, 5002
 Fürstenberger, G., 4624
 Furukawa, T., 2456, 4222
 Furusato, M., 2076
 Furuya, A., 2053
 Fusco, A., 426, 823, 2888, 4193, 4745, 5523
 Fuse, E., 3248
 Fusenig, N. E., 2200
 Futreal, P. A., 2500

G

- Gabbianelli, M., 562
 Gabrielson, E., 4515
 Gaedicke, G., 2925
 Galehdari, H., 1124
 Gallagher, A. P., 2029
 Gallagher, P. M., 4314
 Gallagher, R. E., 5770
 Gallinger, S., 500, 4040
 Galloway, D. A., 3839
 Galoforo, S. S., 1358
 Gamallo, C., 1344
 Gammon, M. D., 588
 Gan, L., 232
 Gan, Y., 2141, 2777
 Ganapathi, R., 5298
 Gannon, F. H., 2784
 Gansauge, F., 2703
 Gansauge, S., 2703
 Ganss, R., 4673
 Gao, A. C., 1391, 2350
 Gao, B., 4646
 Gao, J., 2537, 3299
 Gao, X., 2141
 Garces, C., 767
 Garcia-Closas, M., 3307
 García-Marco, J. A., 1736
 Garlick, J. A., 2200
 Garnett, M. J., 5046
 Garrido, C., 5495
 Garrigue-Antar, L., 1986, 4805
 Gartenhaus, R. B., 4233
 Gartsbein, M., 1435
 Garwood, M., 5083
 Garzotto, M., 2260
 Gasparri, A., 3866
 Gasser, T. C., 2304
 Gassmann, M., 5678
 Gastaldi, M., 5367
 Gately, S., 5686
 Gattinoni, L., 2969
 Gayther, S. A., 4086
 Gazdar, A. F., 3237
 Gazzeri, S., 3926
 Geddes, T., 4047
 Geirsdottir, E. K., 4421
 Geiser, C. F., 1387
 Geisler, C., 2433
 Geller, S. A., 4475
 Gelmann, E. P., 2520, 3275
 Gemma, A., 2533
 Gemmill, R. M., 4701
 Gendler, S. J., 315, 2675
 Gensler, H. L., 711
 Gentile, M., 4799
 Georg, B., 4845
 George, K., 1654
 Geradts, J., 4740
 Gerard, C. J., 3957
 Gerardy-Schahn, R., 779
 Gerde, P., 1417
 Gerken, M., 1195
 Germano, D., 871
 Gesson, J.-P., 1195
 Ghatan, S., 1068
 Ghigna, C., 5818
 Ghirelli, C., 5032
 Giaccia, A. J., 1408, 1779
 Giancotti, V., 426, 4193
 Giardiello, F. M., 1750, 5267
 Gibbs, J. B., 1253
 Gier, S., 863
 Gies, R. A., 219
 Giglia, G., 4402
 Giguère, V., 877
 Gilbertson, R. J., 3932
 Gilboa, E., 2965
 Gilewski, T., 1839
 Gilles, C., 5529
 Gillespie, G. Y., 1893, 5738
 Gillespie, Y., 4871
 Gilliard, G., 1654
 Gillies, S. D., 3918
 Gilmour, R. S., 5057
 Gimenez-Conti, I., 4624
 Ginanni, N., 1641
 Ginestra, A., 4468
 Ginsberg, J. P., 3542
 Giordano, A., 1325, 4531, 5049
 Giorello, L., 3654
 Giovannucci, E., 442, 5117
 Girijavallabhan, V. M., 4947
 Giudice, L. C., 4168
 Giuliano, A., 823
 Giulini, S. M., 2234
 Giuntini, C., 4122
 Giuntoli, R. L., II, 5546
 Glaab, W. E., 2978
 Glaser, M., 4363
 Glazer, P. M., 5466
 Glenn, G., 1719
 Glennie, M., 3051
 Glickson, J. D., 1063
 Gloriosio, J. C., 5731
 Glover, R. A., 5870
 Glover, T. W., 3409
 Gludovacz, D., 1850
 Glüer, S., 779
 Gobl, A., 2375
 Godfrey, T., 1972
 Goel, A. S., 4787
 Goepfert, H., 1135
 Goessl, C., 4728
 Goggins, M., 509, 4740, 5329
 Goi, K., 4923
 Göke, B., 1583
 Goldberg, J. L., 3571
 Goldbaum, G., 3839

- Golde, D. W., 3009
 Golden, W., 3986
 Goldenberg, G. J., 4519
 Goldman, H., 1730
 Goldman, J. M., 421
 Goldstein, D. J., 3415
 Goldstein, M., 5523
 Goletz, S., 2541
 Gomez, R. A., 3986
 Gómez-Navarro, J., 2134
 Gonzales, F. A., 1245
 Gonzalez, D. E., 519
 Gonzalez, F. J., 1833
 Gonzalez, R. G., 1825
 Gonzalgo, M. L., 1245
 Gooch, J. L., 4199
 Gooden, G. C., 5009
 Goodman, H. A., 3231
 Gora-Tybor, J., 421
 Gordon, G. B., 921
 Gordon, M., 1087
 Gordon, T., 4543
 Gorelik, L., 5301
 Goren, M. P., 4358
 Gorringer, K. L., 4086
 Gorski, D. H., 5686
 Gotley, D. C., 3719
 Gottardis, M. M., 479
 Gottesman, M. M., 268, 4688
 Gottlob, K., 3566
 Gould, M. N., 5097
 Gounari, F., 5439
 Gouyette, A., 4577
 Goyal, J., 4782
 Graber, H. U., 753
 Grady, W. M., 3101
 Graeme-Cook, F., 3706
 Graessmann, A., 1325, 3566
 Graff, J., 1972
 Graff, J. G., 2515
 Graff, J. R., 2063
 Graham, G. E., 2724
 Graham, S., 2107
 Gramacho, C., 473
 Gramatzki, M., 3051
 Granberg, B., 4113
 Grant, D. F., 5196
 Grasso, A. W., 1920
 Grasso, Y. Z., 1456
 Gratadour, A.-C., 1451
 Gratas, C., 2057
 Grauer, L. S., 4787
 Gray, J., 1972
 Greco, W. R., 3036, 5749
 Green, C. E., 5137
 Greenberg, V. E., 2063
 Greenberger, L. M., 5850
 Gregor, M., 3942
 Gregory, C. W., 5718
 Grehan, N., 4086
 Grellier, P., 1670
 Gretarsdottir, S., 859
 Grever, M. R., 4342
 Gribble, G. W., 717
 Griffin, C. A., 3105
 Griffini, P., 3312
 Griffith, J., 2857
 Griffiths, A., 991
 Griffiths, E., 4682
 Griffiths, J. R., 1185
 Grignani, Fa., 14
 Grignani, Fr., 14
 Grignon, D., 4771
 Grignon, D. J., 4047
 Grigolato, P., 737
 Grim, J., 1893, 2134
 Grimley, P. M., 1914
 Grimm, E. A., 3132, 3142
 Cristina, R., 4799
 Grombacher, T., 3950
 Groner, B., 2661
 Grösch, S., 3950, 4410
 Groshen, S., 1090, 5396
 Grossi, M., 4269
 Grubbs, C. J., 921
 Gruber, S. B., 5267
 Gruetter, R., 5083
 Grundy, P. E., 5046
 Gryfe, R., 4040
 Gschwendt, M., 526
 Gu, X.-G., 3385
 Guan, L.-S., 4180
 Guanti, G., 4799
 Gudas, L. J., 166, 2007
 Gudkov, A. V., 3423
 Gudlaugsdottir, S., 859
 Gudmundsson, J., 4421
 Guerra-Vladusic, F. K., 210
 Guerrette, S., 4537
 Güézmás, A., 4383
 Guggler, E. T., 5231
 Guillaume, N., 2733
 Guillou, L., 5411
 Guinebrière, J.-M., 1588
 Guinee, D. G., 2533
 Gulino, A., 2957
 Gumbs, A. A., 5466
 Gumbs, C., 2500
 Gunn, L., 1804
 Guo, N.-h., 3154
 Guo, X., 166, 1909
 Guo, X.-Z., 753
 Guo, Y., 3376, 4864
 Gupta, M. K., 1456
 Gupta, S., 1785
 Güre, A. O., 1034
 Gurley, K. E., 3111
 Gusella, J. F., 5321
 Gusterson, B. A., 4721
 Gutman, M., 60
 Guttenplan, J., 2881
 Guttenplan, J. B., 581
- H**
- Ha, H. C., 2711
 Ha, H. T., 2724
 Haas, B., 1839
 Haas-Kogan, D. A., 3819
 Haaz, M.-C., 468
 Habuchi, H., 1099
 Habuchi, T., 5835
 Hacker, H. J., 5439
 Hackett, N. R., 4368
 Hadaczek, P., 2946
 Haffty, B. G., 5466
 Haga, A., 2667
 Hagemann, C., 2986
 Haggarty, S. J., 5701
 Hagmar, L., 4117
 Hahn, S. A., 1124
 Hahn, S. M., 1562
 Haidacher, S. J., 76
 Haidar, M., 4552
 Haile, R. W., 661, 1620
 Haimovitz-Friedman, A., 2260
 Hainaut, P., 2057
 Haines, G. K., III, 3188
 Haite, N. E., 5042
 Hakumäki, J. M., 3791
 Hakvoort-Cammel, F. G. A. J., 448
 Halachmi, N., 509
 Haldar, S., 1609
 Hale, L. P., 302
 Hall, S. H., 5718
 Hall, S. J., 3221
 Hallahan, D. E., 5216, 5484
 Hallam, S. J., 5770
 Halling, K., 4086
 Halloran, P. J., 3855
 Halmos, G., 4132
 Haluska, F. G., 109
 Hamada, H., 1946
 Hamada, K., 3700
 Hamaguchi, M., 900
 Hamann, U., 1004
 Hamano, H., 549
 Hamaoka, T., 2426
 Hamasaki, V., 2793
 Hamblin, M. R., 5425
 Hamil, K. G., 5718
 Hamilton, A. D., 1754
 Hamilton, C. J., 927
 Hamilton, G., 1850
 Hamilton, J. W., 453
 Hamilton, S. R., 1405, 1750, 5248, 5267
 Hamilton, T. C., 2973, 3579
 Hamm, H., 2170
 Hammarström, L., 2293
 Hammond, T. G., 4940
 Hampson, R., 135
 Hamza, R., 1291
 Han, K., 3751
 Han, W. F., 4611
 Hanagiri, T., 4138
 Hanahan, D., 4673
 Hanai, N., 2053
 Hanania, E. G., 3957
 Hanawalt, P. C., 599
 Handelsman, D. J., 5105
 Handgretinger, R., 2925
 Handmaker, H., 1850
 Handschumacher, R. E., 5418
 Hanfelt, J., 352
 Hanisch, F.-G., 2541
 Hankinson, S. E., 667
 Hansen, L., 1435
 Hansen, L. L., 2166
 Haqqi, T., 962
 Hara, A., 2550
 Harada, H., 3429
 Harada, K., 4694
 Harada, M., 3073
 Harakidas, P., 3461
 Hara-Kuge, S., 4301
 Haraldsson, K., 1367
 Harder, J., 5662
 Harding, C. V., 3660
 Harduin-Lepers, A., 4066
 Haridas, K., 3782
 Harousseau, J.-L., 5640
 Harper, J. C., 34
 Harpey, J.-P., 2298
 Harris, A. C., 1087
 Harris, A. L., 2737
 Harris, C. C., 334, 2533, 4023
 Harris, T., 2881
 Hart, C. A., 2003
 Hart, J., 1074
 Hart, S., 2293
 Hartgers, F., 3094
 Hartmann, A., 3712
 Hartmann, O., 448
 Haruki, N., 1380
 Harvey, K. J., 402
 Hasan, T., 5425
 Hasegawa, S., 4217
 Haslam, S. Z., 3833
 Haslett, C., 5239
 Hasty, P., 3441
 Hatahet, Z., 189
 Hatooka, S., 3429
 Hausheer, F. H., 3782
 Hausner, P., 535
 Havill, A. M., 933
 Havre, P. A., 4733
 Havsmark, B., 1099
 Hawes, S. E., 3839
 Hawighorst, H., 3598
 Hawkins, R., 3353
 Hayakawa, T., 2935, 5725
 Hayashida, T., 1245
 Hayes, R. B., 2176
 Hazra, T. K., 3950
 He, G., 1120
 He, H., 5850
 He, J., 940
 He, L., 4238
 Headlee, D., 3248
 Heaney, J. A., 2078
 Heasley, L. E., 910
 Hebbard, M., 4066
 Heberer, M., 4567
 Hecht, J. E. D., 4391
 Hecht, S. S., 4102
 Heerdt, B. G., 2869
 Hegde, R., 5201
 Heicappell, R., 4728
 Heikkilä, P., 1599
 Heimann, R., 2766, 3215
 Heitmiller, R. F., 5690
 Heitz, P. U., 5559
 Hektoen, M., 2923
 Helbig, M., 5
 Helffer, E., 4572
 Helfferich, W. G., 3833
 Helfrich, B., 910
 Helfrich, M. H., 5294
 Hellman, P., 377
 Hellman, S., 2766, 5686
 Helman, L., 4426
 Helmerhorst, T. J. M., 1700, 3812
 Hemenway, D., 4543
 Hemmer, S., 2715
 Hemminki, A., 2087
 Hemminki, K., 2961
 Henderikx, P., 4324
 Henderson, B. E., 585, 1620
 Henderson, B. E., 4497
 Hendges, S. K., 4001
 Hendrix, M. J. C., 5681
 Hendry, J. H., 5637
 Henne-Bruns, D., 1741
 Hennekens, C. H., 3307
 Henner, W. D., 2568
 Hennings, H., 1435
 Henrar, R. E. C., 2410
 Henry, J. P., 2379
 Henry, R. R., 2042
 Hensel, T., 149
 Henske, E. P., 4766
 Hensley, K. L., 4548
 Henzen-Logmans, S., 4880
 Herberman, R. B., 2489
 Herkel, J., 5447

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

- Herlea, V., 3777
Herman, E. H., 195
Herman, J., 1972
Herman, J. G., 237, 591, 2063, 2515, 4515, 5310
Hermans, I. F., 3909
Hermans, K. G. L., 2720
Hermine, O., 2680
Hernández, L., 1762
Hernández, S., 1762
Hero, B., 448
Herrington, C. S., 2941
Herschman, H., 1208
Herscovitch, P., 2612
Herzig, G. P., 55
Herzog, C. E., 5298
Hess, M. T., 1978
Hesselager, G., 5275
Hessman, O., 377
Heuser, C., 1116
Heyman, R. A., 479
Hiai, H., 1660
Hiasa, A., 3385
Hibi, K., 1405, 5690
Hickey, R. J., 3259, 3264
Hicklin, D. J., 737, 3209
Hickman, J. A., 5453
Hida, T., 3761
Higashi, S., 1660
Higashiyama, T., 4913
Higgins, M. J., 4269
High, W. B., 5083
Hilakivi-Clarke, L., 654
Hilbe, W., 4918
Hilbert, D. M., 535
Hildebrandt, H., 779
Hilgers, J. H. M., 4324, 5577
Hilgers, W., 509, 2339
Hill, D. C., 933
Hill, D. E., 4375
Hiller-Hitchcock, T., 1348
Hillman, G. G., 4047
Hiltbold, E. M., 5066
Hinkel, A., 956
Hino, S., 549, 4434
Hinoda, Y., 2838
Hiraga, S., 2117, 2935
Hiraga, T., 4138
Hiraguri, S., 1972
Hirahara, Y., 3800
Hirai, K., 2359
Hirano, T., 290
Hirasawa, K., 759
Hirata, S., 5565
Hirata, T., 1108
Hirayama, Y., 1660
Hirohashi, S., 512, 3526, 3700
Hirose, M., 2158, 4307
Hirota, S., 641
Hirschaut, Y., 1839
Hiruki, T., 500
Hirvonen, A., 4505, 5291
Hishiki, T., 2158
Hitchcock, A., 1707, 2095
Hitchcock, C. L., 237
Hitomi, M., 962
Hitomi, S., 1108
Hittelman, W. N., 38
Hiwada, K., 2014
Hixon, J. A., 3391
Hlatky, L., 5673
Ho, C.-T., 4096
Ho, W. L., 328
Hobisch, A., 4640
Hochadel, J. F., 3590
Hock, R. A., 3986
Hoefflich, A., 3551
Hoeijmakers, J. H. J., 89
Hoff, D., 5310
Hoffman, A. R., 4168
Hoffman, P., 5577
Hoffman, R. M., 2583, 4217
Hofland, L. J., 437
Hogan, K. T., 5144
Hoge, A. W., 3409
Höglund, M., 5859
Hohoff, C., 4015
Hojo, K., 2583
Holden, S., 3344
Hole, K., 1348
Hulgaard, E. F., 1238
Humm, J., 4333
Hunt, C. R., 3986
Hunt, D. F., 5144
Hunt, K. K., 5656
Hunter, D. J., 667, 3307
Hunter, J., 1515
Hunter, N., 2404
Hunter, S. M., 1338
Huntsman, D., 4086
Hurst, H. C., 5466
Hurst, E., 5825
Husain, A., 1120
Husain, S. R., 3649
Huschtscha, L. I., 3508
Hussain, S. P., 4023
Hussey, H. J., 2359
Hutchinson, A., 5337
Huynh, H., 215
Hwang, J.-J., 1444
Hyakuna, N., 5182
Hyder, S. M., 392
Hylind, L. M., 1750
Hyman, R., 3736
Hynes, R. O., 848
Hyytinen, E.-R., 34
- I**
- Iatropoulos, M. J., 4096
Iba, H., 867
Ichikawa, T., 1231, 3561
Ichikawa, W., 4823
Ichikawa, Y., 3561
Ichimiya, S., 2076, 2158
Ichinose, M., 3751, 4107
Iczkowski, K. A., 2461
Ide, N., 2583
Iggo, R. D., 1793
Iijima, R., 1202
Iizuka, H., 296
Ijuhin, N., 5725
Ikeda, H., 3032, 3385
Ikeda, M., 594
Ikeda, Y., 4307
Ikebara, Y., 512, 4301
Ikono, T., 2067
Illopoulos, O., 4957
Im, S., 47
Imai, K., 2838
Imamura, M., 3429
Imaoka, S., 1021, 2524
Imazu, S., 5725
Inagaki, Y., 2991
Inanäs, M., 1451
Ingles, S. A., 661, 1620
Ingrosso, M., 4799
Ingvarsson, S., 4421
Inoko, H., 5079
Inoue, M., 1558
Ioannides, C. G., 4790
Isaacs, J. T., 1391, 2350, 2537, 3299
Isaacs, W. B., 204, 5280, 5310, 5652
Ishibe, N., 667
Ishida, K., 2067
Ishiguro, S., 1021
Ishikawa, T., 685
Ishitsuka, H., 685, 1165
Ishiwata, T., 3769
Ishizaka, Y., 962
Ishizaki, K., 3429
Ishizuka, T., 2991
Isogai, E., 2158
Isohashi, F., 1095
Israel, M. A., 3769, 3819
Issa, J.-P. J., 5489
Ito, H., 4694
Ito, N., 4307
Ito, T., 4107
Itoh, T., 1048
Itoharu, S., 1048
Iuchi, K., 1105
Ivanovich, M., 1298
Iwai, A., 5182
Iwai, T., 5182
Iwao, K., 1021, 2524
Iwasaki, H., 512
Iwasaki, M., 2426
Iwasaki, T., 3339
Iwata, H., 1833
Iwata, S., 4923
Iyer, S., 4510
Izbicka, E., 2568
Izumoto, S., 2117, 2935
- J**
- Jaccard, A., 5640
Jackson, C. E., 4086
Jackson, R. C., 3036
Jacquiemier, J., 1588
Jaeger, E., 4090
Jain, R. K., 5866
Jalava, P., 432
Jalili, T., 2633
Jameson, B., 4233
Jang, J. J., 1140, 3787
Jang, J.-J., 504
Jang, S. H., 2141
Jani-Sait, S. N., 4269
Jansen, J. G., 2850
Jansen, M., 1741
Jansen, R. C., 4794
Janson, E. T., 2375
Janssen, Y. M. W., 189
Janssens, M. Y., 5646
Jantzer, P., 3078
Janz, S., 1616
Jarrard, D. F., 5310
Jarrard, J. A., 5582
Jaspers, N. G. J., 2449
Jaurand, M.-C., 840
Javaherian, A., 2200
Jefcoate, C. R., 2366
Jeffers, M., 1719
Jehle, P. M., 3551
Jen, J., 509, 1405, 3513, 5690
Jenkins, N. A., 5023
Jenkins, R. B., 759, 2298
Jensen, E. V., 263
Jensen, L. H., 1460

- Jensen, M. R., 123
 Jensen, P. B., 1460
 Jensen, P. R., 1111
 Jensen, R. T., 3706
 Jessup, J. M., 1524
 Jiang, J., 5061
 Jiang, J.-D., 2126, 5389
 Jiang, P., 4217
 Jiang, X., 1707
 Jiang, X.-R., 633
 Jiang, Y., 2260, 5009
 Jin, C., 5859
 Jin, Y., 5859
 Johannesdottir, G., 4421
 Johannsson, O., 1367
 Johnsen, A., 3660
 Johnsen, H., 2923
 Johnson, A. L., 2141
 Johnson, B. H., 3684
 Johnson, D. E., 2331
 Johnson, G. R., 4314
 Johnson, K., 1972
 Johnson, L., 2881
 Johnson, T. M., 5221
 Johnston, J., 2141
 Johnston, P. G., 2606, 5042
 Johnston, S. L., 3519
 Jonasson, J. G., 859, 4421
 Jones, A. B., 3590
 Jones, A. G., 276
 Jones, A. S., 2003
 Jones, D., 2699
 Jones, I. M., 604
 Jones, J. G., 2528
 Jones, M. C., 2724
 Jones, P. A., 95, 1245, 5348
 Jones, S. J., 1646
 Jonges, L. E., 3094
 Jordan, M. A., 1177
 Jordan, V. C., 1872
 Joshi, A., 4185
 Joshi, R., 4185, 4333
 Jothy, S., 4957
 Jounaidi, Y., 4391
 Jove, R., 2973
 Jox, A., 4930
 Ju, J., 1723
 Judson, I. R., 1185
 Jung, M., 3495
 Junker, K., 1719
 Jussila, L., 1599
- K**
- Kabickova, H., 367
 Kaboo, R., 956
 Kacinski, B. M., 1027
 Kadkhodaian, M. M., 4963
 Kadlubar, F. F., 2107, 4307
 Kadono, Y., 2240
 Kaelin, W., 4957
 Kagan, C., 76
 Kageshita, T., 2417
 Kähäri, V.-M., 2310
 Kahn, T., 5
 Kaina, B., 3950, 4410
 Kaipainen, A., 1599
 Kakar, S. S., 4558
 Kakehi, Y., 2282, 5835
 Kakeya, H., 704, 4888
 Kakizuka, A., 2282
 Kakkar, A. K., 4461
 Kaku, S., 2091
 Kakumoto, M., 2550
- Kalbacher, H., 5803
 Kalden, J. R., 3051
 Kalinichenko, T., 5301
 Kalmes, A., 2986
 Kalousek, I. V., 2469
 Kalthoff, H., 1741, 5662
 Kam, J. L., 5577
 Kamada, H., 290
 Kamahora, T., 4434
 Kamataki, T., 1833
 Kameda, T., 867
 Kamen, B. A., 2952
 Kameyama, M., 1021
 Kamiakito, T., 2053
 Kamoto, T., 1660
 Kamps, W. A., 448, 4840
 Kan, M., 1509
 Kanai, F., 1946
 Kanamori, Y., 4585
 Kanaya, T., 1558
 Kandilogiannaki, M., 4324
 Kaneda, Y., 290, 1099
 Kaneko, H., 5182
 Kaneko, M., 3032
 Kaneko, Y., 3751
 Kanemura, Y., 2117
 Kang, M., 4740
 Kankaanranta, A., 432
 Kanke, Y., 4923
 Kantarjian, H., 4552
 Kanugula, S., 1936
 Kanz, L., 732
 Kao, G., 2639
 Kaplan, L., 5466
 Kapusta, L. R., 542, 619
 Karjalainen, A., 4997
 Karlan, B., 2919
 Karlsson, P., 1372
 Karnes, W. E., Jr., 5473
 Karsten, U., 2541
 Kasai, H., 2583
 Kaserer, K., 1850
 Kashefi, C., 4417
 Kashino, G., 5188
 Kashiwabara, K., 2876
 Kast, W. M., 3094
 Kastan, M. B., 5637
 Katagiri, M., 296
 Kataoka, M., 4761
 Katayama, H., 4811
 Katayose, Y., 2838
 Kato, K., 3826
 Kato, Y., 5137
 Katoh, H., 322
 Katoh, O., 5565
 Katsuoka, Y., 5079
 Katsuyama, T., 2067
 Kauffman, J., 4864
 Kaufmann, R., 5803
 Kaufmann, W. K., 1993
 Kauppinen, R. A., 3791
 Kauvar, L. M., 2568
 Kawabata, K., 2550
 Kawabata, Y., 2440
 Kawakami, K., 5182
 Kawakami, T., 1946
 Kawakami, Y., 322, 4895
 Kawamata, H., 549
 Kawamori, T., 409
 Kawasaki, H., 3806, 4434, 5071
 Kawasaki, S., 2067
 Kazarov, A. R., 3423
 Kazmi, R., 1789
 Kazmierczak, B., 2278
- Keane, W. M., 5523
 Keating, M., 4552
 Keck, C. L., 2196
 Keefer, C. J., 3231
 Keenan, E. J., 5123
 Keirsebilck, A., 4587
 Kelleher, D. K., 2693
 Kelliher, K., 1616
 Kelloff, G. J., 921, 3282
 Kelly, M. T., 5701
 Kelly, P., 3932
 Kelsall, S. R., 4061
 Kelsell, D., 1004
 Kelsey, K. T., 667, 1804, 3307
 Kelsey, S. M., 633
 Kemp, B. L., 4082
 Kemp, C. J., 3111
 Keng, P., 2036
 Kenigsberg, M., 1170
 Kennedy, A. P., 4375
 Kennedy, B. P., 500
 Kennedy, K. A., 3059
 Kenwick, S., 1460
 Kerbei, R. S., 4957
 Kerkhoff, E., 1636
 Kern, F. G., 352
 Kern, S. E., 509, 2339, 4592, 4740, 5329, 5652
 Keshelava, N., 5396
 Khalil, M., 5361
 Khalili, K., 4505
 Khan, J., 5009
 Khan, M. A., 2533
 Khan, S. H., 396
 Khanna, R., 310
 Kharbanda, S., 352
 Khazaeli, M. B., 4871
 Khazaei, K., 5439
 Kherzai, A. W., 3504
 Khrapko, K., 1268, 2857
 Khwaja, Z., 2190
 Kiang, D. T., 1498
 Kibel, A. S., 5652
 Kidd, V. J., 2624
 Kikkawa, F., 900
 Kikuta, A., 5182
 Killary, A. M., 3533
 Kim, C. N., 3202, 4561
 Kim, C. S., 3787
 Kim, C.-S., 504
 Kim, C.-Y., 3455, 5473
 Kim, D., 5718
 Kim, H., 4963
 Kim, H. S., 1140
 Kim, J. W., 3787
 Kim, K., 5097
 Kim, K. M., 1140, 3787
 Kim, K.-W., 348
 Kim, S., 3538, 4055
 Kim, S. H., 3787
 Kim, Se. Y., 3787
 Kim, Su Y., 1140, 3787
 Kim, Y.-M., 2825
 Kimata, K., 1099
 Kimmel, D. W., 2298
 Kimoto, N., 4307
 Kimura, A., 594
 Kimura, G., 3073
 Kimura, M., 2456
 Kimura, S., 296, 3751
 Kimura, T., 5182
 Kinder, D. H., 5570
 King, S. W., 1952
 Kinney, W. A., 2784
- Kinoshita, H., 5310
 Kinoshita, I., 322
 Kinoshita, M., 1021
 Kinsella, T., 14
 Kinsella, T. J., 767, 2245
 Kinzler, K. W., 1130, 5267
 Kipps, T. J., 1965
 Kirchgessner, C. U., 2316
 Kirkland, S. C., 2323
 Kirsch, M., 4654
 Kirschenbaum, A., 4245
 Kirschmeier, P., 4947
 Kishida, H., 4548
 Kitada, S., 3116
 Kitamura, Y., 641
 Kitano, M., 1660
 Kitayama, W., 3028, 4548
 Kitoh, K., 4107
 Kittstein, W., 526
 Kiviat, N. B., 3839
 Klatzmann, D., 3529
 Kleeff, J., 3769
 Klein, E. A., 1456
 Klein, R. S., 5770
 Klein, S., 334
 Klein, W., 5
 Kleuser, B., 1817
 Klevecz, R., 2793
 Klich, G., 2541
 Klieverik, L., 3312
 Klingelhöfer, J., 1238
 Klinger, M. F., 4864
 Klocker, H., 4640
 Klotz, L. H., 542, 619
 Klotz, L.-O., 4297
 Klugbauer, S., 198
 Klump, B., 3942
 Kmiec, E. B., 4733
 Knabbe, C., 263
 Knapstein, P. G., 3598
 Knebelmann, B., 226
 Knecht, H., 3974
 Knee, D., 3116
 Knezevich, S. R., 5046
 Knol, J. A., 1688
 Knopp, M. V., 3598
 Knowles, B. B., 4598
 Knox, S. J., 1779
 Knudsen, E. S., 2042
 Knudsen, K. E., 2042
 Knudsen, L. E., 4117
 Knuth, A., 2149
 Knuutila, S., 34, 55, 892, 2715, 4274
 Kobari, M., 2456, 4222
 Kobayashi, E., 1202
 Kobayashi, H., 296, 3248
 Kobayashi, M., 5565
 Kobayashi, N., 3032
 Kobayashi, S., 3248
 Kobayashi, Y., 2053, 4548
 Koch, A., 4480
 Koch, C. J., 1478
 Koch, M., 1195
 Koch, W. M., 509
 Kochel, K., 3116
 Kodama, C., 4923
 Kodama, H., 2838
 Kodama, S., 5188
 Koefler, H. P., 2618, 3344, 3370
 Koerner, F., 2876
 Koezuka, Y., 1202
 Koganty, R. R., 5151
 Kogner, P., 448

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 58

- Kohl, N. E., 1253
Kohn, E. C., 5326
Kohno, N., 2014
Kohno, T., 3700, 5478
Koide, A., 3806
Koike, M., 2053, 2618, 3370
Koizumi, M., 4222
Koizumi, S., 5182
Kojima, A., 4368
Kok, J. W., 4840
Kokubo, T., 296
Kolachana, P., 2176
Kolchinsky, A., 5216
Kolesnick, R., 2260
Kolodner, R. D., 5027
Kolonel, L. N., 1620, 4497
Kolstoe, D. D., 1068
Kondo, K., 2014, 2158
Kondo, M., 1380
Kondo, S., 962
Kondo, Y., 962
Kong, A-N. T., 402, 2102
Kong, D., 4802
Kong, F. M., 302
Konishi, H., 1380
Konishi, Y., 3028, 4548
Kontny, H. U., 5842
Kooij, P. P. M., 437
Koons, J. S., 3611
Kopantzev, E., 535
Koppan, M., 4132
Kopper, L., 614
Korc, M., 753, 3769, 4250
Korfmacher, W. A., 4947
Körner, U., 5374
Kornhuber, B., 367
Kornmann, M., 4250
Koshikawa, T., 1042
Koshimizu, K., 2550
Koshizuka, K., 3344, 3370
Kosma, V-M., 342
Kotake, Y., 4548
Kotaniides, H., 3209
Kotchekov, R., 367
Kotkansalo, T., 432
Koul, D., 5285
Koutcher, J., 4333
Koutsky, L. A., 3839
Kovar, H., 2469
Kow, Y. W., 189, 222
Koya, K., 71
Koyama, K., 5176
Kozaki, K-i., 3761
Kraeft, S-K., 4776
Kraft, A. S., 834
Krajewska, M., 3116
Krajewski, S., 256, 3116, 4940
Krambovitis, E., 4324
Kramer, D. L., 3883
Kramarov, D., 1238
Krammer, P. H., 526
Krantz, M. J., 4079, 5577
Kraus, J. A., 4480
Krause, H., 2707, 4728
Kreitman, R. J., 968, 3649
Kremer, B., 1741
Krenning, E. P., 437
Kreuzer, K. N., 1260
Krill, C. E., 1387
Krishna, M. C., 1562
Krisky, D., 5731
Krizman, D. B., 5326
Kroemer, G., 4453
Kroemer, H. K., 1195
Kronauge, J. F., 276
Kronqvist, P., 432
Kruh, G. D., 1332, 2741
Kruse, C. A., 2020
Kruse, T. A., 2166
Kruttsch, H. C., 3154
Krynska, B., 4505
Krystal, G. W., 4660
Ku, Y., 3339
Kuan, H-Y., 1688
Kuang, J., 2639
Kubicek, M. F., 4001
Kubo, T., 2426
Kubonishi, I., 2618
Kubota, H., 4694
Kubota, T., 3344, 3370
Kucherlapati, R., 5713
Kuchibhotla, J., 5484
Kudo, T., 512, 2838
Kuefer, M. U., 1057
Kufe, D. W., 3215, 5686
Kuh, H-J., 2141
Kühr, T., 4918
Kukhanova, M., 1909
Kuki, W., 2550
Kulesz-Martin, M., 2091
Kuma, K., 4913
Kumagai, K., 2343
Kumanishi, T., 1231
Kumar, A., 4787
Kumar, M. V., 2461
Kumar, N. S., 1860
Kumar, P., 4426
Kumar, S., 4426
Kumari, S. R., 5075
Kung, H-J., 1920
Kunkel, T. A., 2978, 3579
Kunugi, K. A., 767
Kunzendorf, U., 2707
Kuo, M-L., 2245
Kuo, W-L., 3677
Kuopio, T., 432
Kuppusamy, P., 1562
Kuramoto, K., 5565
Kurata, N., 3248
Koul, D., 5285
Kurdistani, S. K., 4439
Kuribayashi, K., 3385
Kuriki, K., 2053
Kurman, R. J., 3254
Kuroda, Y., 3339
Kuroishi, T., 1042
Kurooka, M., 1105
Kurz, B., 5803
Kurzawa, H., 491
Kushida, H., 1833
Kusunoki, N., 3339
Kuwabara, T., 3248
Kuypers, J., 3839
Kuzumaki, N., 322
Kwiatkowski, J. L., 4602
Kwon, K. H., 3101
Kwong, D. L. W., 5019
Kyo, S., 1558
Kyprianou, N., 4864

L

Labrie, C., 60
Labrie, F., 60, 877
Lacey, D. L., 933
Lacini, E., 5825
Laffargue, F., 5367
Lafond-Walker, A., 4342
Lahti, J. M., 2624
Laing, N. M., 1332
Laken, S. J., 5267
Lakhani, S. R., 4721
Lallemant, F., 871
Lamant, L., 1057
Lamb, C. C., 1395
Lamm, G. M., 801
Lamph, W. W., 479, 5110
Landuzzi, L., 1225, 4127
Lanfranccone, L., 14
Lang, L., 2612
Langmark, F., 448
Lapidus, R. G., 2515
LaPushin, R., 5285
LaRoche, W. J., 5157
Larick, J. W., 5570
Larsen, C-J., 3926
Larsen, M. C., 2366
Larson, S. M., 4333
Larsson, C., 1004
LaRue, K. E. A., 1305
Lastoria, S., 1850
Latera, J., 2784
La Thangue, N. B., 1325
Lau, A. F., 4858
Lau, K., 5713
Laug, W. E., 2209
Laughlin, K. V., 1641
Laughlin, R., 2107
Laughner, E., 5280
Lauvau, G., 2969
Lavin, M. F., 84
Lavine, J. E., 2724
Lavrukhin, O. V., 887
Lawler, J., 3154
Lawlor, K. D., 4787
Lawlor, E. R., 2469
Lawrence, D., 55, 4173
Lawrence, T. S., 2588
Lázaro, C. A., 5514
Le, P. U., 1631
Leach, M. O., 1185
Leach, S. D., 3231
Le Beau, M. M., 3561
LeBoit, P. E., 2170
Leclerc, N., 1631
Le Dai, J., 4592
Leder, P., 5637
Lee, A. H., 1901
Lee, A. T., 3163
Lee, A. V., 4199
Lee, C., 947, 2801
Lee, C. S. L., 1353
Lee, C-W., 1494
Lee, E. R., 661
Lee, G-H., 1665
Lee, H., 328, 1338, 2528
Lee, H. K., 759
Lee, H. R., 5582
Lee, J., 1478
Lee, J. J., 2288
Lee, J. Y., 1140, 3787
Lee, J-Y., 504
Lee, K., 2741
Lee, M. J., 4155
Lee, M. P., 1052, 4155
Lee, M-J., 348
Lee, O-H., 348
Lee, S., 4947
Lee, S. H., 1140, 3787
Lee, S. J., 5770
Lee, S. W., 4439, 4782
Lee, S-D., 985
Lee, W. M. F., 491
Lee, W-H., 2699
Lee, W-J., 1494
Lee, Y. J., 1358
Lee, Y. S., 1140
Lehar, S., 570
Lehmann, J., 5662
Lehrnbecher, T. M., 5842
Lei, W., 2102
Lei, X-D., 921
Leighton, S. B., 5009
Leimer, M., 1850
Leitzmann, M., 5117
Lekstrom, K. J., 5144
Lemaigre, G., 3896
Le Marchand, L., 4858
Lemoine, N. R., 4461
Lengfelder, E., 198
Leonard, J. H., 1503
Leonetti, C., 283
Leong, L., 2793
Leppert, M. F., 4909
Lerner, S., 4552
LeRoith, D., 3021
Lesley, J. F., 3736
Leslie, K. K., 1860
Lethé, B., 743
Leung, D., 5713
Levasseur, L. M., 5749
Levenson, A. S., 1872
Lévi, F., 3896
Levin, A. M., 5267
Levin, H. S., 1456
Levine, V., 1538
Levine, A. C., 4245
Levine, K. S., 3819
Levine, R. L., 3254
Levero, M., 1325, 3566
Lewis, C. M., 2952
Lewis, J. L., 1417
Leygue, E., 1348, 3197
Lhuillery, C., 3529
Li, C., 2404
Li, D., 38, 2141
Li, G., 2176, 5523
Li, J., 4102, 5667
Li, J. T., 4358
Li, J-Y., 5640
Li, L., 3466, 5305
Li, L-Y., 4510
Li, Q., 5489
Li, W-P., 5559
Li, X. M., 3896
Li, Y., 3538
Li, Y-X., 5411
Li, Z., 5271
Li, Z-R., 4282
Lian, Z., 5406
Liang, F-X., 1291
Liao, M., 5523
Liao, W-C., 2260
Liaw, L., 5206
Lichtenstein, A., 256
Lichter, P., 29, 1798
Lidereau, R., 1004, 2081
Lieber, M. M., 759
Liekens, S., 2562
Lieubeau-Teillet, B., 4957
Lilja, H., 2537
Lillington, D. M., 633
Lim, D. D., 462
Lim, J. F., 2469
Lim, L. Y., 5701
Limoli, C. L., 3712
Lin, C-C., 4947

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 58

- Lin, J.-T., 1494
 Lin, Y. J., 5123
 Lin, Z. P., 3059
 Lindberg, D., 377
 Lindblom, A., 1004, 1376, 2923
 Lindblom, P., 1376
 Lindel, T., 1111
 Lindholm, E., 5374
 Linehan, W. M., 504, 1719
 Ling, G., 2449
 Ling, V., 4160
 Ling, Y.-H., 3633, 5389
 Ling, Y.-Z., 3826
 Lingen, M. W., 5551
 Linnainmaa, K., 4505
 Linnekin, D., 4660
 Linnoila, R. I., 5582
 Liotta, L. A., 2533, 5326
 Lipari, P., 4947
 Lipkin, M., 5713
 Lipman, J., 1730
 Lippens, R. J. J., 448
 Lippman, M. E., 3415
 Lipponen, P., 342
 Lipshultz, S. E., 195
 Liskay, R. M., 1087
 Lister-James, J., 1850
 Litman, E., 1860
 Little, J. B., 2036, 4277
 Litz, J., 4660
 Liu, A. Y., 232
 Liu, A.-x., 2973
 Liu, D. F., 3101
 Liu, G., 4913
 Liu, H., 4055
 Liu, J., 962
 Liu, J. M., 3538
 Liu, J.-j., 4180
 Liu, L., 4238
 Liu, M., 1723, 4947, 5418
 Liu, N., 3264
 Liu, P. C.-C., 704
 Liu, Q., 5690
 Liu, R. Y., 2217
 Liu, Wanguo, 759, 2347
 Liu, Wenbiao, 2288, 4008
 Liu, X., 2601, 4752, 5432
 Liu, X. H., 3896
 Liu, X.-H., 4245
 Liu, Y., 570, 3376, 3826
 Livingston, P. O., 2844
 Ljubimov, A. V., 4475
 Ljubimova, J. Y., 4475
 Ljung, A., 2449
 Ljung, B.-M., 3677, 5271
 Lloyd, R. S., 887
 Lo, H.-H., 4624
 Loadman, P. M., 5263
 Loda, M., 1730, 3732
 Lode, H. N., 2925, 3918
 Loe, D. W., 5130
 Loeb, L. A., 1013
 Löfman, E., 1451
 Loftus, D. J., 2433
 Loimas, S., 3791
 Lollini, P.-L., 1225, 4127
 Loman, N., 1367
 Lombard, M. A., 4001
 Long, B. H., 1111
 Long, B. J., 3259, 3264
 Long, L., 3243
 Longenecker, B. M., 4079, 5151, 5577
 Longmate, J., 2793
 Longo, K. A., 1866
 Longo, P. A., 5267
 Longy, M., 1588
 Lopes de Menezes, D. E., 3320
 López-Otín, C., 1624
 Lord, E. M., 1478
 Lorenzo, P. S., 1423
 Lothe, R. A., 2087, 2923
 Lott, S. T., 3533
 Lotto, A., 4701
 Lotze, M. T., 380
 Lou, W., 1391, 2350
 Loughlin, K. R., 1395
 Louis, D. N., 1825
 Loukola, A., 2087
 Lovato, L. C., 1149
 Lovell, M., 3533
 Lowry, D., 1435
 Lozano, G., 698
 Lu, C.-D., 1808, 5071
 Lu, D., 3209
 Lu, F.-m., 2293
 Lu, H., 84
 Lu, K. H., 2328
 Lu, M.-L., 1291
 Lu, Q., 3826
 Lu, S., 1253
 Lu, S. C., 1444
 Lu, Y., 3677, 5285
 Lu, Y.-J., 4721
 Lu, Z.-N., 933
 Lubensky, I., 1719
 Lubensky, I. A., 504, 4715
 Lubet, R. A., 921, 3282
 Lubinski, J., 2946
 Lucania, G., 4468
 Lucas, S., 743
 Luchetti, L., 562
 Ludwig, C. U., 626
 Lui, W.-Y., 985
 Luison, E., 4146, 5812
 Lukanidin, E., 1238, 4587
 Lukas, J., 5053
 Lum, A., 4858
 Lundberg, J., 2449
 Lundholm, K., 5374
 Lunec, J., 3932
 Luo, J. C., 2594, 2652
 Luo, L., 2293
 Luo, Y., 2727
 Lupu, R., 210
 Lurquin, C., 743
 Lush, R. D., 3248
 Lutz, M. P., 3551
 Luu, H. H., 3561, 4963
 Luzzatto, L., 2727
 Lyerly, H. K., 2965
 Lykkesfeldt, A. E., 4264
 Lynch, M. A., 4227
 Lyons, J. C., 2504
 Lyons, J. G., 4970
 Mackey, J. R., 4349
 MacLeod, P., 4086
 MacMeekin, W., 3932
 Madden, S. L., 5690
 Mader, R. M., 2982
 Mader, S., 5110
 Madsen, B., 4845
 Madsen, M. W., 4264
 Maeda, H., 159
 Maeda, M., 2550
 Maekawa, R., 2583
 Magee, P. N., 5380
 Magni, F., 3866
 Maher, M. G., 5466
 Mai, M., 2347
 Maier, C. C., 1217
 Maitland, N. J., 23
 Maki, C., 2036
 Maki, H., 2583
 Malecize, F., 1429
 Maliszewski, C., 380
 Malkas, L. H., 3259, 3264
 Malkowski, M., 4947
 Mallams, A. K., 4947
 Mallofré, C., 1762
 Malmström, A., 1099
 Maloisel, F., 5640
 Malumbres, M., 1253
 Manara, M. C., 4127
 Mancuso, T., 3654
 Mandes, B., 4708
 Mandekar, S., 402, 2102
 Manenti, G., 3401
 Manenti, S., 1429
 Manfioletti, G., 426, 4193
 Mangion, J., 863
 Mangold, G., 2568
 Manges, R., 1253
 Mani, K., 1099
 Mani, R. S., 4349
 Manjeshwar, S., 3677
 Manki, A., 1960
 Mann, J., 1469
 Mannervik, B., 2568
 Manseau, E. J., 1278
 Manshour, T., 4552
 Mantovani, F., 426
 Manzoli, L., 5057
 Mao, J. T., 1208
 Mao, L., 4082
 Mao, Z., 1444
 Marcelino, L. A., 2857
 Marcelli, M., 76
 Marches, R., 691
 Marconi, P., 5731
 Marcucci, G., 55, 790
 Marcusson, J. A., 2961
 Mareel, M., 4587
 Maren, C., 4799
 Maresco, D. L., 3193
 Margolin, K., 2793
 Margulies, I., 3215
 Mariani, A., 1843
 Maric, M., 3376
 Marignac, J. L., 4787
 Marinescu, R. C., 4537, 5023
 Marionnet, C., 102
 Maris, J. M., 3226
 Markiewski, M., 2946
 Markl, I. D. C., 5348
 Markowitz, S., 3101
 Marks, J. D., 485
 Marquis, J. C., 3435
 Marrugat, R., 1544
 Marsh, S., 5042
 Marshall, J. R., 2107
 Marshall, K., 485
 Marti, W. R., 4567
 Martin, M., 654
 Martin, M. L., 2253
 Martinelli, S., 135
 Martinez-Tello, F. J., 4193
 Martín-Satué, M., 1544
 Martinsson, T., 1372
 Martorana, A. M., 4970
 Maruta, F., 2067
 Maruyama, H., 4250
 Maruyama, K., 3526
 Maschek, H., 1124
 Masella, B., 562
 Maser, E., 2996
 Mashimo, T., 4572
 Mason, D. Y., 1057
 Mason, R. W., 904
 Massagué, J., 2727
 Mastro, A., 4193
 Masuda, A., 1042
 Mathiesen, T., 3226
 Matikainen, M.-T., 1599
 Matrisian, L. M., 5206, 5500
 Matsubara, A., 1509
 Matsubara, K., 2440
 Matsubara, N., 594
 Matsui, I., 3032
 Matsui, M., 4823
 Matsumoto, K., 5182
 Matsumoto, R., 609, 1793
 Matsumura, F., 704
 Matsumura, H., 2117, 2935
 Matsumura, T., 462
 Matsuno, S., 2456, 2838
 Matsuno, Y., 3700
 Matsushima, K., 3993
 Matsushima, M., 4585
 Matsushita, T., 5182
 Matsuchi, H., 1660
 Matsuzuka, F., 4913
 Matteucci, A., 5057
 Matutes, E., 1736
 Mauceri, H. J., 5686
 Maudelonde, T., 5367
 Maurer, C., 753
 Maurer-Gebhard, M., 2661
 Mawal-Dewan, M., 1
 Maxwell, G. L., 2500
 Mayer, R. J., 4173
 Maynard, R., 4740
 Mayo, M. S., 5738
 Mayumi, T., 290, 5725
 Mazière, J.-C., 3571
 McCall, A. M., 485
 McCarty, T. M., 2601
 McCormick, D. L., 3282
 McCue, P. A., 2946
 McDevitt, T. M., 2353
 McDonald, J. M., 1387
 McDonnell, S. K., 1713, 5473
 McGonigle, K., 2793
 McKeehan, W. L., 1509
 McKenna, W. G., 1754, 2639
 McLane, M. P., 2784
 McLeod, H. L., 5042
 McPherson, J. P., 4519
 McSheehy, P. M. J., 1185
 Medh, R. D., 3684
 Medrano, E. E., 47
 Megahed, M., 1798
 Megosh, L., 1654

M

- Ma, W.-y., 4102
 Maccubbin, A. E., 453
 Macdonald, J. S., 1149
 MacDonald, T. J., 2469
 Machado, J. C., 4086
 Macintosh, C. A., 23
 Macintyre, E. A., 2680
 Mackall, C. L., 5842
 Mackay, A. R., 2957
 Mäcke, H. R., 437

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 58

- Mehlen, P., 5495
 Mehta, S. R., 241
 Meijer, C. J. L. M., 1700, 3812
 Meisner, L. F., 5310
 Melani, C., 4146, 5812
 Melief, C. J. M., 724, 3087, 3094
 Meling, G. I., 2923
 Melki, J. R., 3508
 Melo, J. V., 421
 Meltzer, P. S., 5009
 Meltzer, S. J., 2929, 4802, 5248
 Melvin, W. S., 237
 Mencarelli, A., 14
 Mendelsohn, J., 2825
 Mendoza-Alvarez, H., 5075
 Mendrola, J., 3401
 Meng, Z. H., 5271
 Mensdorff-Pouilly, S., 4324
 Menzies, S., 5361
 Merkle, H., 5083
 Merlino, G., 5157
 Merriam, W. G., 334
 Mertens, F., 5859
 Mescher, M., 5083
 Mese, H., 462
 Meshorer, A., 2397
 Mett, H., 3883
 Metzger, S., 5803
 Metzger, U., 5559
 Meyer, D. J., 2353
 Meyer, D. M., 1930
 Meyer, H. E., 5803
 Meyers, J., 5321
 Meyers, M., 767
 Meyskens, F. L., Jr., 1149
 Mezzananza, D., 991
 Miano, M. G., 2888
 Mibu, R., 594
 Miccoli, L., 5777
 Michalides, R. J. A. M., 871
 Michel, K., 956
 Michels, V. V., 1713
 Middleton, K., 5389
 Midthun, D. E., 2533
 Mignotte, H., 1451
 Mihalik, R., 614
 Mihara, K., 5565
 Mihatsch, M. J., 2304
 Mike, N., 2149
 Miki, K., 4107
 Milas, L., 2404
 Miliareis, C., 5667
 Millenbaugh, N. J., 2141
 Miller, C. R., 5738
 Miller, D. E., 3409
 Miller, D. L., 219
 Miller, G., 4155
 Miller, G. J., 3116
 Miller, K., 4728
 Miller, M. J., 2196
 Miller, P. W., 1208
 Miller, W. H., Jr., 5110
 Mills, G. B., 2253, 5285
 Mimaya, J., 5182
 Mims, B., 698
 Min, C. J., 4581
 Minaguchi, T., 4585
 Mine, S., 4138
 Mineo, A., 4745
 Miner, J., 5271
 Minna, J. D., 1605, 3237
 Mintz, B., 630, 1521, 4061
 Misiura, K., 3773
 Mitchell, J. B., 1562
 Mitchell, M. A., 4001
 Mitchell, S., 2217
 Mitchell, T. I., 5321
 Mitra, S., 3950
 Mitsudomi, T., 1042, 3761
 Mitsumori, K., 5835
 Miwa, M., 1165
 Miwa, Y., 549
 Miyagawa, T., 4185, 4333
 Miyahara, E., 2117
 Miyajima, A., 556
 Miyake, M., 5182
 Miyao, N., 3800
 Miyashita, T., 3116
 Miyata, H., 4434
 Miyauchi, A., 4913
 Miyokawa, N., 296
 Miyoshi, I., 2618, 3344, 3370
 Miyoshi, Y., 1021, 2440, 2524, 3499, 5176
 Mizoguchi, H., 3773
 Mizoi, T., 1524
 Mizuguchi, H., 5725
 Mizutani, S., 900, 4923
 Moch, H., 2304
 Modica-Napolitano, J. S., 71
 Moerman, P., 2278
 Moffat, J., 500
 Mohan, A. L., 5489
 Mohler, J. L., 3603, 5718
 Mohrenweiser, H., 604
 Moiraghi, L., 5032
 Mok, S. C., 2328
 Moky, M. B., 5301
 Möller, P., 526, 4930
 Momburg, F., 2149
 Momma, T., 5425
 Monaco, C., 823
 Monden, M., 2440, 5176
 Monden, T., 114, 2440
 Monneret, C., 1195
 Monnet, I., 840
 Monsaert, C., 5646
 Montera, M., 4799
 Montgomery, J. C., 3401
 Montserrat, E., 1762
 Montuori, N., 1315
 Mooijart, R. J. D., 3094
 Mookerjee, B., 4531
 Moon, R. D., 921
 Moon, T. E., 479
 Moore, D., 3555, 3677
 Moore, J. V., 4426
 Moore, M. J., 947
 Moore, S. M., 5239
 Moossa, A. R., 4217
 Morava-Protzner, I., 542
 Morecki, S., 3891
 Morgan, A. S., 2568
 Morgan, D. L., 1435
 Morgan, R. J., Jr., 2793
 Morgan, W. F., 3712
 Mori, N., 3993
 Mori, Y., 3806
 Morikawa, T., 322
 Morimatsu, M., 3441
 Morimoto, A., 2331
 Morimoto, I., 4138
 Morin, P. J., 1130
 Morineau, N., 5640
 Morisawa, K., 1813
 Morita, S., 4913
 Moriuchi, S., 5731
 Moriyama, H., 594
 Morland, S. J., 1707, 2095
 Morlière, P., 3571
 Moro, O., 47
 Moroni, M., 5818
 Morra, F., 815
 Morris, S. W., 1057
 Morrison, S. L., 3905
 Morrow, J. D., 362, 2323
 Morse, M. A., 2965
 Morton, C. L., 20, 2646, 3627
 Moses, M. A., 1395
 Moslehi, R., 2919
 Moss, D. J., 310
 Mossman, B., 4543
 Mossman, B. T., 189
 Motoki, K., 1202
 Motzer, R. J., 4260
 Moutet, M., 5495
 Mowles, D., 4349
 Moy, E. L., 3508
 Moy, P., 4055
 Mrózek, K., 55
 Mrsny, R. J., 519
 Mudipalli, A., 4282
 Mueller, H., 622
 Muggenburg, B. A., 1417
 Mujumdar, U. J., 5267
 Mukaida, N., 3993
 Mukattash, R., 5201
 Mukherjee, P., 5231
 Mukherji, B., 1363, 5305
 Mukhopadhyay, D., 1278
 Mukhopadhyay, T., 4761
 Mukhtar, H., 1785
 Mulder, K. M., 4752
 Mulders, P., 956
 Mullenders, L. H. F., 1978, 2850
 Muller, C., 1789
 Müller, C. A., 5803
 Müller, J., 2703
 Müller, M., 2982, 4728, 5439
 Muller, M. T., 976
 Müller, S., 2541
 Müller, V., 263
 Muller, W. J., 5500
 Mullin, J. M., 1641
 Multani, P., 4211
 Multon, M.-C., 1170
 Münch, K., 1583
 Munker, R., 4728
 Muntané, J., 1762
 Murai, H., 641
 Murakami, A., 2550, 4832
 Murali, D., 3782
 Muramatsu, H., 3761
 Muramatsu, S., 3339
 Murata, M., 2524
 Murata, Y., 5176
 Murphy, L. C., 1348, 3192, 471
 Murtha, A. D., 1779
 Murthy, G. G. K., 2633
 Murthy, L., 392
 Murty, V. V. V. S., 2727, 4260
 Muscarella, P., 237
 Muschel, R. J., 1754, 2020, 2639
 Musser, S. M., 2385
 Muto, M., 2991
 Muto, P., 1850
 Myeroff, L., 3101
 Myers, M. P., 5667
 Myöhänen, S. K., 591
- N**
- Na, E. Y., 1140, 3787
 Nabi, I. R., 1631
 Nachman, A., 1524
 Nadal, A., 1762
 Nadeau, J. H., 3694
 Naef, M., 753
 Naegeli, H., 1978
 Nagabhushan, T. L., 2489
 Nagao, M., 1127
 Nagasawa, H., 2036
 Nagasawa, Y., 2524
 Nagase, H., 4468
 Nagata, M., 3499
 Nagata, Y., 3385
 Nagura, H., 3491
 Nagy, A., 2537, 4132
 Nagy, J. A., 1278
 Naidoo, D., 473
 Naiki, H., 1108
 Nair, M. G., 3036
 Nair, S. K., 2965
 Naito, Y., 3491
 Naitoh, J., 2895
 Nakae, D., 4548
 Nakagama, H., 1127
 Nakagawa, H., 5176
 Nakagawa, R., 1202
 Nakagawa, S., 5725
 Nakagawa, T., 5725
 Nakagawara, A., 2076, 2158, 4238
 Nakajima, E., 594
 Nakajima, T., 5478
 Nakajima, Y., 1105
 Nakamori, S., 1021
 Nakamura, H., 1202, 1972, 3385
 Nakamura, J., 222
 Nakamura, S., 1042, 3761
 Nakamura, T., 4138
 Nakamura, Y., 1021, 2158, 2524, 3499, 4585, 4832, 5176
 Nakane, H., 641
 Nakanishi, M., 5725
 Nakanishi, T., 5725
 Nakanishi, Y., 2991
 Nakao, M., 5182
 Nakashima, R., 4227
 Nakashiro, K.-i., 549
 Nakatsu, Y., 641
 Nakayama, E., 1960
 Nakayama, F., 512
 Nakazawa, N., 5182
 Namiki, M., 2240
 Nanni, P., 1225, 4127
 Narayanan, R., 622
 Narimatsu, H., 512
 Narod, S. A., 2919
 Narumiya, S., 2282
 Naruse, K., 900
 Nass, S. J., 2515
 Nassif, N., 5310
 Nasu, M., 4255
 Nath, R. G., 581
 Nathan, C., 717
 Nauta, L. E., 3542
 Navab, R., 3243
 Navar, G. L., 4940
 Navarro, B., 1736
 Navarro, V., 4055
 Nawa, A., 900
 Naylor, S. L., 3533
 Negrini, M., 3777
 Nelsen, L. L., 2253
 Nelson, H. H., 1804
 Nelson, P. S., 232
 Nemoto, T., 2107
 Nervi, C., 5110

- Neumann, A. A., 3508
 Neumann, E., 4090
 Neumann, H., 1719
 Nevanlinna, H., 2715
 Neven, P., 2278
 Newbold, R. F., 2863, 4572
 Newland, A. C., 633
 Newlands, E. S., 4363
 Newman, E. M., 2793
 Newman, R. A., 2404
 Newmark, H., 5713
 Neyts, J., 384, 2562
 Nezu, M., 2991
 Ng, E. Y., 2588
 Nguyen, H. D., 1245
 Nguyen, J. T., 5673
 Nguyen, T. D. T., 1245
 Nguyen, T. N., 1631
 Nibu, K.-I., 5523
 Nicholls, J. M., 310, 5019
 Nicholson, J. C., 3668
 Nickols, G. A., 1930
 Nickols, M. A., 1930
 Nicola, T., 5
 Nicolaou, K. C., 2925
 Nicoletti, G., 1225, 4127
 Nicosia, D., 4146
 Nicosia, S. V., 2973
 Nie, D., 4047
 Nie, J., 1813
 Nielsen, L., 4947
 Nielsen, M.-B., 2433
 Niinaka, Y., 2667
 Niinuma, K., 5137
 Niitsu, Y., 1677, 2568
 Nijhof, W., 4840
 Nimer, S. D., 2727
 Nimura, Y., 2076, 2158
 Nirde, P., 5367
 Nisen, P. D., 3504
 Nishi, M., 322
 Nishihara, S., 512
 Nishikawa, K., 5182
 Nishimoto, H., 1048
 Nishimura, N., 4044
 Nishiyama, A., 462
 Nishizaki, M., 2288
 Nishizaki, T., 4694
 Nishizono, A., 4255
 Nistér, M., 5275
 Nitiss, J. L., 1460
 Niwa, K., 5406
 Njoroge, F. G., 4947
 Nnane, I. P., 3826
 Noble, J. R., 3508
 Noda, I., 794
 Nodzenski, E., 3215
 Noe, M., 4733
 Noguchi, M., 3700
 Noguchi, T., 1588
 Nohmi, T., 1833
 Nolan, G. P., 14
 Nomeir, A. A., 4947
 Nomoto, K., 3073
 Nomoto, S., 1380
 Nomura, T., 1105
 Nooijen, P. T. G. A., 4880
 Nooijen, W. J., 2410
 Noppen, C., 4567
 Nordling, M., 1372
 Nordlund, J. J., 47
 Nordqvist, A.-C. S., 4113
 Noronha, E. J., 2417
 Norppa, H., 4117
 North, W. G., 1866
 Norton, L., 1839, 2825
 Noss, A., 5787
 Notter, M., 2707
 Nouel, A., 1736
 Novault, S., 2680
 Novogrodsky, A., 2397
 Novotny, D. B., 3765
 Nozaki, M., 609
 Nozawa, S., 3526
 Nusskern, D. R., 204
- O**
- Obata, K., 2095
 Öberg, K., 2375
 Oberkircher, A. R., 55
 Oberley, L. W., 2809
 Obici, L., 991
 O'Brien, S., 4552
 O'Brien, T. G., 1654
 Ocando, J. E., 581
 O'Connell, M. J., 1713
 O'Connor, R., 570, 2477
 Odashima, S., 2550, 4811
 Ødum, N., 2433
 Oertli, D., 4567
 Oesterreich, S., 3004
 Offerhaus, G. J., 5267
 Offerhaus, G. J. A., 4740
 Offit, K., 1839, 2727, 3193
 Offringa, R., 724, 3087, 3094
 Ogata, N., 149
 Ogawa, M., 2426, 3761
 O'Grady, R. L., 4970
 Ogunfusika, M. O., 334
 Oguri, T., 5565
 Ohashi, M., 1946
 Ohashi, P. S., 4682
 Ohgaki, H., 2057
 Ohigashi, H., 2550, 4832
 Ohira, M., 3032
 Ohishi, N., 3773
 Ohkubo, I., 2353
 Ohlsson, H., 4264
 Ohnishi, T., 2117, 2440, 2935
 Ohnishi, Y., 2456
 Ohnuma, N., 2158
 Ohta, M., 2946, 3401
 Ohta, S., 5182
 Ohta, T., 1095
 Ohtani, H., 3491
 Ohto, Y., 4832
 Ohuchi, A., 3491
 Ojugo, A. S. E., 1185
 Oka, M., 4107
 Oka, T., 5182
 Okada, Y., 2240
 Okajima, E., 3028
 Okami, K., 204, 509, 4233
 Okamoto, K., 1095
 Okamoto, T., 1677
 Okamoto, Y., 2343
 Okcu, M. F., 1538
 Oku, T., 4185, 4333
 Okubo, K., 2440
 Okuda, T., 5182
 Okumura, Y., 5188
 Okura, H., 512
 Okuyama, A., 641
 Olah, E., 1004
 Old, L. J., 1034
 Oldfield, E. H., 4715
 Oleinick, N. L., 940
 Oliff, A., 1253
 Oligino, T., 5731
 Oliveri, R. S., 1460
 Olivotto, M., 815
 Olsson, H., 1367
 Olsson, K., 3957
 Oltersdorf, T., 5315
 Olumi, A. F., 4525
 Omata, M., 1946
 Omotchara, F., 549
 Ong, H., 4682
 Onimaru, R., 1793
 Onishi, S., 1813
 Ono, M., 1813
 Ono, T., 1960
 Onose, R., 704, 4888
 Onozawa, C., 704
 Ooasa, T., 1665
 Ooms, M. E., 724
 Ootsuyama, A., 5649
 Oren, R., 5825
 Orimo, H., 594
 Orlandi, F., 3015
 Orlow, S. J., 1521
 Orłowski, M., 4342
 Orłowski, R. Z., 4342
 Ormandy, C. J., 1353
 Ormandy, H. F., 1353
 Orr, E. A., 2020
 Orth, K., 4667
 Ortiz, N., 3668
 Osada, H., 704, 1042, 4888
 Osanai, M., 1665
 Oscier, D., 1736
 Oser, S. M., 334
 Oshimura, M., 5188
 Osin, P., 4721
 Osman, I., 1291
 Ostrand-Rosenberg, S., 1486
 Ostrowski, M. C., 2253
 Ota, K., 1813
 Ota, T., 2550, 4811
 Otsuka, T., 5157
 Otsuki, T., 3538
 Otsuki, Y., 2343
 Ottenhoff, T. H. M., 724
 Ouchi, K. F., 1165
 Oudard, S., 5777
 Oudshoorn, M. J., 4616
 Ouyang, H., 2456
 Overgaard, J., 2166
 Overhauser, J., 4537, 5023
 Overkamp, W. J. I., 2863
 Owen, G., 1860
 Owens, G. C., 2020
 Owens, J. W., 5157
 Oyama, T., 2876
 Ozaki, K., 3499, 3806
 Ozaki, S., 4694
 Ozaki, T., 2158
 Ozawa, H., 4138
 Özçelik, H., 785
 Özelius, L. J., 5321
 Ozono, S., 3028
 Ozturk, M., 1451
- P**
- Pacelli, K. A., 3059
 Pacilio, C., 871
 Pack, S., 4715
 Padayatty, S. J., 76
 Pagano, J. S., 384
 Pagano, M., 1730
 Pagano, S., 3566
 Pai, R. B., 1909
 Pai, S. B., 1909
 Pai, S. I., 3513
 Pairolero, P. C., 2533
 Paku, S., 2667
 Pal, A., 5340
 Palacios, J., 1344
 Palanisamy, N., 4260
 Palazzo, J. P., 4708
 Paljärvi, L. A., 3791
 Pall, G., 4918
 Pan, J., 5019
 Panasci, L., 1789
 Pandolfi, P. P., 2007
 Pang, D., 3495
 Pang, S., 956
 Pangerl, T., 1850
 Panvichian, R., 4667
 Pao, M. M., 95, 1245
 Paoletti, P., 4122
 Paperin, M.-P., 1451
 Papoian, T., 195
 Papp, J., 1004
 Parenza, M., 1225, 5812
 Park, B. C., 348
 Park, H. J., 2504
 Park, S., 2618
 Park, S.-H., 1144
 Park, W. S., 1140, 3787
 Park, W.-S., 504
 Parker, J., 4079
 Parkes, S., 448
 Parkhurst, M. R., 4895
 Parkkinen, J., 342
 Parl, F. F., 65, 2515, 5038
 Parmiani, G., 2433, 4146
 Parodi, S., 3654
 Parsian, A. J., 3986
 Parsons, R., 5667
 Partanen, T. A., 1599
 Pasche, B., 2727
 Passaro, E., Jr., 4417
 Pastan, I., 268, 968, 2612, 3215, 3649, 4688
 Pastorino, U., 5032
 Patel, K. J., 1338
 Patierno, S. R., 3059
 Patil, S. R., 4173
 Patterson, A. V., 2737
 Patton, S. E., 2253
 Patya, M., 2397
 Paul, C., 2568
 Paulo, E., 5271
 Paulsen, H., 2541
 Paulson, D., 3603
 Pauluschke, J., 5662
 Paus, R., 2707
 Pavan, A., 4468
 Pawlik, C. A., 20, 2646
 Pawlita, M., 4930
 Payne, G., 570
 Payne, J., 3415
 Payne, M. M., 947
 Paz, B., 2793
 Pazzagli, C., 2042
 Pearce, J., 5263
 Pearson, A. D. J., 3932
 Peck, K., 2761
 Peck-Radosavljevic, M., 1850
 Pedersen, N., 1843
 Pegg, A. E., 1936, 2748, 5380
 Pegg, J. A., 1930
 Pegram, M. Y., 3668

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

- Pekarsky, Y., 2946, 3401
 Pelicci, P. G., 14
 Pelliçer, A., 1253
 Pelling, J. C., 1723
 Peloux, N., 1451
 Pemberton, P. A., 5681
 Pena, J. C., 2111
 Peng, A., 5089
 Peng, F., 47
 Pentimalli, F., 4193
 Peralta, E. A., 2601
 Peralta Soler, A., 1654
 Perantoni, A. O., 3590
 Pere, H., 892, 4274
 Pérez-Díez, A., 5305
 Perez-Perez, G. I., 588
 Perez-Soler, R., 3633, 5389
 Perini, R., 283
 Perkins, C., 3202, 4561
 Perlman, E. J., 3105
 Pernow, Y., 4113
 Perri, P., 5014
 Perrotte, P., 808
 Perry, R. H., 3932
 Persson, S., 1099
 Perucho, M., 997
 Peruzzi, D., 5057
 Pescarolo, M. P., 3654
 Peschle, C., 14, 562
 Pestka, S., 2489
 Peták, I., 614
 Peters, G., 1353
 Petersen, G. M., 5267
 Peterson, L. A., 5326
 Petkov, P. M., 5825
 Petluru, P. N. V., 3782
 Petrarca, C., 4324
 Petrizzzi, V. B., 871
 Petrovic, L. M., 4475
 Petruzzelli, S., 4122
 Pettenati, M. J., 4173
 Pettersson, C., 5374
 Petzold, G. L., 4001
 Peyrat, J-P., 1588, 4066
 Peyrat, M-B., 3529
 Pezzella, F., 5032
 Pfahl, M., 4607, 4817
 Pfeffer, L. M., 2489
 Pfuhl, A., 5
 Phang, J. M., 2379
 Phelan, C. M., 1004
 Phillips, R. M., 5263
 Picci, P., 4127
 Piché, A., 2134
 Piedrafit, F. J., 4607
 Pienta, K. J., 4667
 Pierce, G. F., 933
 Pierce, J. H., 3415
 Pierce, L., 4858
 Pierotti, M. A., 5032
 Piers, E., 5701
 Pierson, C., 4047
 Pietenpol, J. A., 3231
 Pietsch, T., 4480
 Pihan, G. A., 3974
 Pike, M. C., 585, 4497
 Pilarski, L. M., 3320
 Pilat, M. J., 4667
 Platte, Y., 840
 Pilotti, S., 5032
 Pink, J. J., 1876
 Pinkel, D., 1972, 2170
 Pinto, E., 4086
 Pitchford, S., 2784
 Pittman, B., 4096
 Pivano, G., 3015
 Pizer, E. S., 4611
 Pizzomo, G., 5418
 Planchon, S. M., 1876
 Plank, T. L., 4766
 Plate, J., 2832
 Plonowski, A., 4132
 Plötz, B., 5662
 Plouzek, C. A., 2379
 Plymate, S. R., 232
 Pohida, T., 5009
 Pohl, C., 1116
 Pohl, T., 2707
 Polverini, P. J., 5551
 Polymeropoulos, M. H., 5267
 Pommier, Y., 2576
 Pompella, A., 2693
 Ponder, B., 1004
 Ponder, B. A. J., 1338, 4086
 Pontén, F., 2449
 Pontén, J., 2449
 Pooley, F. D., 4505
 Popescu, N. C., 2196
 Poptani, H., 3791
 Porcellini, A., 2888
 Poremba, C., 2469
 Porschen, R., 3942
 Porta, C., 5818
 Porter, A. T., 3466
 Porter, C. W., 3883
 Portolani, N., 2234
 Poruchynsky, M. S., 3331
 Potten, C. S., 933, 5453
 Potter, P. M., 20, 2646, 3627
 Poulaki, V., 3021
 Poupon, M-F., 5777
 Pourquier, P., 2576
 Powell, B. L., 55
 Powell, D. J., Jr., 5523
 Powell, S. M., 34, 4086
 Pozzi, S., 4799
 Praml, C., 5014
 Prasnikar, N., 1583
 Prescott, S. M., 4909
 Pressman, P., 1839
 Pretlow, T. G., 5718
 Price, C. M., 1736
 Price, S. A., 2359, 4827
 Prifti, S., 5439
 Primus, F. J., 1469
 Prinsep, M. R., 3571
 Prioli, N., 4947
 Pritchard, D. M., 5453
 Proffitt, J., 759
 Proietti, E., 5795
 Prosiak, M., 4233
 Prough, R. A., 921
 Przyborski, S. A., 4598
 Ptaszniak, A., 4980
 Puisieux, A., 1451
 Pujol, P., 5367
 Pulaski, B. A., 1486
 Pulerà, N., 4122
 Pulford, K. A. F., 1057
 Puligheddu, B., 3015
 Pulyaeva, H., 5529
 Pumphrey, J. G., 535
 Punturieri, A., 5221
 Puri, P. L., 1325
 Puri, R. K., 3649
 Purohit, A., 3974
 Putz, T., 4640
 Puumalainen, A-M., 3791
 Pyon, K. H., 1417
 Pysher, T. J., 5046
 Pytowski, B., 3209
- Q**
- Qian, C., 2347
 Qian, J., 389, 759
 Qian, Y., 1754
 Quan, G., 1149
 Quesenberry, P., 3974
 Quinn, D. L., 1773
- R**
- Raab-Traub, N., 384
 Rabbani, H., 2293
 Rabbani, S. A., 3461
 Raben, D., 5738
 Rabenhorst, S. H., 4701
 Rabes, H. M., 198
 Rabindran, S. K., 5850
 Radford, I. R., 2817
 Raffel, C., 896
 Raffoux, C., 310
 Ragnarsson, G., 4421
 Ragno, P., 1315
 Ragupathi, G., 2844
 Rahmann, H., 779
 Rahmati, R., 4055
 Rajan, P., 1839
 Rajasekaran, A. K., 4055
 Rajput, A., 3101
 Rak, J., 4957
 Raleigh, J. A., 3547, 3765
 Ramachandra, M., 4688
 Ramadani, M., 2703
 Ramakrishna, V., 4146
 Ramakrishnan, S., 622
 Ramana, C. V., 3950
 Ramanathan, R., 3957
 Ramanujam, K. S., 2929
 Ramaswamy, A., 1124
 Ramljak, D., 3590
 Rammensee, H-G., 732
 Ramsay, R. G., 5168
 Ramsey, E. E., 5123
 Ramus, S. J., 4086
 Ran, S., 4646
 Rancourt, C., 1893, 2134
 Rankin, W., 4113
 Ranzani, G. N., 5248
 Rao, C. V., 409
 Rao, K. V. N., 3282
 Rao, P. H., 2727, 4260
 Rao, P. N., 55
 Rapp, M-J., 5640
 Rapp, U. R., 1636, 2986
 Raschko, J., 2793
 Rastad, J., 377
 Ravi, R., 882, 4531
 Rayburn, H., 848
 Raygada, M., 654
 Raz, A., 2667
 Raza-Egilmez, S. Z., 4269
 Reading, C., 3957
 Reardon, J. T., 5196
 Recchi, M-A., 4066
 Reddel, R. R., 3508
 Reddish, M. A., 5151
 Reddy, B. S., 409
 Reddy, D. G., 3782
 Redston, M., 785, 4040
 Reed, A. L., 509
 Reed, J. C., 256, 2134, 3116, 4940, 5315
 Reeder, J. A., 3719
 Reeves, C., 4155
 Regimbald, L. H., 5577
 Rehemtulla, A., 2588
 Reich, R., 808
 Reichardt, J. K. V., 4497
 Reichart, D. B., 1159
 Reichert, T. E., 5344
 Reid, N., 23
 Reifenberger, G., 29, 1798
 Reifenberger, J., 1798
 Reimer, C. L., 4439
 Reinhardt, J. C., 4096
 Reinikainen, M., 5291
 Reisfeld, R. A., 2925, 3743, 3918
 Reiss, K., 3353
 Reiss, M., 1986, 4805
 Reiter, A., 2618
 Remiszewski, S., 4947
 Remmink, A. J., 1700
 Ren, C., 1285
 Ren, J. P., 1538
 Ren, Z-P., 2449
 Renault, B., 2727
 Renkonen, R., 1599
 Renner, S., 256
 Repp, R., 3051
 Reske, K., 4107
 Resnick, M. A., 5333
 Resnicoff, M., 2477
 Resnik, J. L., 1159
 Rensing, M. E., 724
 Resta, N., 4799
 Rettig, M., 256
 Retz, M., 5662
 Reuter, V. E., 4260
 Reuterwall, C., 4117
 Rex, K. L., 933
 Rey, J-M., 5367
 Reynolds, C. P., 5396
 Reynolds, P. N., 5738
 Reznikoff, C., 767
 Rezzani, R., 737
 Rhee, E., 5523
 Rhee, S-G., 5057
 Rhei, E., 3193
 Rhim, J. A., 5514
 Rice, M. C., 4733
 Riché, C., 468
 Richer, J., 1860
 Richter, J., 2304
 Rickard-Dickson, K., 1469
 Riddick, D. S., 947
 Rieber, M., 5876
 Rieber, M. S., 5876
 Rifai, N., 195
 Riganelli, D., 14
 Riggins, G., 509
 Riminucci, M., 535
 Rimm, E. B., 442, 5117
 Rinker, L. H., 3765
 Rinker-Schaeffer, C. W., 3561, 4572, 4963
 Rintoul, R. C., 5239
 Rio, P., 1004
 Riopel, M. A., 3105
 Rioseco-Camacho, N., 5280
 Rioux, N., 5354
 Risch, H. A., 588
 Risinger, J. I., 2500, 2978, 3579
 Risse, E. K. J., 3812
 Ristimäki, A., 4997

- Ritchie, D. S., 3909
 Ritland, S. R., 2675
 Riva, S., 5818
 Rivenson, A., 4096
 Rivera, J., 2528
 Rivi, R., 2007
 Rivoltini, L., 2433
 Rivory, L., 468
 Rixe, O., 4577
 Rizzo, P., 4505
 Robbins, J., 1965
 Robbins, P. F., 3519
 Roberge, M., 5701
 Roberson, M. S., 3163
 Robert, J., 468
 Roberts, D. D., 3154
 Robertson, C., 3603
 Robertson, J., 4909
 Robertson, M., 4909
 Robinson, C. R., 1405, 1750
 Robinson, S. P., 1185
 Roboz, J., 2126
 Robson, M., 1839
 Robson, M. E., 3193
 Roche, P. C., 1713, 3455
 Rochefort, H., 5367
 Rockwell, P., 3209
 Roddie, M., 4363
 Rodella, L., 737
 Röder, C., 5662
 Rodolfo, M., 5812
 Rodov, S., 1027
 Rodrigues-Lima, F., 2733
 Rodriguez, G. C., 5546
 Rodriguez-Bigas, M. A., 997, 5248
 Rodriguez-Valenzuela, C., 3264
 Roeder, C., 1741
 Roffler, S. R., 2761
 Roger, P., 5367
 Rogers, F. A., 4864
 Rogers, M. J., 5294
 Rogler, C., 2881
 Rognum, T. O., 2923
 Rokhlin, O. W., 5870
 Rollman, O., 2449
 Romano, G., 2477
 Romano-Spica, V., 5337
 Rommens, A. J. M., 4616
 Ronchese, F., 3909
 Rong, H., 4113
 Roninson, I. B., 3423
 Roodi, N., 65, 5038
 Rooney, P. H., 5042
 Roos, E., 1569
 Ropponen, K., 342
 Rosati, B., 815
 Roschke, V., 535
 Rosen, D. M., 2385
 Rosen, P. P., 1839
 Rosenauer, A., 5110
 Rosenberg, S. A., 3519, 4895, 4902
 Rosenstein, B. S., 976
 Rosenthal, D., 3495
 Rosenthal, D. S., 4510
 Rosenthal, E. L., 5221
 Rosenthal, M. A., 5168
 Rösner, H., 779
 Ross, M. M., 5144
 Ross, R. K., 1620, 4497
 Rossi, G., 1315
 Rossi, I., 1225
 Rossini, F. P., 4799
 Rote, N., 4646
 Roth, J., 5559
 Roth, J. A., 2288, 4761
 Roth, M., 956
 Roth, S., 2087
 Rothman, N., 2176
 Rothstein, J. L., 5523
 Rotter, V., 5447
 Rotterdam, H., 114, 588
 Roughley, P. J., 1348
 Roviello, F., 4086
 Rowse, G. J., 315, 2675
 Ruan, S., 1538
 Rubie, H., 448
 Rubio, C., 1376
 Rubsam, L. Z., 3873
 Rückert, R., 2707
 Rudikoff, S., 535
 Rudin, C. M., 2111, 3331
 Rudolph-Owen, L. A., 5500
 Rugge, M., 4708
 Rui, H., 1914
 Ruiter, D. J., 4880
 Ruiz, P. J., 5447
 Ruminski, P. G., 1930
 Rupnow, B. A., 1779
 Rusch, V., 4505
 Rusin, M., 2533
 Russ, G., 4688
 Russell, J., 5523
 Russell, R., 5418
 Russell, R. G. G., 5294
 Russell, R. L., 3059
 Russo, P., 3654
 Russo, T., 2888
 Rustighi, A., 426
 Rustin, G. J. S., 4363
 Rustum, Y. M., 1695, 3036, 3270, 5749
 Rutkowski, J. L., 4602
 Rutter, J. L., 5321
 Ruutu, T., 55
 Ruzicka, T., 1798
- S**
- Sacchi, A., 3866
 Sacré-Salem, B., 3529
 Sadata, A., 1946
 Sadee, W., 519
 Sadler, R., 384
 Sadoff, M. M., 4537
 Saeed, M. F., 3684
 Saeki, H., 2838
 Safabakhsh, N., 5866
 Safer, M., 4333
 Sage, E. H., 5529
 Sager, R., 5681
 Saggiorato, E., 3015
 Saibara, T., 1813
 Said, J. W., 3344
 Saigenji, K., 3491
 Saigo, P. E., 3193
 Sailer, B. L., 413
 Saito, H., 794
 Saito, K., 3491
 Saito, R., 5478
 Saiji, M., 2063
 Sakaki, Y., 4107
 Sakakibara, M., 4307
 Sakamaki, S., 1677
 Sakamoto, M., 3526
 Sakiyama, S., 2158
 Sakurai, K., 1099
 Sakurai, N., 2838
 Salen, G., 1684
 Salles, B., 1789
 Salloum, R. M., 5686
 Salmona, M., 3654
 Salnikow, K., 2182
 Salovaara, R., 2087
 Saltzman, W. M., 672
 Salven, P., 1599
 Salzano, S., 871
 Salzmann, J.-L., 3529
 Samson, L. D., 3965
 Samuel, S. K., 3004
 Sanchez, A. M., 3845
 Sánchez-Barceló, E. J., 4383
 Sandefur, C., 5310
 Sanderson, P. E., 2568
 Sandström, R., 5374
 Sané, A.-T., 3066
 Sanford, M. A., 3221
 Sang, H., 4548
 Sangregorio, R., 3866
 Sano, T., 5285
 Santamaria, I., 1624
 Santell, R. C., 3833
 Santella, R. M., 3448
 Santelli, G., 823, 4745
 Santen, R. J., 927
 Santini, S. M., 5795
 Santoni-Rugiu, E., 123
 Santoro, E., 4708
 Santoro, M., 823, 4193, 4745, 5523
 Santoro, R., 4708
 Santoro, S. A., 2224
 Santus, R., 3571
 Sapi, E., 1027
 Sarantaus, L., 2715
 Sarasin, A., 102, 4402
 Sard, L., 5032
 Sarkaria, J. N., 4375
 Sarma, S., 3376
 Sasajima, T., 4185, 4333
 Sasaki, A., 462
 Sasaki, H., 1677, 2991, 5649
 Sasaki, K., 4694
 Sasaki, Y., 2524, 3028, 3248, 3385
 Sasco, A. J., 448
 Satagopan, J. M., 2727
 Satgé, D., 448
 Sato, H., 2240
 Sato, K., 296
 Sato, M., 549
 Sato, T., 1677
 Satoh, K., 4222
 Satoh, M., 3800, 4044
 Satoh, R., 4255
 Saukkonen, K., 4997
 Saunders, N. A., 1646
 Sausville, E., 5315
 Sausville, E. A., 3248
 Sauter, G., 2304, 3555
 Sauvan, R., 1588
 Savelyeva, L., 863, 5014
 Sawada, N., 685
 Sawai, H., 997
 Sawamura, Y., 609, 1793
 Sawaya, B. E., 4233
 Sawicki, M. P., 4417
 Sayers, T. J., 3391
 Scaglione-Sewell, B., 1074
 Scanlan, M. J., 1034
 Scatena, C. D., 3231
 Schaaf, L. J., 2410
 Schaber, J. D., 1914
 Schaefer, C., 4567
 Schaid, D. J., 1713, 5473
 Schalkwijk, L., 4880
 Schally, A. V., 2537, 4132
 Scharff, M. D., 3905
 Schendel, D. J., 3078
 Schepers, R. J., 1700
 Scher, H., 1291
 Scher, H. I., 3009
 Scherneck, S., 1004
 Scheuermann, R. H., 691
 Schier, R., 485
 Schiestl, R. H., 2633
 Schiffer, C. A., 55, 4173
 Schirmer, W. J., 237
 Schirmacher, V., 5439
 Schlag, P., 863
 Schliess, F., 4297
 Schmid, R., 2982
 Schmidt, L., 1719
 Schmidt, M., 2661
 Schmidt, M. A., 437
 Schmiegel, W., 1124
 Schmitt, A., 4155
 Schmitt, M., 3385
 Schmitz, S.-F. H., 5559
 Schmutte, C., 4537, 5023
 Schnaper, L., 3259, 3264
 Schned, A. R., 2078
 Schneider, N. R., 3237
 Schnieders, B., 4292
 Schoenberg, J. B., 588
 Schoenberger, S. P., 3087, 3094
 Schoenlein, P. V., 3845
 Scholes, A. G. M., 2003
 Schönberg, S. O., 3598
 Schraml, P., 626, 2304
 Schrappe, M., 2618
 Schreurs, M. W. J., 2509
 Schriml, L. M., 5337
 Schroers, A., 1124
 Schumacher, G., 4761
 Schuster, T., 2986
 Schutte, M., 4592, 5652
 Schütz, A., 4567
 Schuurhuis, D. H., 724
 Schwab, M., 863, 5014
 Schwab, M. E., 149
 Schwabe, D., 367
 Schwarte-Waldhoff, I., 1124
 Schwartz, E. L., 1551
 Schwarzbauer, J. E., 3586
 Schweighoffer, F., 1170
 Sckell, A., 5866
 Scotlandi, K., 4127
 Scudiero, D., 3116
 Scudiero, D. A., 5315
 Seal, S., 1384
 Sebestyén, A., 614
 Sebt, S. M., 1754
 Seeger, R. C., 2209, 5396
 Seelentag, W. K. F., 5559
 Seely, B. L., 1159
 Seetharam, S., 3215
 Seetharamulu, P., 3782
 Seftor, E. A., 5681
 Seftor, R. E. B., 5681
 Segall, J. E., 2528
 Segawa, T., 2282
 Sehested, M., 1460
 Sehgal, I., 4288
 Seibert, K., 409
 Seifried, A., 4858
 Seiki, M., 2240
 Seino, Y., 1960
 Seitz, S., 1004

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 58

- Seki, N., 2158
 Seki, T., 3806
 Sekiguchi, F., 685
 Sekimoto, M., 2440
 Sekine, I., 5182
 Seko, A., 4301
 Sekowski, J. W., 3259, 3264
 Selig, R. A., 473
 Seliger, B., 2149, 4090
 Sell, C., 1, 4980
 Selner, M., 4349
 Semenza, G. L., 5280
 Senderowicz, A. M., 3248
 Senter, P. D., 4075
 Sentz, D. L., 4864
 Seppälä, M., 2715, 4274
 Seriu, T., 2618
 Serra, M., 4127
 Seruca, R., 4086
 Sethi, T., 5239
 Seto, M., 3773
 Sette, A., 4895
 Settle, S. L., 1930
 Seufferlein, T., 2703
 Seyam, R. M., 215
 Sgambato, A., 114, 3448
 Sgouros, G., 3009
 Shabanowitz, J., 5144
 Shabram, P. W., 2331
 Shafritz, D. A., 5825
 Sham, J. S. T., 5019
 Shames, L. S., 585
 Shan, A., 389
 Shankar, R. A., 1562
 Shantz, L. M., 2748
 Shao, J., 362, 1515
 Shao, Z.-M., 4851
 Sharma, S., 1208
 Sharp, N. J. H., 3353
 Sharp, R., 5157
 Shattuck-Brandt, R., 5473
 Shaw, H., 2500
 Shay, J. W., 3237
 Shayesteh, L., 1972
 Sheikh, M. S., 1593
 Shekher, M., 5329
 Shekher, M. C., 2339
 Shen, D.-w., 268
 Shen, M. R., 604
 Shen, Z.-Z., 4851
 Sheng, H., 362
 Sheng, S., 5681
 Shephard, L., 3712
 Sher, Y.-P., 2761
 Sheu, J.-C., 1494
 Shewach, D. S., 3873
 Shi, S.-R., 1090
 Shi, Y., 5310
 Shi, Y. E., 4015, 4238
 Shibata, D., 1087
 Shibata, K., 900, 1095
 Shibata, S., 2793
 Shibutani, S., 647
 Shibuya, M., 2594, 2652
 Shields, J. M., 1750
 Shields, P. G., 334, 2107
 Shigenari, A., 5079
 Shigeta, T., 4923
 Shih, J.-Y., 2761
 Shih, Y.-L., 985
 Shiiba, K., 3491
 Shikany, J. M., 661
 Shiku, H., 3385
 Shimada, A., 4434
 Shimada, H., 2209, 4217
 Shimada, T., 594
 Shimada, Y., 3248, 3429
 Shimano, T., 2524
 Shimizu, K., 594
 Shimizu, N., 2067
 Shimosaka, A., 1202
 Shin, M. S., 1140, 3787
 Shine, J., 1353
 Shinkai, A., 2652
 Shinkai, Y., 622
 Shinoda, M., 2838, 3429
 Shinohara, A., 5406
 Shinohe, Y., 1793
 Shinoki, N., 2440
 Shiota, G., 4434
 Shipley, J. M., 4721
 Shipman, C. M., 5294
 Shirai, T., 4307
 Shiraki, K., 4434
 Shirato, H., 1793
 Shiratori, Y., 1946
 Shisa, H., 1660
 Shitara, K., 2652
 Shoji, Y., 1524
 Shono, K., 2583
 Shou, J., 3401
 Shows, T. B., 4269
 Shultz, K. L., 3694
 Shun, C.-T., 1494
 Shungu, D. C., 1063
 Shurin, M. R., 380
 Shyjan, A. W., 1515
 Shyr, Y., 2323
 Siccardi, A. G., 3866
 Siddik, Z. H., 698
 Sidransky, D., 204, 509, 1405,
 3513, 5248, 5690
 Siegal, G. P., 1893
 Sier, C. F. M., 1843
 Sies, H., 4297
 Sietsma, H., 4840
 Sigal, E. V., 5590
 Sigbjörnsdóttir, B. L., 4421
 Signoretto, S., 1730
 Sigurdsson, A., 4421
 Sigurdsson, S., 859
 Silber, J. R., 1068
 Sills, A., 672
 Sills, A. K., Jr., 2784
 Silvers, W. K., 630, 1521
 Sim, J. E., 3986
 Simbulan-Rosenthal, C., 3495
 Simon, B., 1583
 Simon, C., 1135
 Simon, R., 5009
 Simone, C., 4799
 Simons, J. W., 5280
 Simpson, J. F., 1469
 Simpson, J. M., 5105
 Simpson, L., 5667
 Singh, B., 3633
 Singh, M., 5850
 Singh, R. K., 1532
 Singh, S. P., 1730
 Singh, S. V., 5340
 Sinha, D., 4947
 Sipes, J. M., 3154
 Sipos, E. P., 672, 2784
 Siprashvili, Z., 2946
 Siracusa, L. D., 3401
 Sircar, R., 1116
 Sitrin, M., 1074
 Sivaraman, L., 4858
 Skarosi, S. F., 1074
 Skinner, D. G., 1090
 Skogseid, B., 377
 Slater, R., 2863
 Slavin, S., 3891
 Slebos, R. J. C., 5333
 Sleeman, J. P., 2350
 Slingerland, J. M., 542, 619
 Slingluff, C. L., Jr., 5144
 Slocum, H. K., 3036, 5749
 Smith, A. K., 2952
 Smith, C. D., 3571
 Smith, D. E., 1688
 Smith, D. I., 759, 2347
 Smith, H. S., 3677
 Smith, J. S., 2298
 Smith, K. M., 4782
 Smith, M. T., 2176
 Smith, P. D., 5009
 Smith, R. C., 3561
 Smolinski, K. N., 4802
 Smorenburg, S. M., 3312
 Smotkin, D., 2919
 Smulson, M. E., 3495, 4510
 Snell, L., 1348
 Snijders, P. J. F., 3812
 Sober, A. J., 109
 Sobol, H., 1588
 Soff, G. A., 5686
 Soh, J.-W., 3448
 Solary, E., 5495
 Solomon, G., 3353
 Shyjan, M. J., 4682
 Somlo, G., 2793
 Sommelet, D., 448
 Sone, H., 4044
 Song, C. W., 2504
 Song, H., 4227
 Song, Q., 84
 Song, S. Y., 3231
 Sonoda, Y., 5182
 Sontheimer, H., 4871
 Soravia, C., 500
 Sorensen, P. H. B., 2469, 5046
 Soroceanu, L., 4871
 Southern, S. A., 2941
 Southwood, S., 4895
 Souza, R. F., 4802
 Sozzi, G., 5032
 Spagnoli, G. C., 4567
 Spaliviero, J. A., 5105
 Spannake, E. W., 1750
 Sparks, A. B., 1130
 Speiser, D. E., 4682
 Speizer, F. E., 667
 Speleman, F., 1503
 Spellerberg, A., 3105
 Spencer, V. A., 3004
 Spengler, B., 5803
 Sperker, B., 1195
 Spiegel, S., 1817, 3275
 Spiegelman, D., 667, 5117
 Spillman, M. A., 3237
 Spirio, L. N., 4909
 Spitz, D. R., 3986
 Spitz, M. R., 1605
 Spoonde, A., 3495
 Sporn, M. B., 717
 Sprent, J., 5795
 Spriggs, D. R., 1120
 Squarcina, P., 2433
 Srikanth, S., 834
 Srinivasan, A., 437
 Srinivasula, S. M., 5201
 Srivastava, S., 5248
 Srivastava, S. K., 5340
 Staba-Hogan, M. J., 5216
 Stadler, W. M., 4963
 Stampfer, M. J., 442, 3307, 5117
 Stanbridge, E. J., 2190
 Stancel, G. M., 392
 Stanczyk, F. Z., 585, 4497
 Stanford, J. L., 588
 Stanley, P., 2881
 Starnes, C. O., 933
 Starostik, P., 4552
 Stary, A., 102
 Stastny, V. A., 3237
 Stec, W. J., 3773
 Steck, P. A., 5285
 Steele, V. E., 921, 3282
 Steenbergen, R. D. M., 3812
 Steger, G. G., 2982
 Stein, J. P., 1090
 Steinarsdóttir, M., 859
 Steinberg, M. S., 3586
 Steinberg, S. M., 5582
 Steiner, B., 2982
 Stemmerman, G., 1149
 Stenwig, A. E., 2087
 Stephens, E., 3603
 Stephens, L. C., 2404
 Stephens, R., 1843
 Stephens, T., 1417
 Sterling-Levis, K., 473
 Stern, P. L., 1700
 Soloski, M. J., 1688, 2588
 Stevanovic, S., 732
 Stevenson, D. A. J., 5042
 Stewart, C. A., 4548
 Stiegler, P., 5049
 Stiller, C. A., 448
 Stobbe, C. C., 3571
 Stockert, E., 1034
 Stöckle, M., 5662
 Stöcklin, E., 2661
 Stockman, S. L., 4314
 Stockmeyer, B., 3051
 Stoica, A., 654
 Stokoe, D., 5285
 Stolina, M., 1208
 Stone, A., 2107
 Stoppacciaro, A., 1225
 Stoppa-Lyonnet, D., 1588
 Störkel, S., 4090
 Storme, G. A., 5646
 Stower, M., 23
 Strasser, J., 4654
 Sträter, J., 526
 Stratford, I. J., 2737
 Stratton, M. R., 863, 1384
 Straub, R., 1195
 Strauchen, J., 2126
 Strauss, M., 5053
 Stridsberg, M., 2375
 Stringer, C. M., 5701
 Strobel, T., 4776
 Stroeken, P. J. M., 1569
 Strömberg, U., 4117
 Strome, S., 3668
 Strong, L. C., 1387
 Strongin, A., 3743
 Stroun, M., 4728
 Strout, M. P., 55, 790
 Stuhler, G., 732
 Stukart, M. J., 1700
 Sturgis, L., 76
 Su, G. H., 2339

- Su, K., 4155
 Subbegowda, R., 2772
 Subbotin, V. M., 380
 Subramanian, D., 976
 Sugano, K., 512
 Sugar, A. Y., 4592
 Sugihara, K., 4823
 Sugimura, T., 42, 1127
 Sugita, K., 2583
 Sugita, M., 914
 Sugiura, T., 3761
 Sugiura, Y., 2209
 Sugiyama, A., 2067
 Sugiyama, Y., 5137
 Sugrue, M. M., 4439
 Suh, N., 717
 Sukata, T., 3806
 Sukhatme, V. P., 226, 5686
 Sukow, K. A., 2366
 Süli-Vargha, H., 614
 Sullivan, S. J., 3986
 Sulman, E. P., 3226
 Sun, H., 2224
 Sun, J-M., 3004
 Sun, J-Y., 2601
 Sun, L-Q., 5411
 Sun, T-T., 1291
 Sun, X-Y., 2379
 Sunaga, H., 794
 Sunamoto, J., 3385
 Sunamura, M., 2456, 4222
 Sundaram, S., 2881
 Sundberg, J. P., 4314
 Surawicz, C., 3839
 Sureau, F., 5777
 Susca, F., 4799
 Susin, S. A., 4453
 Sutherland, R. L., 1353, 1773
 Suzui, M., 1127
 Suzuki, A., 1833
 Suzuki, F., 4811
 Suzuki, H., 204, 5137
 Suzuki, J. S., 4044
 Suzuki, K., 5188
 Suzuki, M., 2838, 3499
 Suzuki, S., 1099
 Svanberg, E., 5374
 Svoboda, D. L., 2445
 Swaine, D. J., 5263
 Swart, J. M., 241
 Swenberg, J. A., 222
 Sy, M-S., 3660
 Syed, J., 4947
 Symmans, W. F., 1253
 Sytkowski, A. J., 3150, 3732
 Szabo, E., 5582
 Szállási, Z., 1423
- T**
- Taatjes, D. J., 189
 Tabatabai, G., 29
 Tabatabaie, T., 4548
 Tacconelli, A., 2957
 Tada, M., 609, 1793, 4307
 Tafra, L., 4581
 Tagliabue, E., 5032
 Tagliatela, M., 815
 Takagi, M., 4923
 Takahama, M., 3028
 Takahashi, E-i., 3499
 Takahashi, Hidetoshi, 296
 Takahashi, Hideyo, 2158
 Takahashi, Hiroyuki, 2076
 Takahashi, Mami, 42
 Takahashi, Michelle, 5667
 Takahashi, Minoru, 1677
 Takahashi, S., 4307
 Takahashi, Takao, 1042
 Takahashi, Takashi, 1042, 1380, 3761
 Takahashi, Takeshi, 5835
 Takahashi, Toshiaki, 5565
 Takahashi, Toshitada, 1042, 1380
 Takahashi, Y., 2550, 5406
 Takaku, K., 4823
 Takakura, M., 1558
 Takano, T., 4913
 Takao, S., 3727
 Takasu, T., 2504
 Takatsuji, T., 5188
 Takau, Y., 5182
 Takayama, H., 5157
 Takayama, S., 3116
 Takayama, T., 2568
 Takebayashi, H., 2282
 Takeda, K., 195
 Takeda, T., 5182
 Takei, K., 3700
 Taketani, Y., 4585
 Taketo, M. M., 4823
 Takeuchi, S., 641, 2618
 Takita, J., 3700
 Talalay, P., 4632
 Talbot, D. C., 2737
 Tallini, G., 4193
 Tallman, M. S., 5770
 Talmant, P., 5640
 Tamada, K., 3073
 Tamano, S., 4307
 Tamaya, T., 5406
 Tamm, I., 5315
 Tammi, M., 342
 Tammi, R., 342
 Tampellini, M., 3896
 Tamura, T., 3248
 Tan, Y., 4217
 Tanabe, M., 2158
 Tanaka, A., 2053
 Tanaka, H., 3429
 Tanaka, K., 641
 Tanaka, M., 1558
 Tanaka, N., 594
 Tanaka, T., 1946, 2440, 2550, 3362, 4811, 4832, 5231
 Tanaka, Y., 962, 1165, 4138
 Tang, C. K., 3415
 Tang, D. G., 3466
 Tang, D. J., 2339
 Tang, K., 4047
 Tang, L., 5151
 Tang, M-s., 2070
 Tang, P., 5285
 Tang, R., 4052
 Tang, W-H., 753
 Tang, Y., 4940
 Tangvoranuntakul, P., 4250
 Taniere, P., 2057
 Tanigawa, N., 1808, 5071
 Tanigawara, Y., 3248
 Taniguchi, E., 1105
 Taniguchi, T., 1813, 4461
 Tani, H., 3248
 Tanimura, M., 3032
 Tanioka, M., 1048
 Taniwaki, M., 5182
 Tannock, I. F., 1901, 2801
 Tanooka, H., 5649
 Tantravahi, R., 4173
 Tanuma, J-i., 1660
 Tao, W., 2469
 Tapper, J., 892, 2715, 4274
 Taquia, E., 4930
 Tarabykina, S., 1238
 Tateishi, K., 1946
 Tatematsu, M., 2067, 4107
 Tate, A. D., 2850
 Tatsuka, M., 4811
 Taub, H. E., 2618
 Taveras, A. G., 4947
 Taverna, D., 848
 Tavian, D., 2234
 Tavtigian, S. V., 2331
 Taylor, C. R., 1090
 Taylor, J., 256
 Taylor, J. A., 3603, 5333
 Tazelaar, H. D., 2533
 Teebi, A. S., 2724
 Teichmann, P., 4624
 Teillaud, J-L., 1170
 Tempero, R. M., 315
 Tenconi, R., 4799
 Tenjo, T., 5071
 Tennekoon, G. I., 4602
 Tenenbaum, T., 1435
 Tennent, B. J., 3694
 Tepper, R. I., 1515
 Terachi, T., 5835
 Terada, M., 2991
 Terada, T., 4434
 Terada, Y., 4811
 Terai, Y., 2343
 Terashima, I., 647
 te Riele, H., 248
 Termine, A., 3015
 Terpstra, M., 5083
 Terwilliger, E. F., 5673
 Terzaghi-Howe, M., 4445
 Testa, J. R., 1332, 2741, 2973, 4505
 Testa, U., 562
 Tester, D., 1713
 Tester, D. J., 3455, 5473
 Tetef, M., 2793
 Teti, A., 2957
 Tew, K. D., 1332, 2568
 Thai, G., 698
 Thaler, J., 4918
 Thant, A. A., 900
 Theillet, C., 1004
 Thews, O., 2693
 Thibodeau, S. N., 1713, 3455, 5248, 5473
 Thiele, C., 109
 Thilly, W. G., 1268, 2857
 Thistlethwaite, F. C., 1338
 Thomas, C. F., 921
 Thomas, E., 2965
 Thomas, E. J., 1707, 2095
 Thomason, A., 933
 Thompson, A. M., 1004
 Thompson, C. B., 2111, 3202
 Thompson, E. B., 3684
 Thompson, E. W., 5529
 Thompson, M. A., 5168
 Thompson, P. A., 2107
 Thompson, R., 672
 Thompson, T. A., 5097
 Thompson, T. C., 1285, 4288
 Thorgeirsson, S. S., 123, 2196
 Thorlacius, S., 859, 1004
 Thorpe, P. E., 1952, 4646
 Thrall, B. D., 219
 Tibbetts, R. S., 4375
 Tigchelaar, W., 3312
 Tillmann, T., 1116
 Tillotson, L. G., 3706
 Tilton, B., 4233
 Timblin, C., 4543
 Timme, T. L., 1285
 Timmerman, D., 2278
 Tindall, D. J., 2347, 2461
 Tindall, K. R., 2978
 Tisdale, M. J., 2353, 2359, 4827
 Tishkoff, D. X., 5027
 Titenko-Holland, N., 2176
 Tjuvajev, J. G., 4185, 4333
 Tlsty, T. D., 4525
 Tocci, A., 562
 Tocqué, B., 1170
 Todorov, P. T., 2353
 Toebes, M., 724
 Toes, R. E. M., 3094
 Tohma, Y., 2057
 Tohyama, C., 4044
 Tokieda, M., 4255
 Tomasz, M., 3965
 Tominaga, M., 3339
 Tomita, N., 114, 2440
 Tomizawa, Y., 5478
 Tomlinson, G. E., 1605, 3237
 Tommasino, M., 829
 Tonk, V., 3237
 Tonks, N., 5667
 Tooke, N., 1451
 Torikai, K., 4832
 Tornelli, S., 5032
 Tornos, C., 3633
 Torres, A., 1268
 Torres, K., 3620
 Torrisi, M. R., 4468
 Tough, D. F., 5795
 Toyoda, M., 2594, 5071
 Toyosawa, S., 5725
 Traer, E., 4909
 Tran, Q-C., 1090
 Trapasso, F., 823
 Trapman, J., 2720
 Trastek, V., 2533
 Traversari, C., 2969
 Travis, W. D., 2533
 Treilleux, I., 1451
 Tremblay, A., 877
 Tremblay, G. B., 877
 Trent, J. M., 5009, 5267
 Tresini, M., 1
 Trikha, M., 4771
 Trimoreau, F., 5640
 Trinchieri, G., 491
 Tripathi, P. K., 1217
 Trosko, J. E., 2588
 Trotta, P. P., 2489
 Trout, A. B., 1695, 3270
 True, L. D., 232
 Truica, C. I., 2520
 Tsacmacidis, N., 4297
 Tsai, Y. C., 1245
 Tsao, H., 109
 Tsao, J-L., 1087
 Tsao, S. W., 5019
 Tschachler, E., 1599
 Tsihlias, J., 542
 Tso, C-L., 956
 Tsokos, M., 3021, 4715
 Tsuchiya, T., 5182
 Tsuda, H., 3526
 Tsuda, M., 3800

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 58

- Tsujimura, T., 2426
Tsujuchi, T., 4548
Tsukamoto, A., 3751
Tsukamoto, T., 3800
Tsunoda, S.-i., 290
Tsutsumi, Y., 290, 5725
Tsuzuki, H., 794
Tu, Y., 256
Tu, Z.-J., 1498
Tuddenham, E. G. D., 4461
Tudor, G., 3116
Turbyville, T., 5432
Turnacioglu, K., 5329
Turnacioglu, K. K., 4592
Turner, B. C., 5466
Tuschong, L. M., 5298
Tutt, A. L., 3051
Tyler, B. M., 2784
Tyson, C. A., 5137
- U**
- Uchida, D., 549
Uchida, N., 2583
Ucker, D. S., 402
Ueda, K., 3499, 5137
Ueda, M., 2343
Ueki, K., 2343
Ueki, M., 2343
Uemura, K., 3727
Uenaka, A., 1960
Ueno, H., 1202
Uetake, H., 4823
Ueyama, H., 2353
Uezato, H., 3700
Uhlén, M., 2449
Uhr, J. W., 691
Uhrbom, L., 5275
Uhrhammer, N., 3480
Ulaner, G. A., 4168
Ulrich, T. R., 933
Ullman-Culleré, M., 848
Umar, A., 2978, 3579
Umbach, D. M., 3603
Umehara, K., 2426
Ungefroren, H., 1741
Ungureanu, D., 2707
Upton, P. B., 222
Ura, M., 1165
Urena, J. M., 4515
Uskokovic, M., 3370
Utell, M. J., 1268
Uwagawa, S., 3806
- V**
- Vaccariello, M., 2200
Vacek, P., 189, 4543
Vagman, L., 3181
Vahteristo, P., 2715
Vaillancourt, M.-T., 2331
Vainio, H., 4997
Vaisman, A., 3579
Valdez, J. G., 413
Valent, P., 1850
Valerius, T., 3051
Valgardsdottir, R., 859
Valtieri, M., 14, 562
Valtola, R., 1599
van Alewijk, D. C. J. G., 2720
van Asperen, J., 2410
Van Bladeren, P. J., 4616
Van den Berge, D. L., 5646
Van den Berghe, H., 2278
Van den Berghe, I., 2278
Vandeputte, M., 2562
van de Rhee, N. E., 3087
van der Valk, M., 248, 2410
van der Valk, M. A., 1569, 4794
Vandesompele, J., 1503
van de Winkel, J. G. J., 3051
Vande Woude, G., 1719
Vandier, D., 4577
van Duin, M., 3812
van Endert, P. M., 2969
Van Gele, M., 1503
van Hall, T., 3087
VanHeele, A., 5151
van Hensbergen, Y., 4531
Van Houten, B., 189
Vanichkin, A., 2397
van Kaick, G., 3598
van Kooyk, Y., 4138
VanLith, M. L., 315
Van Noorden, C. J. F., 3312
Van Oostrom, C., 2850
van Rees, B., 3254
van Rijthoven, E. A. M., 1569
van Rossum, A., 248
van Roy, F., 4587
Van Roy, N., 1503
van Steeg, H., 2850
van Steenbrugge, G. J., 2720
van Tellingen, O., 2410
Van Waes, C., 3668
van Zeeland, A. A., 1978, 2850
Varchenko, M., 3579
Varela-Garcia, M., 4701
Varia, M. A., 3765
Varney, M. L., 1532
Varvayanis, S., 3163
Vasilev, S., 2793
Vaughan, E. D., 2003
Vaughan, T. L., 588
Vaupel, P., 2693, 3598
Velasco, G., 1624
Vellenga, E., 4840
Vellucci, V. F., 1986
Vena, J. E., 2107
Venkatraman, E. S., 1120
Venkitaraman, A. R., 1338
Verbanac, K. M., 4581
Vergote, I., 2278
Verheijen, R. H. M., 1700, 3812
Vermassen, P., 4587
Vermeulen, H., 724
Vernillet, L., 468
Veronese, M. L., 823, 4708
Verovski, V. N., 5646
Verreck, F. A. W., 3087
Verrier, C. S., 65
Vescio, R., 256
Vesprini, D., 2919
Viars, C. S., 743, 5027
Vidaud, D., 2298
Vidaud, M., 2298
Viegi, G., 4122
Vieira, W., 5157
Vierboom, M. P. M., 724, 3087
Viglietto, G., 823
Vigna, N., 5315
Vikhanskaya, F., 3654
Villegas, C., 1650
Vincent, J., 5701
Violini, S., 4468
Virgolini, I., 1850
Virmani, A. K., 3237
Virone-Oddos, A., 1170
Virshup, D., 1387
Virudachalam, S., 5216, 5484
Visconti, R., 4745
Visser, T. J., 437
Vissing, H., 4845
Vitale, M., 737
Vitelli, L., 562
Vittorelli, M. L., 4468
Vivo, C., 840
Vladusic, E. A., 210
Vlietstra, R. J., 2720
Vo, K., 3111
Vockerodt, M., 4930
Vockley, C. W., 1713
Voeller, H. J., 2520
Vogel, J.-U., 367
Vogels, I. M. C., 3312
Vogelstein, B., 1130, 5267
Volpert, O. V., 1298
von Bernuth, H., 2707
von der Weid, N., 448
Von Hoff, D. D., 2568
Von Kapp-Herr, C., 3986
von Reyher, U., 526
von Scholtz, E., 4113
Vořechovský, I., 2293
Vortmeyer, A. O., 504, 4715
Vos, J.-M. H., 2445
Voss, M., 1741
Voynow, J. A., 5546
Vreeswijk, M. P. G., 1978
Vrieling, H., 1978, 2850
Vignaud, P., 3896
Vu, T. H., 4168
- W**
- Wachtlin, J., 2707
Wada, H., 1108
Wada, T., 2583
Wada, Y., 3800
Wagman, L., 2793
Wagner, B. A., 2809
Wagner, E. M., 5344
Wagner, G. S., 1423
Wahl, G. M., 396
Wahlberg, K., 3294
Wahlström, J., 1372
Wahlström, T., 892
Wain, J. C., 1804
Waisman, A., 5447
Wakabayashi, K., 42, 3028
Wakao, H., 556
Wakui, S., 2076
Walboomers, J. M. M., 1700, 3812
Waldman, F. M., 3555
Wali, R. K., 1074
Walker, T. R., 5239
Walker, V. E., 222
Wallace, J., 3974
Wallace, S., 2404
Wallace, T. L., 4001
Wallgren, A., 1372
Walsh, A. H., 3611
Walsh, E., 4543
Walsh, G., 4082
Walsh, M. D., 3719
Walter, M. R., 2489
Walther, M., 1719
Wan, E., 1551
Wan, X., 5406
Wanebo, H. J., 241
Wang, D., 4227
Wang, E. E., 3331
Wang, E. H., 4417
Wang, F.-S., 1551
Wang, H., 1217, 5570
Wang, H.-P., 1494
Wang, J., 3538
Wang, J.-P., 927
Wang, J.-Y., 4052
Wang, K., 232
Wang, L., 4947
Wang, L.-M., 3415
Wang, M., 38, 4096
Wang, M.-s., 4238
Wang, Q., 5762
Wang, Q.-c., 2612
Wang, R.-F., 3519
Wang, S., 4802
Wang, T. T. Y., 2379, 2754
Wang, T.-C. V., 4052
Wang, Wei, 1620
Wang, Weiguang, 4426
Wang, Weizang, 4426
Wang, X., 2417, 3519, 3826, 4217, 5019
Wang, Yan, 5315
Wang, Yian, 921
Wang, Yue, 2126
Wang, Yunxia, 2176
Wang, Y.-C., 328
Wang, Z., 2149
Wang, Z.-Y., 4180
Wang-Johanning, F., 1893
Wanibuchi, H., 3806
Wanke, E., 815
Wanschura, S., 2278
Ware, J. L., 232
Warnes, S., 5787
Warren, A. J., 453
Warren, W., 1384
Warshaw, A. L., 3706
Washiyama, K., 1231
Wasserman, A. J., 1111
Watabe, K., 3561, 4572
Watabe, M., 4572
Watanabe, A., 5182
Watanabe, Haruo, 2991
Watanabe, Hideomi, 2667
Watanabe, Hiromitsu, 5565
Watanabe, Hiroshi, 2991
Watanabe, M., 1833, 2076, 5188
Watanabe, N., 1677
Watkins, L., 4646
Watson, P. H., 1348, 3197
Watson, R. H., 2095
Watts, M., 672
Waxman, D. J., 4391
Wazer, D. E., 4782
Weber, C. K., 2986
Weber, E., 432
Weber, R. G., 29, 1798
Weber, T. K., 997
Webster, A. D. B., 2293
Webster, N. J. G., 1159
Wedge, S. R., 4363
Weeda, G., 89
Weghorst, C. M., 2327, 4227
Wegner, R.-D., 2316
Wehage, S. L., 5690
Wei, M. X., 3529
Wei, Q. S., 5570
Wei, T., 2624
Weichselbaum, R. R., 3215, 5686
Weidauer, H., 5
Weikel, W., 3598
Weil, R. J., 4715

- Weiner, L. M., 485
 Weinstein, I. B., 114, 3448
 Weirich, G., 1719
 Weiss, S. J., 5221
 Weissler, M. C., 3765
 Weisspapir, M., 2397
 Weisz, A., 871
 Weisz, J., 256
 Weitzman, S. A., 2515
 Weizer, V., 5137
 Welch, W. R., 2328
 Welcker, M., 5053
 Weldon, C. B., 4940
 Wells, J. D., 1149
 Wels, W., 2661
 Wenger, R. H., 5678
 Wennerberg, J., 5859
 Wernick, M., 3677
 Wessel, I., 1460
 West, A. B., 588
 West, M., 2070
 Westergren-Thorsson, G., 1099
 Westermarck, B., 5275
 Westin, G., 377
 Westland, B. E., 1978
 Westlin, J-E., 2375
 Westlin, W. F., 1930
 Westphal, C. H., 5637
 Westra, W. H., 2063, 5690
 Wetzler, M., 3173
 Whatley, M., 2612
 Wheeler, C. M., 3839
 Wheeler, T. M., 1285
 Wheelock, M., 1972
 Whitacre, C. M., 940
 Whitaker, R. S., 5546
 Whitcomb, K. L., 933
 White, L., 473
 White, M. F., 4250
 White, P. S., 3226
 White, R., 4909
 White, R. L., 4038
 Whitehead, R. H., 5168
 White-Jones, M., 2260
 Whitesell, L., 5432
 Whiteside, T. L., 5344
 Wible, B., 815
 Wiederschain, D., 1395
 Wiemann, B., 933
 Wiemels, J., 2176
 Wiencke, J. K., 1804
 Wientjes, M. G., 2141, 2777
 Wierdl, M., 3627
 Wiernik, P. H., 5770
 Wijesuriya, R., 2426
 Wilander, E., 829
 Wilber, K., 759
 Wilentz, R. E., 4740
 Wilke, C. M., 3409
 Wilkens, L. R., 4858
 Wilks, J. W., 4001
 Willett, W. C., 442, 667, 3307, 5117
 Williams, B. R. G., 2489
 Williams, C., 717, 2449
 Williams, J. I., 2784
 Williams, T., 5466
 Williamson, E. A., 3344
 Williamson, R. C. N., 4461
 Willingham, T., 3504
 Willis, J., 3101
 Wills, K. N., 2331
 Wilson, K. T., 2929
 Wilson, L., 1177
 Wilson, M., 2588
 Wilson, S. E., 4475
 Wilson-Van Patten, C., 767
 Winter, G., 991
 Wistuba, I. I., 3237
 Witschi, H., 5582
 Witte, L., 3209
 Witte, O., 2895
 Wixler, L., 2986
 Woda, B., 3974
 Wolf, E. J., 485
 Wolf, J., 4930
 Wolfert, R. L., 4787
 Wolff, H., 4997
 Wolff, J. H., 2385
 Wolk, A., 442
 Wolkowicz, R., 5447
 Wollman, J., 1208
 Wolter, M., 29, 1798
 Wolverton, J. S., 3627
 Wong, S. C. H., 5019
 Wood, T. L., 3021
 Woods, K. V., 3132, 3142
 Woolf, E. A., 1515
 Woolgar, J. A., 2003
 Woster, P. M., 2711
 Wrasidlo, W., 2925
 Wright, C., 3932
 Wright, J. A., 1650
 Wright, P. W., 3391
 Wright, S. C., 5570
 Wu, A. Y., 4417
 Wu, C-W., 2761
 Wu, F., 904
 Wu, G. S., 1593, 3513
 Wu, H. C., 5425
 Wu, J., 159, 1754, 2217, 4851
 Wu, L., 509, 1405, 3513
 Wu, M-S., 1494
 Wu, P., 5673
 Wu, R-L., 1291
 Wu, W., 4082
 Wu, X., 1605
 Wu, X-R., 1291
 Wu, Y-L., 633
 Wuertzberger, S. M., 1876
 Würflein, D., 3051
 Wyatt, M. D., 3965
 Wyckoff, J. B., 2528
 Wysocka, M., 491
- X**
- Xi, L., 2176
 Xi, L. F., 3839
 Xia, H., 5340
 Xia, L., 500
 Xia, Y., 4055
 Xia, Z., 3173
 Xiang, R., 3918
 Xiao, G-H., 4505
 Xie, K., 2733, 4008
 Xie, Q-w., 717
 Xing, R., 904
 Xiong, Y., 1095
 Xu, F-h., 256
 Xu, H. J., 1090
 Xu, J., 1914
 Xu, L., 5701
 Xu, X., 2832
 Xu, Y-H., 4180
 Xue, L-y., 940
 Xu-Welliver, M., 1936
- Y**
- Yacovlev, E., 3891
 Yagi, K., 3773
 Yagi, S., 2583
 Yakovlev, A., 3495
 Yamada, M., 3116
 Yamada, Y., 1660, 5514
 Yamaguchi, N., 5478
 Yamaguchi, S., 1095, 2652
 Yamamoto, H., 114, 997, 1099
 Yamamoto, M., 4107
 Yamamoto, N., 3993
 Yamamoto, S., 3806
 Yamamoto, T., 5079
 Yamamoto, Y., 290
 Yamane, T., 2550
 Yamasaki, M., 2053
 Yamashiro, D. J., 4602
 Yamashita, K., 4301
 Yamashita, T., 556
 Yamauchi, N., 1677
 Yamazaki, V., 2316
 Yan, W., 1986
 Yan, X-H., 421
 Yang, C., 5695
 Yang, C-r., 3712
 Yang, G., 1285
 Yang, J., 3909
 Yang, K., 5713
 Yang, L., 3231
 Yang, M., 3150, 3732, 4217
 Yang, P., 2347
 Yang, P-C., 2761
 Yang, Q-c., 4238
 Yang, S. C., 5690
 Yang, V. W., 1750
 Yang, W. K., 985
 Yang, Y., 2703, 3633
 Yang, Y. M., 3787
 Yang, Z., 1688
 Yannelli, J., 1217
 Yao, S., 3782, 4245
 Yao, Y., 114
 Yaremko, B., 4947
 Yasumoto, K., 3073, 4138
 Yatabe, Y., 1042, 3761
 Yatani, R., 2076
 Yatsuoka, T., 2456
 Yee, C. J., 65
 Yee, D., 4199
 Yeh, G. C., 2754, 5707
 Yeh, R. L., 4160
 Yen, A., 3163
 Yen, Y., 2793
 Yeo, C. J., 2339, 4740, 5329
 Yeung, R. S., 4766
 Yewdell, J. W., 4688
 Yilmaz, M., 2166
 Yin, J., 4802
 Yin, S., 933, 2176
 Ylä-Herttuala, S., 3791
 Yokomizo, A., 2347
 Yokota, J., 3700, 5478
 Yokota, S., 5182
 Yokoyama, A., 2014
 Yokoyama, M., 3032
 Yokoyama, T., 2456
 Yokoyama, Y., 5406
 Yokozawa, T., 4913
 Yonei, H., 2550
 Yoo, N. J., 1140, 3787
 Yoo, N-J., 504
 Yoon, C. Y., 3787
- Yoshida, A., 2576
 Yoshida, B. A., 4963
 Yoshida, H., 549, 1048, 2053, 2583
 Yoshida, O., 2282, 5835
 Yoshida, T., 3751
 Yoshida, Y., 1946
 Yoshikawa, H., 4585
 Yoshimoto, K., 2876
 Yoshioka, T., 1048, 2583
 Yoshitake, A., 3806
 You, M., 921
 You, S., 1498
 Young, J. D., 4349
 Yount, G. L., 3819
 Youssef, E. M., 2456
 Yousoufian, H., 3538
 Yu, D-F., 2404
 Yu, F., 55
 Yu, J., 3538
 Yu, J. X., 4238
 Yu, M. C., 4497
 Yu, R., 402, 2102
 Yu, V. P. C. C., 1338
 Yu, W-G., 2426
 Yu, Y., 2036, 4277
 Yu, Z-X., 195
 Yuan, B-Z., 2196
 Yudoh, K., 2098
 Yue, J., 4752
 Yue, W., 927
 Yuille, M. R., 2293, 3488
 Yumet, G., 2477
 Yung, W. K. A., 5285
 Yuspa, S. H., 1435
- Z**
- Zabrenetzky, V. S., 3154
 Zagaja, G. P., 3561
 Zajac, P., 4567
 Zaks, T. Z., 4902
 Zanaria, E., 2969
 Zanonati, F., 426
 Zanke, B. W., 2801
 Zannini, M., 2888
 Zapata, J. M., 3116
 Zasloff, M., 2784
 Zauli, G., 737
 Zbar, B., 504, 1719
 Zbieranowski, I., 542
 Zdzienicka, M. Z., 2863
 Zebrowski, B., 4008
 Zehbe, I., 829
 Zeiger, M. A., 2063
 Özören, N., 3513
 Zeng, G., 3519
 Zeng, Z-L., 5089
 Zhang, B., 4044
 Zhang, C-L., 609
 Zhang, H., 2844
 Zhang, J., 195, 4654, 5466
 Zhang, L., 352, 2176, 5656
 Zhang, Q-X., 1367
 Zhang, S., 2844
 Zhang, S-J., 1231
 Zhang, W., 619, 1538
 Zhang, Y., 4632
 Zhang, Y-J., 3448
 Zhang, Z-F., 1291
 Zhao, H., 3226
 Zhao, S-C., 4292
 Zhao, Y., 1605
 Zheng, G., 4970

AUTHOR INDEX TO VOLUME 58

- | | | | |
|----------------------|-----------------------------|------------------------|-----------------------|
| Zheng, P., 3376 | Zhu, J., 5061 | Zimmermann, A., 753 | Zuna, I., 3598 |
| Zheng, Y., 2070 | Zhu, L., 1208 | Zimniak, P., 5340 | Zunino, F., 1886 |
| Zhong, H., 5280 | Zhu, Q., 4752 | Zimonjic, D. B., 2196 | Zuo, Z., 3611 |
| Zhong, Q., 2699 | Zhu, Z., 3209 | Zippe, C. D., 1456 | Zupi, G., 283 |
| Zhou, B-K., 1521 | Zhuang, Z., 504, 1719, 4715 | Zlotnikov, G., 5271 | Zurakowski, D., 1395 |
| Zhou, D., 2182, 5695 | Zi, X., 1920 | Zon, G., 283 | Zurawel, R. H., 896 |
| Zhou, D-C., 5770 | Zigman, A. F., 2724 | Zorbas, M. I., 5168 | Zutter, M. M., 2224 |
| Zhou, J-R., 5231 | Zilocchi, C., 5812 | Zou, T., 4802 | Zweier, J. L., 1562 |
| Zhou, W., 5061 | Zimmer, S. G., 2063 | Zuckerman, K. S., 2217 | Zweit, J., 4333 |
| Zhu, B. T., 2269 | Zimmerman, C., 1325 | Zuckier, L. S., 3905 | Zwelling, L. A., 5298 |

* For title of article and coauthors, see listing in Contents of Volume 58 beginning on page i at the end of this index issue.

SUBJECT INDEX

Volume 58

A

- 1'-Acetoxychavicol acetate**
oxidative stress inhibition, mouse skin, 4832
- N-Acetylation**
polymorphisms, smoking-associated bladder cancer, 3603
- N-Acetylglucosamine**
GlcNAc-TIII
hepatic tumor progression and, 2881
- Acetylsalicylic acid**
lung tumorigenesis prevention, A/J mice, 5354
- N-Acetyltransferase**
genotype
and colorectal carcinoma risk, 3307
- O-Acetyltransferase**
Salmonella harboring, 1833
- Acidic environments**
heat-induced apoptosis, 2504
- Acidification**
stress-activated protein kinase and, 2801
- Actin**
cytoskeleton disruption
folate uptake regulation, 2952
- β -Actin**
expression, Moloney sarcoma virus-MDCK cell variants, 1631
- Activator protein 1**
MGMT activation, 3950
stimulation by paclitaxel, 241
- Adeno-associated virus**
anti-angiogenic gene delivery, 5673
- Adenocarcinoma: see also specific sites**
Barrett's-associated
p27 subcellular localization, 1730
Peutz-Jeghers syndrome
pathogenesis, 5267
- Adenoma: see also specific sites**
prostanoid levels, familial adenomatous polyposis, 1750
- Adenoma malignum**
chromosome 19p deletion, 1140
- Adenomatous hyperplasia**
atypical
allelic imbalance, prostate, 389
- Adenomatous polyposis**
familial
adenoma prostanoid levels, 1750
carcinoma, dietary modulation, mouse model, 5713
- Adenomatous polyposis coli**
APC/ β -catenin/Tcf pathway
mutations, colorectal carcinoma, 1130
- APC gene**
colon cancer risk and, 4038
I1307K mutation, Norwegian cancer patients, 2923
I1307K mutation, ovarian cancer risk and, 2919
I1307K mutation, somatic instability, 4040
- APC homologue APCL**
identification and β -catenin interactions, 5176
- attenuated**
COX-2 mutation, 4909
- Adenosine**
muscle cell
growth inhibition, 3181
- Adenosine triphosphate-binding cassette**
placenta-specific *ABCP* gene, 5337
- Adenosine triphosphate-binding cassette 2**
ABC2 gene amplification
- drug resistance and, ovarian carcinoma, 1332
- Adenovirus**
gene transfer
EGFR-targeted, glioma cells, 5738
heat-inducible double suicide gene, prostate carcinoma, 1358
modified, dendritic cells, 956
glial-specific vector, 3504
poly(L-lysine) conjugates
modified gene transfer, dendritic cells, 956
UV-irradiated
modified gene transfer, dendritic cells, 956
- Adoptive immunotherapy**
p53 targeting, 2601
SEA-conjugated antibody, 2838
- Adriamycin-selected tumors**
recognition by CTLs, 4790
- Aerodigestive tract tumors**
PTEN/MMAC1 alterations, 509
- Aflatoxin B₁ aldehyde reductase (*Afar*) gene**
cloning, 5014
- African Americans**
breast carcinoma
genetic enzyme variants and, 65
prostate carcinoma
vitamin D receptor haplotypes and, 1620
- Aging**
and DNA methylation, colorectal mucosa and carcinoma, 5489
- Airway**
mucosa
NNK dosimetry, 1417
- Akt**
activation inhibition by *MMAC/PTEN*, glioma cells, 5285
- AKT2**
activation, ovarian epithelial carcinoma, 2973
- Alkaline phosphatase**
gene expression, seminoma, 5079
- O⁶-Alkylguanine-DNA alkyltransferase**
random sequence mutagenesis, 1013
- ALL: see Leukemia, acute lymphoblastic**
- Allelic imbalance**
atypical adenomatous hyperplasia of prostate, 389
- Allelic loss**
chromosome 1p32, meningioma, 3226
chromosome 1q31-32 region, breast carcinoma, 4480
chromosome 12q, pancreatic carcinoma, 2456
chromosome 16q23.2-24.2
prognosis and, breast carcinoma, 2166
- Allelotyping**
pancreatic endocrine tumors, 3706
- Allogeneic cell therapy**
mammary carcinoma, murine, 3891
- 17-(Allylamino)-17-demethoxygeldanamycin**
hepatic metabolism, 2385
- Alveolar rhabdomyosarcoma**
gene expression profiling with cDNA microarrays, 5009
PAX3-FKHR target gene analysis, 3542
- Ambient particulate matter**
lung epithelial cells, 4543
- Amiloride**
irradiated cell effects, 413
- 5-Aminolevulinate photodynamic therapy**
mitogen-activated protein kinase effects, 4297
- 2-Amino-3-methylimidazo[4,5-f]quinoline**
tumors
Cnnb1 mutations, 1127
- 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine**
DNA adducts, histochemical detection, 4307
tumors
Cnnb1 mutations, 1127
- Aminosyn II**
dsFv renal uptake blockade, 2612
- AN-238**
growth inhibition, prostate carcinoma, 4132
- Anal carcinoma in situ**
risk
HPV16 variants and, 3839
- Anaplastic lymphoma kinase**
nucleophosmin chimeric kinase
nucleolar localization, 1057
- Androgen**
action site, prostate carcinoma, 3299
metabolism
and prostate cancer, 4497
receptor
activation by IL-6, prostate carcinoma, 4640
expression, recurrent prostate cancer, 5718
expression loss, prostate carcinoma, 5310
receptor promoter
CpG island methylation, prostate carcinoma, 5310
synthesis
novel inhibitors, effects, 3826
withdrawal
apoptosis, blockade by caspase inhibition, 834
- Angiogenesis**
bladder carcinoma, 1298
cervical carcinoma, 2343
dynamic MRI assessment, uterine cervical carcinoma, 3598
gelatinase A-deficient mice, 1048
hollow fiber tumor model, 5263
hypoxia-induced IGF-II, hepatocellular carcinoma, 348
inhibition
primary tumor size-dependent, 5866
squalamine, 2784
TNF470, hepatoma, 3751
nm23
node-negative breast carcinoma and, 2766
stimulation by platelet-type 12-LOX, prostate carcinoma, 4047
viral vector-targeted antiangiogenic gene therapy, 3362
- Angiostatin**
glioma growth inhibition, 4654
ionizing radiation anti-tumor effects potentiation, 5686
- Anoikis**
induction by *MMAC/PTEN*, glioma cells, 5285
- Anti-angiogenic genes**
adeno-associated virus-mediated delivery, 5673
- Antibodies: see also Monoclonal antibodies**
antifolate receptor
scFv/IL-2 fusion protein, 4146
anti-HER2
recombinant humanized, paclitaxel and doxorubicin activity enhancement, 2825
anti-HMW-MAA human scFv antibodies, characterization, 2417
anti-idiotypic
-derived peptides, CEA mimicry, 1217

- anti-MUC1 scFv, phage antibody libraries, 4324
- anti-p53
 - p53 immunity induction, 5447
- anti-VEGF/VPF
 - tumor inhibition, mouse ascites tumors, 2594
- B-cell
 - antibody-dependent cellular cytotoxicity, 3051
- BPDE-DNA adduct
 - serum, 4122
- chimeric
 - half-life, 3905
- phage libraries
 - anti-MUC1 scFv, 4324
 - panning, Fab isolation, ovarian carcinoma cells, 991
- Ras knockout, 1170
- SEA-conjugated
 - adoptive immunotherapy, 2838
- single-chain
 - HPV16 E7 downregulation, 1893
 - VEGF inhibition, 3209
- single-chain Fv
 - anti-MUC1, phage antibody libraries, 4324
 - Bcl-2 modulation, cytotoxicity and, 2134
 - tumor delivery, affinity increase and, 485
- somatostatin receptor subtype 2, carcinoid tumors, 2375
- Antibody-dependent cellular cytotoxicity**
 - B-cell antibodies, 3051
 - immunotoxin additivity, 5787
- Anticancer drugs; see also Drugs; specific drugs**
 - apoptosis
 - molecular ordering, neuroblastoma cells, 4453
- Anticarcinogenic phase 2 enzymes**
 - isothiocyanate inducer potencies, 4632
- Antiestrogens**
 - activity
 - cyclin D1 overexpression and, 871
 - breast cancer cells, 263
 - estrogen receptor mutant inhibition, 877
 - raloxifene
 - mechanism of action, 1872
- Antigen**
 - HLA-A2
 - loss, melanoma, 2149
 - HLA class I
 - downregulation, breast carcinoma, 737
 - HMW-melanoma-associated
 - anti-HMW-MAA human scFv antibodies, characterization, 2417
 - immunogenic lung cancer
 - chromosome 3p21.3, 1034
 - Lewis
 - lung adenocarcinoma cell adhesion, 1544
 - melanocyte lineage-specific
 - gp100, genetic vaccination, 2509
 - membrane
 - localization on shed vesicles, breast carcinoma, 4468
 - proliferating cell nuclear antigen, breast carcinoma, 3264
 - prostate-specific
 - doxorubicin-peptide prodrug activation, 2537
 - nested RT-PCR assay, prostate carcinoma, 1456
 - polyglutamine expression amplification, 2282
 - prostate-specific membrane
 - internalization, 4055
 - nested RT-PCR assay, prostate carcinoma, 1456
- tumor-associated
 - DAM gene family, 2969
 - expression, renal cell carcinoma, 4090
 - peptide vaccination, murine leukemia, 1960
 - reactive CD8+ TH1 cells, 1363
 - recombinant vaccinia virus expressing B7 molecules and, 4567
- Antigenicity**
 - MUC1
 - enhancement by glycosylation, 2541
- Antigen presentation**
 - and CTL precursors, 3909
 - P-glycoprotein role, 4688
- Antigen-presenting cell**
 - engineered fibroblast
 - direct CTL priming, 3094
- Antigen processing**
 - nasopharyngeal carcinoma, 310
- Antigen-processing genes**
 - expression
 - decrease by tumor cells, 3660
- Antioxidants**
 - COX-2 expression reduction, colorectal carcinoma, 2323
 - p53-mediated apoptosis, 1723
- Antisense**
 - CD44v6
 - colorectal tumor metastasis and, 3719
 - oligodeoxynucleotides
 - c-myc, cisplatin and, melanoma chemotherapy, 283
 - oligodeoxynucleotide against *MLL-LTG19*
 - apoptosis, infantile leukemia cells, 3773
 - vascular endothelial growth factor
 - tumor growth modulation, 4185
- Apaf-1**
 - overexpression
 - apoptosis promotion, HL-60 cells, 4561
- APO-1; see Fas**
- Apoptosis; see also Cell death**
 - AN34, HL-60 cells, 2576
 - androgen withdrawal
 - blockade by caspase inhibition, prostate cancer, 834
 - antisense ODN against *MLL-LTG19*, infantile leukemia cells, 3773
 - camptothecin-induced
 - DNA fragmentation pathway, 3066
 - caspase-mediated
 - inhibition by BCNU, 614
 - CD95-mediated
 - resistance, colon carcinoma, 526
 - and cell survivability, prostate cancer, 3466
 - ceramide synthase-mediated, LNCaP cells, 2260
 - cervical carcinoma, 2343
 - DFMO effects, esophageal carcinogenesis, 5380
 - drug-induced
 - inhibition by radiation, glioma, 3819
 - inhibition by VEGF, hematopoietic cells, 5565
 - molecular ordering, neuroblastoma cells, 4453
 - Fas-mediated
 - inhibition by Ras, 3391
 - TGF- β 1 and, glioma, 302
 - fractionated radiotherapy tumor responses and, 1779
 - heat-induced, acidic environments, 2504
 - human gene homologue *TSSC3*
 - genomic imprinting, 1052
 - induction
 - benzo(a)pyrene, 2102
 - betulinic acid, neuroectodermal tumors, 5876
- BIS, prostate carcinoma cells, 4864
- chemopreventive agents, 402
- combretastatin A-4, 4510
- IFN- γ , 2832
- IGF-IR COOH terminus, 2477
- IGF-IR C terminus, 570
- IL-4, breast carcinoma, 4199
- intestinal histopathology and, murine epithelia, 5453
- β -lapachone, MCF-7:WS8 breast carcinoma cells, 1876
- NS398, LNCaP cells, 4245
- retinoid antagonist, breast cancer, 4607
- TIMP-3, melanoma cells, 2310
- topoisomerase II α , 4519
- inhibition
 - ectopic *TAL1/SCL* expression, leukemic T-cells, 2680
 - survivin, 5315
 - survivin, colorectal carcinoma, 5071
 - ionizing radiation-induced, 4277
 - lymphomagenesis, SCID mice, 3111
 - mitochondrial membrane potential, colonic carcinoma, 2869
- modulation
 - ataxia telangiectasia, 4923
 - PGE₂, colon cancer, 362
 - nucleotide excision repair impairment, 1978
 - p53 and PARP interactions, 5075
 - PEITC-induced
 - p53 role, 4102
 - p53 hinge domain mutant response, 2190
 - p36 MBP kinase activation, 4888
 - p53-mediated
 - antioxidants, 1723
- promotion
 - Apaf-1 overexpression, HL-60 cells, 4561
 - mutant RAS, myeloid leukemia, 2029
 - prostate cancer cells, 76
 - radiation-induced
 - Rb-mediated, 3275
 - response modulation by *Pseudomonas* exotoxin-chimeric protein, 3215
 - susceptibility, breast carcinoma cells, 4940
 - Taxol-induced
 - loop domain, 3202
- Apoptotic nuclease AN34**
 - apoptosis, HL-60 cells, 2576
- Apoptotic protease AP24**
 - activation
 - Bcl-2 effects, 5570
- Apurinic/aprimidinic endonuclease**
 - induction, 4410
 - pleural cells, 189
- Apurinic/aprimidinic sites**
 - ARP-slot-blot assay, 222
- Aromatase**
 - expression modulation by ERR α -1, breast, 5695
- ARP-slot-blot assay**
 - AP sites, 222
- Asbestos**
 - AP-endonuclease induction, mesothelial cells, 189
 - mutagenicity
 - iron and nitric oxide, 1144
- Asites tumors**
 - inhibition by anti-VEGF/VPF antibody, mouse, 2594
 - VEGF expression, mouse, 2652
- Ashkenazi Jews**
 - ovarian cancer risk
 - 11307K APC* allele and, 2919
- AsPc-1 cells**
 - peptide transport, 519
- Aspirin**
 - toxicity, colonic tumor cells *in vitro*, 2772

- Astrocytes**
HSV-TK expression
 selective glioma cell killing, 4577
- Astrocytic tumors**
mdm2 variants, 609
- Ataxia telangiectasia**
 apoptosis control, 4923
- ATM gene**
 B-cell chronic lymphocytic leukemia, 4552
 lack, radiosensitization, 5637
 T-cell leukemia and, 2293
 heterozygotes, familial breast carcinoma, 1376
 radiosensitivity, 4923
 Seventh International Workshop on A-T, meeting report, 3480
 spindle checkpoint, 4923
 T-cell leukemia and, 2293
- Auraptene**
 colon tumorigenesis inhibition, 2550
- Aurora- and Ipl-like midbody associated protein mitotic kinase**
 overexpression, cancer cells, 4811
- 5-Aza-2'-deoxycytidine**
 DNA methylation inhibition
 growth inhibition, tumor cells, 95
- Azoxy methane**
 colon tumors
 β -catenin mutations, rat, 42
- B**
- B7**
 recombinant vaccinia virus expressing tumor-associated antigen and, 4567
- B7.1**
 spontaneous metastases reduction, 1486
- Bannayan-Riley-Ruvalcaba syndrome**
PTEN/MMAC1 mutations, 2724
- Barrett's associated adenocarcinoma**
 p27 subcellular localization, 1730
- Barrett's esophagus**
 iNOS and COX-2 expression, 2929
- Basal cell carcinoma**
 sporadic
*SMO*H mutations, 1798
- Basement membrane**
 invasion
 and liver metastases, gastrointestinal carcinoma, 3727
- BAX**
 and intracellular paclitaxel, 4776
- BCH-4556**
 tumor growth and metastases effects, prostate carcinoma, 3461
- Bcl-2**
 AP24 activation effects, 5570
 modulation by sFv
 cytotoxicity and, 2134
 phosphorylation
 site, 1609
 Taxol-induced, loop domain, 3202
- BCL-X**
 expression, multiple myeloma, 256
- Bcl-x_L**
 malignant conversion, skin papilloma, 2111
 phosphorylation after microtubule disruption, 3331
- BCP8**
 MHC class I-associated MUC1 motif definition, 5151
- Benzene**
 exposure
 translocation t(8;21), workers, 2176
- Benzo(a)pyrene**
 apoptosis induction, 2102
 caspase-3 activation, 2102
- JNK1 activation, 2102
- Benzo(a)pyrene diol-epoxide**
 chromosome 3p21.3 aberrations and lung cancer, 1605
 DNA adducts
 replication, cell extract, 887
 serum antibodies, 4122
- Benzoporphyrin**
 derivative
 photodynamic therapy, orthotopic prostate cancer, 5425
- O⁶-Benzylguanine**
 resistance, 1936
- Betulinic acid**
 apoptosis induction, neuroectodermal tumors, 5876
- Biliary adenocarcinoma**
 TGF β receptor gene alterations, 5329
- Biliary carcinoma**
DPC4/Smad4 mutations, 1124
MKK4 alterations, 2339
- Binding anti-apoptotic protein BAG-1**
 expression, tissues and tumors, 3116
- Biochanin A**
 LNCaP cell effects, 2379
- Biotin**
 TNF- α conjugate
 tumor targeting, 3866
- Birth weight**
 low-birth-weight children
 hepatoblastoma risk, 3032
- 1,3-Bis(2-chloroethyl)-1-nitrosourea**
 caspase-mediated apoptosis inhibition, 614
 resistance
 WAF1/Cip1, glioblastoma, 1538
- Bisdioxopiperazine**
 resistance
 Y49F topoisomerase II α , 1460
- Black tea**
 lung carcinogenesis inhibition, 4096
- Bladder carcinogenesis**
p53 knockout mice, 3807
- Bladder carcinoma**
 angiogenesis, 1298
 chemoprevention by nimesulide, 3028
 comparative genomic hybridization, 3555
 genetic alterations, 3555
 invasive
 MUC7 gene expression, 5662
 metastasis
 comparative genomic hybridization, 3555
 genetic alterations, 3555
 multifocal
 genetic analysis, 5835
p19/p16 expression
 DNA methylation role, 1245
 retinoblastoma protein and p53 alterations, 1090
 smoking-associated
 N-acetylation polymorphisms, 3603
- Blood vessels**
 hollow fiber
 development, 5263
- Bloom syndrome**
BLM gene
 microsatellite instability, sporadic gastrointestinal tumors, 3777
- B lymphocytes**
 antibodies
 antibody-dependent cellular cytotoxicity, 3051
 autologous EBV-immortalized
 nontumorigenic malignant Burkitt's lymphoma hybrid cells, 4930
 immunoliposomal targeting, 3320
 leukemia, chronic lymphocytic
ATM gene, 4552
- chlorambucil cytotoxicity, 1789
 telomerase activity, 4918
 telomere length, 4918
- Bone**
 metastasis
 inhibition by TNP-470, breast cancer, 462
 visualization by GFP expression, 4217
- Bone marrow**
 EblacZ tumor dormancy, 5439
 -sparing cytotoxin, 2568
- Borderline ovarian tumors**
 advanced
 multifocal origin, 2328
- Bradykinin**
 permeability
 mediation by cyclic GMP, 914
 receptor antagonist
 tumor vascular permeability modulation, 159
- B-Raf**
 PA28 α binding, 2986
- Brain**
 polymeric chemotherapy delivery, monkey, 672
- Brain glioma**
 NMR diffusion spectroscopy, rat, 3791
- Brain lymphoma**
p16 abnormalities, 1231
- Brain slice culture**
 glioma invasion model, 2935
- Brain tumors**
 chlorotoxin targeting, 4871
 HRMAS ¹H magnetic resonance spectroscopy, 1825
 induction by recombinant PDGF B-chain retrovirus, mice, 5275
 permeability
 bradykinin-induced, mediation by cyclic GMP, 914
 telomerase activity, 2117
 telomere length alterations, 2117
- BRCA**
 breast carcinoma
 pathology, 1839
- BRCA1**
 CDDP-induced DNA damage repair role, 1120
 mutations
 breast cancer cell line, 3237
 medullary breast carcinoma, 1588
- BRCA2**
 COOH terminus
 -deleted cells, 3441
 exon 3 deletion, 1372
 mutations
 999del5, loss of heterozygosity, 4421
 germ-line, male breast cancer, 1367
 primary breast carcinoma, 859
 truncating, murine thymic lymphoma, 1338
- 180BR cells**
 radiosensitivity, 84
- Breast**
 aromatase expression
 modulation by ERR α -1, 5695
 atypical lobular hyperplasia
 comparative genomic hybridization analysis, 4721
 epithelial cells
 ER Δ E5 splice variant dominant negative activity, 4264
 fibroblast growth factor 8 expression, 2053
- Breast carcinoma: see also Mammary carcinoma**
 $\alpha_2\beta_1$ and $\alpha_6\beta_3$, 2224
 antiestrogens, 263
 AP-2 expression, 5466

apoptosis
 induction by IL-4, 4199
 induction by β -lapachone, MCF-7:WS8 cells, 1876
 susceptibility, 4940
BRCA-associated, pathology, 1839
BRCA1 mutant cell line, 3237
BRCA2 mutations, 859
 E-cadherin inactivation, 1972
 cathepsin L2, 1624
 cell cultures, 5271
 cell growth
 EM-800 vs tamoxifen effects, xenografts, 60
 chromosome 1q31-32 allelic imbalance region, 4480
 chromosome 17 loss of heterozygosity, 1004
cul-4A overexpression, 3677
CYP1A1, *GSTM1*, and *GSTT1* polymorphisms and, 65
CYP1B1 polymorphisms, 5038
 cystatin A, 432
 ER- β mRNA variants, 210
 error-prone DNA replication apparatus, 3259
 estrogen-nonresponsive
 MAPK activity, 4071
 familial
 AT heterozygotes, 1376
 I1307K *APC* mutation, Norwegian patients, 2919
 genetic enzyme variants and, 65
 growth inhibition
 Ets-2 mutant, 1027
 2-methoxyestradiol, 2269
 MRG, 4015
 vitamin D₃ analogs, 3370
 growth stimulation *in vivo* by genistein, 3833
 GST-P1-1-transfected MCF-7 cells
 thiotepe and, 4616
 HLA class I antigen downregulation, 737
 IGF-IR activity, 1159
 invasion
 inhibition by Ets-2 mutant, 1027
 invasive lobular
 cyclin D1 overexpression, 2876
 invasive properties
 melatonin effects, MCF-7 cells, 4383
 lumican expression, 1348
 male
 BRCA2 germ-line mutations, 1367
 chromosome 9p23-24 tandem duplication, 863
 medullary
 BRCA1 mutations, 1588
 membrane antigen localization on shed vesicles, 4468
 metastasis
 inhibition by IGF-I inhibition, 3353
 osteolytic bone, inhibition by TNP-470, 462
 TBR-1 mutants, 4805
 methotrexate kinetics, 2982
 methylnitrosourea-induced
 modulation by dehydroepiandrosterone, 921
 MKK4 alterations, 2339
 MMP-2 activation induction by SPARC, 5529
 NH₂-terminally truncated Her-2/neu protein, 5123
 node-negative
 nm23, angiogenesis and, 2766
 parathyroid hormone-related protein, 4113
 p53 mutations, 859
 polymerase chain reaction markers, 4581
 preprogalanin gene expression, 1353

prognosis
 chromosome 16q23.2-24.2 allelic loss and, 2166
p53 mutations and, 1451
 proliferating cell nuclear antigen, 3264
 recurrent
 deleted regions, 2081
 retinoid antagonist activity *in vivo*, 4607
 risk
 catechol-O-methyltransferase and, 2107
 CYP1A1 polymorphisms and, 667
 RIZ1 expression, 4238
 sialyltransferase expression, 4066
 sporadic
 I1307K *APC* mutation, Norwegian patients, 2919
 LKB1/Peutz-Jeghers syndrome gene mutations, 1384
 suppression by genistein, 4851
 TAP1 and TAP2 downregulation, 737
 TGF- β signaling through Smad1, 4752
 transcription factor cross-linking to MAR DNA by cisplatin, 3004
 VEGF regulation by progestin, 392
 VIP-R1 regulation by retinoic acid, 4845
Breast carcinoma *in situ*
 lobular
 comparative genomic hybridization analysis, 4721
Breast tumorigenesis
 ER- α and ER- β mRNA expression, 3197
Breast tumors
 cell growth
 in situ aromatization and, 927
 regulation by lysosomal protease, 904
 estradiol levels
 in situ aromatization and, 927
 loss of heterozygosity, *BRCA2* 999del5 mutation-carriers, 4421
3-Bromoacetyl amino benzoylurea
 microtubule assembly inhibition, 2126
Bronchial epithelial cells
 mitochondrial mutational spectra, smoking vs nonsmoking, 1268
Bronchial lesions
 preinvasive
 FHIT functional loss, 5032
Burkitt's lymphoma
 malignant
 nontumorigenic EBV-immortalized B-cell hybrids, 4930
 tumor growth inhibition
 proteasome inhibitor-induced, 4342

C

CA19-9
 serum levels
 Le and *Se* gene dosage effects, 512
CaCo-2 cells
 growth
 PKC- α effects, 1074
Cadherin
 expression
 dexamethasone effects, HT-1080 cells, 3586
E-Cadherin
 CpG island methylation, thyroid carcinoma, 2063
 expression
 inverse metastasis levels, 4587
 inactivation, breast carcinoma cells, 1972
 mutations, gastric cancer families, 4086
***Caenorhabditis elegans cul-4* gene**
 human homologue *cul-4A*
 overexpression, breast cancers, 3677
Caffeine
 lung carcinogenesis inhibition, 4096
 -resistant G₂ block, 2639

Cain Memorial Award
 Seventeenth Lecture, 4211
Calcium
 intake
 and prostate cancer risk, 442
Calicheamicin θ_1
 targeted
 metastasis inhibition, neuroblastoma, 2925
Camptothecin
 apoptosis
 DNA fragmentation pathway, 3066
Cancer cell nests
 CD8+ T cells, colorectal carcinoma, 3491
Cap43
 nickel-specific gene, 2182
Capan-2 cells
 peptide transport, 519
Capecitabine
 efficacy
 correlation with dThdPase and dihydropyrimidine dehydrogenase, 685
Carbobenzoxyl-leuciny-leuciny-leucinal
 drug resistance prevention, 3059
Carbogen
 tumor 5-fluorouracil uptake increase, 1185
Carboxylesterase
 CE gene
 CPT-11 resistance reversal, lung carcinoma, 4368
 rabbit
 cDNA, isolation, 2646
 CPT-11 activation, 20
 CPT-11 metabolism, 3627
Carcinoembryonic antigen
 mimicry by anti-idiotypic-derived peptides, 1217
 transgenic mice, 1469
Carcinogens
 external
 tamoxifen action, 2278
Carcinoid tumors
 somatostatin receptor subtype 2 antibodies, 2375
Carcinoma: see also specific cells, sites, types
 AIM-1 mitotic kinase overexpression, 4811
 chromosomal aberrations and, study report, 4117
 complex developmental disorder, 5633
 dietary modulation, mouse familial adenomatous polyposis model, 5713
 Dpc4 dysfunction, 4592
 molecular epidemiology, 4023
 tr- α IIb integrin expression, 4771
Cardiotoxicity
 troponin T and, 195
Carzelesin
 comparative pharmacology, 2410
Caspase
 activation, prostatic carcinoma, 5870
 apoptosis
 inhibition by BCNU, 614
 inhibition
 androgen withdrawal apoptosis blockade, prostate cancer, 834
 NF- κ B cleavage
 CD95-induced, 882
Caspase-1: see Interleukin 1 β -converting enzyme
Caspase-3
 activation
 BaP, 2102
 ionizing radiation-induced, 4277
 apoptosis
 ionizing radiation-induced, 4277
Caspase-7
 activation

apoptosis, prostate cancer cells, 76
Caspase-14
 identification and characterization, 5201
Catalase
 gene amplification
 chronic oxidative stress-induced, 3986
Catechol-O-methyltransferase
 breast cancer risk and, 2107
 β -Catenin
 APC/ β -catenin/Tcf pathway
 mutations, colorectal carcinoma, 1130
 APC/L interactions, 5176
 CTNNT1 gene
 mutations, endometrioid ovarian carcinoma, 1344
 mutations, IQ and PhIP tumors, 1127
 mutations
 azoxymethane-induced rat colon tumors, 42
 colorectal carcinoma, 1021
 endometrial carcinoma, 3526
 hepatocellular carcinoma, 2524
 medulloblastoma, 896
 prostate carcinoma, 2520
Cathepsin L2
 breast and colorectal carcinoma, 1624
Caucasians
 breast carcinoma
 genetic enzyme variants and, 65
CBL proto-oncogene
 microsatellite instability, sporadic gastrointestinal tumors, 3777
CD4
 T cells
 MART-1-specific, 5305
 MUC1 priming, 5066
CD7
 anti-CD7-saporin immunotoxin
 ADCC additivity, 5787
CD8
 antitumor T-cell clones
 self-peptide ligands, 2433
 T cells
 cancer cell nests, colorectal carcinoma, 3491
 MART-1-specific, 5305
 recruitment and functional maturation, 3376
 TH1 cells
 tumor antigen-reactive, 1363
CD30
 targeting by chimeric T-cell receptor, 1116
CD40
 ligand
 dendritic cell maturation, 2965
CD44
 glycosylation
 and hyaluronan binding states, 3736
 hyaluronan binding states
 glycosylation and, 3736
 metastasis inhibition
 hyaluronate-independent, 2350
 variant 6
 antisense, colorectal tumor metastasis and, 3719
 expression, stage I non-small cell lung cancer, 1108
CD95: see Fas
cdc2
 T-loop deletion variant, 1095
cdc25
 non-Hodgkin's lymphoma, 1762
 overexpression, non-small cell lung cancer, 4082
Ced-3 protease: see Interleukin 1 β -converting enzyme
Celecoxib
 chemopreventive activity, colon carcinogen-

esis, 409
Cell adhesion
 dexamethasone effects, HT-1080 cells, 3586
 Lewis antigens, lung adenocarcinoma, 1544
 MUC1 expression and, 2014
 tumor-infiltrating lymphocytes to stromal cells, 4138
Cell adhesion molecules
 radiation-induced expression
 inhibition by NF κ B dominant negative genetic construct, 5484
Cell cycle
 arrest
 G₁, spindle inhibitors, 396
 G₁-S, p53 tumor cells, 2036
 G₂-M, HSV-tk/GCV-induced, 3855
 G₂-M, MLH1 role, 767
 mlgM-mediated, CDK inhibitors, 691
 checkpoint activation by radiation
 amiloride effects, 413
 checkpoints
 ionizing radiation responses, Nijmegen breakage syndrome cells, 2316
 G₁ phase
 arrest, spindle inhibitors, 396
 regulation, monolayers and spheroids, 1305
 G₁-S checkpoint
 arrest, p53 tumor cells, 2036
 G₂ phase
 caffeine-resistant block, 2639
 inhibition by isogranulatimide, 5701
 G₂-M checkpoint
 arrest, HSV-tk/GCV-induced, 3855
 arrest, MLH1 role, 767
 growth arrest, fostriecin-mediated, 3611
 progression
 MCT-1, 4233
 TSG101 effects, 2699
 regulation
 human papillomavirus, cervical neoplasia, 2941
 silymarin, prostate carcinoma DU145 cells, 1920
 spindle checkpoint, ataxia telangiectasia, 4923
Cell death: see also Apoptosis
 programmed
 CHENSpM-induced, 2711
 PTEN-induced, 5667
 Taxol-induced, 3620
Cell differentiation
 glial cell line-derived neurotrophic factor/neurturin-induced, neuroblastoma, 2158
 inducers
 JAK2 activation, murine erythroleukemia cells, 556
 induction
 4-oxoretinol, NB4 cells, 2007
 RAR β , squamous cell carcinoma, 142
 inhibition
 nuclear PLC β 1, erythroleukemia cells, 5057
 p53 mutation effects, thyroid cells, 2888
 regulators, 4282
 TAL-1 expression and, 562
Cell growth: see also Tumor growth
 arrest
 G₂-M phase, fostriecin-mediated, 3611
 IGFBP-6 and, neuroblastoma, 1670
 senescent-like, nasopharyngeal carcinoma cells, 5019
 DFMO effects, esophageal carcinogenesis, 5380
 disseminated, murine plasmacytoma, 535
 EM-800 effects, breast cancer xenografts, 60
 hypoxia and, 3547

inhibition
 angiostatin, glioma, 4654
 DNA methylation inhibition by 5-Aza-Cdr, 95
 Ets-2 mutant, breast carcinoma, 1027
 FLT3 ligand, melanoma and lymphoma, 380
 inhibitory PLC β , small cell lung cancer, 910
 Int-H1-S6A,F8A, 3654
 lung cancer metastasis, 4761
 mediation by PTEN, glioma, 5002
 MRG, antitumor activity, 4015
 oxythiamine and dehydroepiandrosterone, 3188
 PI-3 kinase, diploid fibroblasts, 1, 4980
 PP1, small cell lung cancer, 4660
 Smad4/DPC4, carcinoma, 5656
 soy isoflavones, bladder tumorigenesis, 5231
 α_v integrin peptidomimetic antagonist, Leydig cell tumors, 1930
 vitamin D₃ analogs, 3370
 xyloside, transformed cells, 1099
 methionine adenosyltransferase expression effects, hepatocellular carcinoma, 1444
 mitochondrial membrane potential, colonic carcinoma, 2869
 pentose phosphate pathways and, 3188
 PKC- α effects, CaCo-2 cells, 1074
 p53 mutation effects, thyroid cells, 2888
 Raf signals and, 1636
 regulation
 lysosomal protease, breast tumors, 904
 PI 3-kinase, small cell lung cancer, 5239
 rhabdomyosarcoma, 2042
 thrombospondin 1, melanoma, 3154
 stimulation *in vivo* by genistein, breast carcinoma, 3833
 tamoxifen effects, breast cancer xenografts, 60
 T-cell
 IFN- α -expressing tumors and, 5795
Cell motility
 living intact metastatic tumors, 2528
 modulation by thrombospondin 1, melanoma, 3154
Cell precursors
 oval
 hepatocyte generation, culture, 5514
Cell proliferation: see Cell growth
Cell survival
 apoptosis and, prostate cancer, 3466
Cell therapy
 allogeneic
 mammary carcinoma, murine, 3891
Cell transformation
 colon adenoma to malignant carcinoma
 TGF- β RII mutations, 3101
 growth inhibition by xyloside, 1099
 H-Ras and RhoA
 ornithine decarboxylase induction, 2748
 R2 and oncogenes, 1650
 suppression by glucocorticoid receptor mutants, 867
Cellular retinoic acid binding protein II
 expression, acute promyelocytic leukemia cells, 5770
CEM-C1 cells
 killing by GC-PKA synergism, 3684
Central nervous system
 myelin
 glioma cells, human and rat, 149
Centrosome
 defects, malignant tumors, 3974
Ceramide synthase
 apoptosis mediation, LNCaP cells, 2260

c-erbB-2: see HER2

Cerebellar development

ErbB-neuregulin signaling network, 3932

Cerebellar hemangioblastoma

sporadic, 504

Cervical carcinoma

angiogenesis, 2343

assessment by dynamic MRI, 3598

apoptosis, 2343

HPV16 E6 variants, 829

p53 polymorphism and, Japanese patients, 4585

ribonucleotide reductase regulation after ionizing radiation, 2245

telomerase activity, 3812

telomerase subunit expression, 1558

Cervical intraepithelial neoplasia

grade III

telomerase activity, 3812

Cervical lesions

HMGI(Y) protein expression, 426

hTERT status, 3812

Cervical neoplasia

cell cycle regulation by HPV, 2941

HPV-16 E7 Th responses, 1700

Chemical inducers

JAK2 activation, murine erythroleukemia cells, 556

Chemically induced mammary tumors

suicide gene therapy, 3529

Chemoprevention

celecoxib, colon carcinogenesis, 409

nimesulide, bladder carcinoma, 3028

Chemopreventive agents

apoptosis induction, 402

Chemoprotection

against chemotherapy toxicity

4-nitrobenzylidene malononitrile, 2397

Chemoresistance: see also Drug resistance;

multidrug resistance

WAF1/Cip1, glioblastoma, 1538

Chemosensitivity

E2F-1 role, 4292

Chemotherapy

apoptosis

inhibition by radiation, glioma, 3819

inhibition by VEGF, hematopoietic cells, 5565

effects

modulation by DNA repair, 3965

gastrointestinal injury

keratinocyte growth factor effects, mice mucositis models, 933

polymeric delivery, monkey brain, 672

survival factor signaling and, 801

toxicity

4-nitrobenzylidene malononitrile protective effects against, 2397

CHENSPm: see N¹-Ethyl-N¹¹-[(cycloheptyl)methyl]-4,8-diazaundecane

Chernobyl

thyroid carcinoma

RET rearrangement, 198

Childhood acute lymphoblastic leukemia

chromosome 6q loss of heterozygosity, 2618

Children

low-birth-weight

hepatoblastoma risk, 3032

Chinese hamster ovary cells

compromised genomic integrity, 3712

Chlorambucil

cytotoxicity, B-cell chronic lymphocytic leukemia, 1789

6-O-(N-Chloroacetyl-carbamoyl)-fumagillol:

see TNP-470

N-(2-Chloroethyl)-N'-cyclohexyl-N-nitro-

sourea

sensitivity, MMR⁻ cells, 135

Chlorotoxin

brain tumor targeting, 4871

Choline-deficient, L-amino acid-defined diet

liver carcinogenesis

inhibition by PBN, rats, 4548

Choriocarcinoma

$\alpha 1 \rightarrow 2$ fucosyltransferase activity, 4301

$\alpha 2 \rightarrow 6$ sialyltransferase activity, 4301

Choroidal melanoma

MARCKS expression, 1429

Chromosome 1

alterations, head and neck carcinoma, 5859

Chromosome 1p32

loss of heterozygosity, meningioma, 3226

Chromosome 1q31-32

allelic imbalance region, breast carcinoma, 4480

Chromosome 3

duplications, non-small cell lung cancer, 4701

Chromosome 3p12

tumor suppressor gene locus, renal cell carcinoma, 3533

Chromosome 3p14

alterations, lung carcinoma, 1804

Chromosome 3p21.3

BPDE-induced aberrations, 1605

immunogenic lung cancer antigens, 1034

Chromosome 4q22

ABCP gene, 5337

Chromosome 6q

loss of heterozygosity, childhood acute lymphoblastic leukemia, 2618

Chromosome 7q31

molecular cytogenetics, prostate cancer, 759

Chromosome 8

translocation, benzene-exposed workers,

2176

Chromosome 9p23-24

tandem duplication, male breast cancer, 863

Chromosome 12

metastasis-suppressor region, identification,

3561

Chromosome 12p

deletions, advanced prostate cancer, 5652

Chromosome 12q

allelic loss, pancreatic carcinoma, 2456

Chromosome 13q14

deletions, splenic lymphoma with villous lymphocytes, 1736

Chromosome 16

metastasis inhibition, prostatic tumor cells, 4572

Chromosome 16q23.2-24.2

allelic loss

prognosis and, breast carcinoma, 2166

Chromosome 17

AT6.1 prostate carcinoma micrometastases

suppression *in vivo*, 4963

loss of heterozygosity

breast carcinoma, 1004

Chromosome 18q

tumor suppressor locus, lung carcinoma, 3700

Chromosome 19p

deletions, adenoma malignum, 1140

Chromosome 19q

familial Wilms' tumor predisposition linkage, 1387

Chromosome 21

growth factor dependency gene, 2863

translocation, benzene-exposed workers,

2176

Chromosomes

aberrations

cancer prediction, study report, 4117

amplification, cisplatin-resistant germ cell

5915

tumors, 4260

imbalances, uterine serous and endometrioid carcinomas, 892

translocation t(8;21)

benzene-exposed workers, 2176

translocation t(4;14)(p16;q32)

incidence, plasma cell malignancies, 5640

translocation t(11;14)(q13;q32)

incidence, plasma cell malignancies, 5640

Cidofovir

antitumor activity, nasopharyngeal carcinoma, 384

hemangioma growth inhibition, 2562

Cigarette smoke

DNA deletions, 2633

Cisplatin

c-myc antisense oligodeoxynucleotides and, melanoma chemotherapy, 283

p53 induction, 698

resistance

chromosomal amplification, germ cell tumors, 4260

pleiotropic defect, 268

transcription factor cross-linking to MAR DNA, 3004

c-jun kinase/stress-activated protein kinase

activation by ambient particulate matter, lung epithelial cells, 4543

c-Jun NH₂-terminal kinase 1

activation by BaP, 2102

stimulation by paclitaxel, 241

Clastogenicity

apurinic endonuclease role, 4410

chemotherapeutic

modulation by DNA repair, 3965

Clear cell renal carcinoma

FHIT expression, 2946

plasma DNA, 4728

c-Met

autocrine activation

malignant melanoma induction, 5157

c-Mos

induction and activation by paclitaxel, ovarian carcinoma, 3633

c-Myb

expression, colonic crypts and colon tumor cells, 5168

c-Myc

antisense oligodeoxynucleotides

cisplatin and, melanoma chemotherapy, 283

expression, non-Hodgkin's lymphoma, 1762

internalization sequence-fused helix 1-type

peptide Int-H1-S6A.F8A

growth and transcription inhibition, 3654

overexpression, small cell lung cancer, 5537

transcription inhibition by Int-H1-S6A.F8A,

3654

Colitis

ulcerative

p16^{INK4a} promoter hypermethylation, 3942

Collagen

degradation regulation, mammary carcinoma, 4970

Colon

crypts

c-Myb expression, 5168

polyps

fecal water ursodeoxycholic acid, rats, 1684

Colon adenocarcinoma

hnRNP and SR factor expression, 5818

metastasis

hepatic, inhibition by KRN7000, 1202

TNF- α receptor shedding inhibition by TIMP-2, 4001

- Colon adenoma**
nitric oxide synthase-2 expression, 334
TGF- β *RII* mutations, 3101
- Colon carcinogenesis**
chemoprevention by celecoxib, 409
- Colon carcinoma**
apoptosis
mitochondrial membrane potential, 2869
modulation by PGE₂, 362
CD95-mediated apoptosis resistance, 526
cell proliferation
mitochondrial membrane potential, 2869
doxorubicin resistance
GST role, 947
Her-2/neu-derived peptides, 732
hMLH1 promoter hypermethylation, 3455
left-sided
STK11 somatic mutations, 3787
metastasis
cytokine-induced tumor-protective immunity, 3918
promotion by Ω -3 PUFAs, 3312
multidrug resistance reversal by fumitremogin C, 5850
risk
and *APC* gene, 4038
sporadic
STK11 mutations, 4799
TP/PD-ECGF expression, 1551
tumorigenicity
hsp27 effects, rat cells, 5495
VEGF regulation by IGF-I, 4008
- Colon tumorigenesis**
inhibition by auraptene, 2550
- Colon tumors**
aspirin toxicity *in vitro*, 2772
 β -catenin mutations, azoxymethane-induced
rat, 42
c-Myb expression, 5168
- Colorectal adenoma**
plasma tocopherol and, 661
sPLA₂ overexpression, 500
- Colorectal carcinogenesis**
p27^{KIP1}, 114
- Colorectal carcinoma**
age-related DNA methylation, 5489
APC/ β -catenin/Tcf pathway mutations, 1130
apoptosis inhibition by survivin, 5071
CA19-9 and DU-PAN-2 serum levels
Le and *Se* gene dosage effects, 512
cancer cell nest CD8+ T cells, 3491
 β -catenin gene mutations, 1021
cathepsin L2, 1624
combination FUra/LV and IL-15 interactions, 1695
COX-2 expression reduction by antioxidants, 2323
cyclooxygenase-2 levels, 4823
defective mismatch repair
COX-2 expression, 5473
E2F4 and *hMSH3* mutations, 594
familial
I1307K *APC* mutation, Norwegian patients, 2919
hereditary nonpolyposis
mouse models, 248
somatic frameshift mutations, 997
hMLH1, 1713
Ki-ras and p53, 1149
LKB1 mutations, 2087
microsatellite instability, 1713
international criteria, meeting report, 5248
mutator phenotypes, 1713
polypoid
K-ras codon 12 mutations, 3289
prognosis
 β 1,6-branched oligosaccharides and, 5559
hyaluronan and, 342
- risk
NAT genotype and red meat intake and, 3307
serum, molecular detection, 1405
sporadic
I1307K *APC* mutation, Norwegian patients, 2919
telomerase activity, 4052
tumor cell killing by sinusoidal endothelial cells, 1524
- Colorectal mucosa**
age-related DNA methylation, 5489
- Colorectal neoplasia**
APC I1307K somatic instability, 4040
- Colorectal tumors**
metastasis
and antisense CD44v6, 3719
- Combretastatin A-4**
apoptosis induction, 4510
- Comparative genomic hybridization**
atypical lobular hyperplasia of breast analysis, 4721
bladder cancers, 3555
changes, ovarian carcinomas, 2715
lobular breast carcinoma *in situ* analysis, 4721
malignant melanoma, 2170
Merkel cell carcinoma analysis, 1503
ovarian germ cell tumor analysis, 3105
patterns, endometrial carcinoma, 892
thymidylate synthase inhibitor resistance analysis, 5042
- Complement**
component C3
-cleaving proteinase, melanoma metastasis, 2733
- Complementary DNA: see also DNA**
directionally cloned libraries
construction from microdissected cells, 5326
microarrays
alveolar rhabdomyosarcoma gene expression profiling, 5009
rabbit carboxylesterase, isolation, 2646
retroviral library, 3519
- Complex atypical hyperplasia**
PTEN mutations and microsatellite instability, 3254
- Connexin 26**
gene modulation by hCG, rat mammary glands, 1498
- Connexin 43**
neoplastic phenotype reversion, glioblastoma cells, 5089
- CpG sequences**
preferential carcinogen binding, 2070
- CPP32 β gene**
retroviral transfer, malignant glioma, 962
- CPT: see Camptothecin**
- CPT-11: see 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin; Irinotecan**
- c-Ras**
MMP-9 activation by fibronectin, ovarian cancer, 900
- CTLA-4**
blockade
therapeutic benefits, 5301
- Cullin gene *cul-4A***
overexpression, breast cancers, 3677
- Cutaneous melanoma**
metastatic, UVR-treated transgenic mice, 4061
- Cyclic adenosine monophosphate**
melanocyte response to UVB light mediation, 47
- Cyclic guanosine monophosphate**
bradykinin-induced permeability mediation, 914
- Cyclin A**
overexpression
hepatocellular carcinoma recurrence and, 985
- Cyclin D**
CDK4(6) complex
promotion by mutant p21^{WAF1/CIP1}, 5053
- Cyclin D1**
inhibition by phosmidosine, 704
overexpression
antiestrogen action and, 871
invasive lobular breast carcinoma, 2876
- Cyclin-dependent kinase**
inhibitors
mIgM-mediated cell cycle arrest, 691
regulation, monolayers and spheroids, 1305
- Cyclin-dependent kinase 4(6)**
CDK4 gene
mutations, 109
cyclin D complex
promotion by mutant p21^{WAF1/CIP1}, 5053
mutations, neuroblastoma, 2624
- Cyclin-dependent kinase *CDKN2A/ARF* pathway**
inactivation
TP53 and, 5348
- Cyclobutane pyrimidine dimers**
mutagenesis, trichothiodystrophy cells, 102
- N-[2-(Cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide: see NS-398**
- Cyclooxygenase**
inhibitors
tumor vascular permeability modulation, 159
- Cyclooxygenase 2**
expression
Barrett's esophagus, 2929
colorectal carcinoma with defective mismatch repair, 5473
lung carcinoma, 3761, 4997
reduction by antioxidants, colorectal carcinoma, 2323
inhibition by triterpenoids, mouse macrophages, 717
inhibitors
chemopreventive activity, colon carcinogenesis, 409
levels, colorectal carcinoma, 4823
mutations, attenuated adenomatous polyposis coli, 4909
tumor
IL-10 and IL-12 modulation, 1208
- Cystatin A**
breast cancer, 432
- Cystic fluid**
cleaved su-PAR, ovarian cancer, 3294
- Cytarabine**
high-dose
remission duration, acute myeloid leukemia, 4173
- Cytochrome P450**
1A1
and breast cancer risk, 667
expression, human mammary epithelial cells, 2366
induction by diosmin and diosmetin, 2754
polymorphisms, breast carcinoma and, 65
polymorphisms, lung cancer association, 4858
transcription inhibition by resveratrol, 5707
1A2
Salmonella harboring, 1833
1B1
expression, human mammary epithelial cells, 2366

- polymorphisms, breast cancer, 5038
 2B6
 gene therapy, 4391
 2E1
 polymorphisms, lung cancer association, 4858
 3A
 irinotecan metabolism, 468
 c17 α gene polymorphism
 serum hormone levels and, 585
Cytokines
 expression, head and neck squamous cell carcinoma, 3132
 proinflammatory, squamous cell carcinoma, 3668
 tumor-protective immunity, colon carcinoma metastases, 3918
Cytomegalovirus
 infection
 drug resistance induction, neuroblastoma cells, 367
Cytoprotection
 gonadal regression-cytoprotection hypothesis, testing, 5105
Cytosine deaminase
 preferential cytotoxicity, 2588
Cytotoxicity
 antibody-dependent cellular
 B-cell antibodies, 3051
 immunotoxin additivity, 5787
 Bcl-2 modulation by sFv and, 2134
 chlorambucil, B-cell chronic lymphocytic leukemia, 1789
 drug
 time-course, 5749
 gemcitabine
 and nucleoside transporters, 4349
 multilog
 mediation by ganciclovir, 3873
 preferential
 cytosine deaminase-transduced cells, 2588
Cytotoxic nucleoside analogues
 G₂-M arrest, 3855
Cytotoxic T lymphocytes
 adriamycin-selected tumor recognition, 4790
 direct priming by engineered fibroblast antigen-presenting cell, 3094
 HLA-A68.2-restricted squamous cell carcinoma of lung-specific
 peptide recognition, 5144
 HPV16 E7-specific
 tumor protection, 724
 plasmid backbone-derived epitopes, 3087
 precursors
 antigen presentation and, 3909
 recruitment and functional maturation, 3376
 renal cell carcinoma-specific
 usage by T-cell receptor, 3078
 TRP2 epitope, 4895
Cytotoxins
 bone marrow-sparing, 2568

D

- DAM gene family**
 new tumor antigens, 2969
DBA/2 lymphoma
 lacZ tagged
 dormancy, bone marrow and lymph nodes, 5439
Death receptor gene KILLER/DR5
 mutations, head and neck squamous cell carcinoma, 3513
 regulation, 1593
Defective bypass replication
 hereditary
 UV damage, xeroderma pigmentosum, 2445
Dehydroepiandrosterone
 MNU-induced breast cancer modulation, 921
 ribose and cell proliferation inhibition, 3188
Deleted in human liver cancer (DLC-1) gene
 cloning, characterization, and chromosomal localization, 2196
Deleted in pancreatic carcinoma (DPC4/Smad4) gene
 dysfunction, cancer cells, 4592
 mutations, biliary tract carcinoma, 1124
 overexpression, carcinoma cells, 5656
Deletions
 BRCA2 exon 3, 1372
 chromosome 19p, adenoma malignum, 1140
 chromosome 12p, advanced prostate cancer, 5652
 chromosome 13q14, splenic lymphoma with villous lymphocytes, 1736
 cigarette smoke, 2633
 FHIT gene
 and survival, non-small cell lung cancer, 2533
 germ-line INK4, melanoma and nervous system tumors, 2298
 induction by cigarette smoke, 2633
 p16, brain lymphoma, 1231
Dendritic cells
 maturation
 CD40-ligand-induced, 2965
 MNG stomach carcinogenesis response, 4107
 modified adenoviral gene transfer, 956
(E)-2'-Deoxy-2'-(fluoromethylene) cytidine
 radioresponse potentiation, solid tumor xenografts, 5411
2'-Deoxy-2'-methylidenecytidine
 antitumor activity modulation by cytidine deaminase, 1165
Development
 telomerase regulation, 4168
Developmental disorders
 complex
 cancer, 5633
Dexamethasone
 cohesion effects, HT-1080 cells, 3586
cis-Diamminedichloroplatinum(II)
 DNA damage repair
 BRCA1 role, 1120
1,12-Diaziridinyl-4,9-diazadodecane
 apoptosis induction, prostate carcinoma cells, 4864
Diet
 carcinoma modulation, mouse familial adenomatous polyposis model, 5713
 choline-deficient, L-amino acid-defined
 liver carcinogenesis, inhibition by PBN, 4548
 α -Difluoromethylornithine
 cell proliferation and apoptosis effects, esophageal carcinogenesis, 5380
Dihydrofolate reductase inhibitors
 super synergy
 polyglutamylase role, 3036
Dihydropyrimidine dehydrogenase
 dThdPase ratio
 capecitabine efficacy correlation, 685
1,25-Dihydroxyvitamin D₃
 cPLA₂ inactivation, TNF resistance, 633
1 α ,25-Dihydroxyvitamin D₃
 sphingosine-1-phosphate and, 1817
Dimesna
 hepatic reduction, rat, 4358
Diosmetin
 CYP1A1 induction, 2754
Diosmin
 CYP1A1 induction, 2754

5917

- β -L-(-)-Dioxolane-cytidine: see BCH-4556**
Disulfide
 -stabilized Fv
 renal uptake blockade by aminosyn II, 2612
DIVEMA
 TNF- α conjugate
 antitumor activity, solid tumors, 290
Divinyl ether
 maleic anhydride copolymer
 TNF- α conjugate antitumor activity, solid tumors, 290
DMDC: see 2'-Deoxy-2'-methylidenecytidine
DNA
 cleavage by DNA topoisomerase II α , 1886
 complementary
 directionally cloned libraries, construction from microdissected cells, 5326
 microarrays, alveolar rhabdomyosarcoma gene expression profiling, 5009
 rabbit carboxylesterase, isolation, 2646
 retroviral library, 3519
 copy number changes
 gastric cancer, 34
 gastro-esophageal junction adenocarcinoma, 34
 ends
 PARP cleavage product binding, 3495
 extrachromosomal
 loss after radiation, 3845
 fragmentation pathway, CPT-induced apoptosis, 3066
 matrix attachment region
 transcription factor cross-linking, 3004
 methylation
 age-related, colorectal mucosa and colorectal, 5489
 inhibition by 5-Aza-Cdr, growth inhibition, 95
 p19/p16 expression role, bladder carcinoma, 1245
 mitochondrial
 chemically induced mutations, 2857
 plasma, clear cell renal carcinoma, 4728
 replication
 inhibition by FAS inhibitors, tumor cells, 4611
 p53-dependent signaling and, UV-irradiated fibroblasts, 1993
 replication bypass
 mismatch repair-defective cells, 3579
 sequences
 CpG
 preferential carcinogen binding, 2070
 synthesis
 error-prone, breast carcinoma, 3259
 topoisomerase I-DNA complex
 stimulation by UV-induced DNA damage, 976
DNA adducts
 BPDE
 replication, cell extract, 887
 serum antibodies, 4122
 α -hydroxytamoxifen-derived
 hydroxysteroid (alcohol) sulfotransferase a, 647
 methylphalan monoadducts
 nucleotide excision repair, 5196
 mitomycin C
 ³²P-postlabeling *in vivo*, 453
 1,N²-propanodeoxyguanosine
 smoking-induced DNA damage biomarkers, 581
 pancreatic tissues, 38
 PhIP, histochemical detection, 4307
 platinum
 replicative bypass, mismatch repair-defective cells, 3579

- DNA alkyltransferase**
random sequence mutagenesis, 1013
- DNA damage**
apoptosis
p53 and PARP interactions, 5075
CDDP-induced
repair, *BRCA1* role, 1120
double-strand breaks, lymphomagenesis in SCID mice, 3111
G₂ block
caffeine-resistant, 2639
hREC2/RAD51B gene sensor, 4733
interstrand cross-links, mitochondria, 1400
nuclear fragmentation
activation by AP24, Bcl-2 effects, 5570
RTP/rit42 responsiveness, 4439
smoking-induced
biomarkers, 581
UV
hereditary defective *in vitro* replication, xeroderma pigmentosum, 2445
topoisomerase I-DNA complex stimulation, 976
UVB-induced
modulation by sunscreen, 2961
- DNA repair**
CDDP-induced DNA damage
BRCA1 role, 1120
chemotherapeutic effect modulation, 3965
genes
polymorphic amino acid substitutions, 604
mismatch
defective, COX-2 expression and, colorectal carcinoma, 5473
-defective cells, CCNU sensitivity, 135
-defective cells, replicative bypass, 3579
genes, somatic frameshift mutations, hereditary nonpolyposis colorectal carcinoma, 997
nucleotide excision
HPV *E6* gene effects, 599
impairment by apoptosis, 1978
melphalan monoadducts, 5196
topoisomerase I recruitment, 976
- DNA topoisomerase**
T4 type II
mutations, 1260
- DNA topoisomerase I**
absence
topotecan lactone-DNA binding, 3782
activation
mutant p53, 2091
DNA complex
stimulation by UV-induced DNA damage, 976
recruitment by DNA repair, 976
- DNA topoisomerase II α**
apoptosis induction, 4519
DNA cleavage, 1886
Y49F, bisdioxopiperazine resistance, 1460
- DNA topoisomerase II β**
RNA expression, HL-60/AMSA cells, 5298
- Docetaxel**
chronopharmacology, mice, 3896
- Double suicide gene**
heat-inducible
adenoviral-mediated transfer, prostate carcinoma, 1358
- Down syndrome**
neuroblastoma, 448
- Doxorubicin**
antitumor activity enhancement by rhuMAB HER2, 2825
arterial vs portal hepatic extraction, 3339
hepatobiliary disposition
multidrug resistance modulators and, 3641
immunoliposomal
targeting to B lymphocytes, 3320
resistance
GST role, colon cancer cells, 947
- Doxorubicin-peptide prodrugs**
activation by prostate-specific antigen, 2537
- Drug resistance: see also Chemoresistance;**
Multidrug resistance
ABC2 gene amplification and, ovarian carcinoma, 1332
induction by human CMV infection, neuroblastoma cells, 367
neuroblastoma patterns, 5396
NF- κ B activation, 3059
prevention by MG-132, 3059
uKHC domain, 3423
- Drugs: see also specific drugs**
apoptosis
inhibition by VEGF, hematopoietic cells, 5565
molecular ordering, neuroblastoma cells, 4453
cytotoxicity
time-course, 5749
prodrugs
doxorubicin-peptide, activation by prostate-specific antigen, 2537
 β -glucuronidase-mediated activation, 1195
prostate xenograft tumor effects, 2777
- DU145 cells**
cell cycle modulation by silymarin, 1920
erbB1 signaling modulation by silymarin, 1920
- Ductal carcinoma in situ**
p53 mutations, 785
- Ductal tumorigenesis**
pancreatic
early diagnosis by FISH, 4222
- DU-PAN-2**
serum levels
Le and *Se* gene dosage effects, 512
- Duplications**
chromosome 3, non-small cell lung cancer, 4701
- Dysplasia**
esophageal
S. anginosus, 2991
- E**
- Early growth response genes**
expression, prostate carcinoma, 2461
- EblacZ tumor**
dormancy, bone marrow and lymph nodes, 5439
- Edelfosine**
sensitivity
oxidative basis, K562 and HL-60 cells, 2809
- Eicosanoids**
and keratinocytes, 4624
- Eicosapentaenoic acid**
lipolysis inhibition, 4827
- Electron paramagnetic resonance imaging**
in vivo
tumor heterogeneity, 1562
- Eleutherobin**
tubulin polymerization induction, 1111
- Elongation factor 2 gene**
mutations, HLA-A68.2-restricted squamous cell carcinoma of lung, 5144
- EM-800**
growth effects, breast cancer xenografts, 60
- EMT-6 cells**
NO-mediated radiosensitization, 5646
- Endocrine tumors**
pancreatic
allelotyping, 3706
MEN1 gene mutations, 4417
- 5918
- Endometrial carcinoma**
 β -catenin mutation, 3526
comparative genomic hybridization patterns, 892
hPMS2 gene complementation, HEC-1-A cells, 2978
PR-B downregulation, 1860
- Endometrial hyperplasia**
PTEN mutations, 2500
- Endometrioid carcinoma**
comparative genomic hybridization patterns, 892
ovarian
CTNNB1 mutations, 1344
- Endometriosis**
ovarian carcinoma and, 1077
- Endothelial cells**
sinusoidal
tumor cell killing, 1524
- Endothelin-1**
expression, prostate cancer cells, 4817
- Endothelium**
tumor
vascular endothelial growth factor marker, 1952
- Energy metabolism**
photoactivated hypericin effects, 5777
- Engineered fibroblast antigen-presenting cell**
direct CTL priming, 3094
- Enzymes**
anticarcinogenic phase 2
isothiocyanate inducer potencies, 4632
- Epidemiology**
molecular, human cancer, 4023
- Epidermal growth factor**
carcinoma invasion
matrix metalloproteinase role, 5221
and oncogenes, hepatocarcinogenesis, 3590
receptor-targeted adenoviral gene transfer, glioma cells, 5738
- Epithelia**
intestinal
apoptosis induction and 5-FU-induced histopathology, 5453
- Epithelial carcinoma**
ovarian
AKT2 activation, 2973
- Epithelial cells**
bronchial
mitochondrial mutational spectra, smoking vs nonsmoking, 1268
lung
ambient particulate matter, 4543
mammary
CYP1B1 and CYP1A1 expression, 2366
ER Δ E5 splice variant dominant negative activity, 4264
p16^{INK4} expression loss by methylation, 3508
p27^{Kip1} overexpression, 3448
UCLA/Jennifer Jones Simon Foundation Symposium on Prostate Cancer and Epithelial Cell Biology, meeting report, 2895
- Epitopes**
cytotoxic T lymphocyte
plasmid backbone-derived, 3087
mapping
thymidylate synthase monoclonal antibodies, 2606
- Epoxide hydrolase**
microsomal
and lung cancer, 5291
- EPR imaging: see Electron paramagnetic resonance imaging**
- Epstein-Barr virus**
autologous immortalized B-cells

- nontumorigenic malignant Burkitt's lymphoma hybrid cells, 4930
 hybrid retrovirus
 GFP-expressing, 14
- erbB**
 neuregulin signaling network
 cerebellar development, 3932
 receptor signaling, granulosa cell tumors, 1773
- erbB-1**
 signaling modulation by silymarin, prostate carcinoma DU145 cells, 1920
- erbB-2: see HER-2/neu**
- erbB-4**
 ribozyme, 3415
- ERR α -1**
 aromatase expression modulation, breast, 5695
- Erythroleukemia**
 cell differentiation
 inhibition by nuclear PLC β_1 , 5057
 JAK2 activation by chemical inducers, murine cells, 556
- Erythropoietin A**
 recombinant
 protective effects, 5374
- Esophageal carcinogenesis**
 inhibition by DFMO, 5380
- Esophageal carcinoma**
 Fas and Fas ligand expression, 2057
 KAI1, 753
S. anginosus, 2991
 squamous cell
 FHIT methylation, 3429
- Esophageal dysplasia**
S. anginosus, 2991
- Esophagus**
 Barrett's
 iNOS and COX-2 expression, 2929
- Estradiol**
 breast tumor levels
 in situ aromatization and, 927
- Estrogen**
 receptor
 ER Δ E5 splice variant, dominant negative activity, breast epithelial cells, 4264
 ER gene CpG island mapping, 2515
 fat and, 654
 retinoid response activation, 5110
 receptor α
 mRNA expression, breast tumorigenesis, 3197
 mRNA expression, ovarian carcinogenesis, 5367
 mutant inhibition by antiestrogens, 877
 receptor β
 mRNA expression, breast tumorigenesis, 3197
 mRNA expression, ovarian carcinogenesis, 5367
 mRNA variants, breast cancer, 210
 mutant inhibition by antiestrogens, 877
 serum levels
 CYP17 polymorphism and, 585
- Ether-a-go-go-related gene**
 human *herg*
 cloning, tumor cells, 815
 K⁺ channels, 815
- Ether lipids**
 sensitivity
 oxidative basis, K562 and HL-60 cells, 2809
- N¹-Ethyl-N¹¹-(cycloheptyl)methyl]-4,8-diazaundecane**
 programmed cell death, 2711
- 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin**
 activation by rabbit liver carboxylesterase, 4611
- Fecal water**
 ursodeoxycholic acid, colon polyps, 1684
- α -Fetoprotein**
 mRNA expression, liver regeneration, 5825
- Fibroblast antigen-presenting cell**
 engineered
 direct CTL priming, 3094
- Fibroblast growth factor**
 basic
 inhibition by IFN- α , 808
 receptor 1
 overexpression, FGF-1-transfected MCF-7 cells, 352
 receptor 2
 growth inhibition, prostate tumor, 1509
- Fibroblast growth factor 1**
 FGFR1 overexpression, MCF-7 cells, 352
- Fibroblast growth factor 8**
 expression, prostate cancer and breast tissues, 2053
- Fibroblasts**
 diploid
 senescence induction by PI-3 kinase, 1, 4980
 G₁ regulation, monolayers and spheroids, 1305
 microsatellite mutation rate, 3946
 prostatic
 LNCaP cell death decrease, 4525
 UV-irradiated
 p53-dependent signaling and DNA replication, 1993
- Fibronectin**
 $\alpha 5$ integrin interactions, tumorigenesis, 848
 MMP-9 activation, ovarian cancer, 900
- Fibrosarcoma**
 cohesion
 dexamethasone effects, HT-1080 cells, 3586
 congenital
 histogenetic link with mesoblastic nephroma, 5046
- Fibrosarcoma 1**
 radiation-induced
 5-fluorouracil response, 1063, 2904
- Finasteride**
 ventral prostate weight reduction, 215
- Fine needle aspirates**
 breast carcinoma
 cell cultures, 5271
- Fine-needle aspiration biopsy**
 thyroid carcinoma
 galectin-3, 3015
- FLT3 ligand**
 antitumor effects, melanoma and lymphoma, 380
- Fluorescence *in situ* hybridization**
 early pancreatic ductal tumorigenesis diagnosis, 4222
- 5-Fluorocytosine**
 activation, MR detection, 4075
- 5-Fluorouracil**
 combined with leucovorin
 IL-15 interactions, colorectal carcinoma, 1695
 histopathology
 apoptosis induction and, intestinal epithelia, 5453
 regional pharmacokinetics, dogs, 1688
 resistance
 gene therapy to overcome, 1946
 RIF-1 tumor response, 1063, 2904
 synergy with rMETase, 2582
 tumor uptake
 increase by carbogen, 1185
- Fms-like tyrosine kinase 3**
 ligand
- ets**
 binding site
 MMP-1 single nucleotide polymorphism, 5321
- ets-2**
 activation by *ras* signaling, ovarian carcinoma, 2253
- ETV6-NTRK3 gene fusions**
 mesoblastic nephroma and congenital fibrosarcoma, 5046
- Eucalcemia**
 parathyroid hormone-related protein, 4113
- European Study Group on Cytogenetic Biomarkers and Health**
 chromosomal aberrations report, 4117
- Ewing's sarcoma**
 Fas and Fas ligand expression, 5842
 gastrin-releasing peptide expression, 2469
 growth inhibition by IGF-IR blockade, 4127
- Exercise capacity**
 rHEPO protective effects, 5374
- EXO1 gene**
 human *EXO1*, identification, 5027
- Exonuclease I**
 hMSH2 interactions, 4537
- Extracellular matrix**
 remodeling
 cell-mediated, MMP-2 activation, 3743
- F**
- 3F8**
 micrometastases eradication, 2844
- Fab fragments**
 isolation by panning phage Ab libraries, ovarian carcinoma cells, 991
- Factor VIIa-tissue factor system**
 pancreatic carcinoma, 4461
- Fallopian tube carcinoma**
 genomic alterations, 4274
- Familial adenomatous polyposis**
 adenoma prostanoid levels, 1750
 carcinoma
 dietary modulation, mouse model, 5713
- Familial carcinoma: see also specific sites**
 "The International Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection and Familial Predisposition," meeting report, 5248
- Fanconi anemia group C gene (FAC)**
 overexpression, transgenic mice, 3538
- Farnesyl transferase inhibitors**
 antitumor effects, 1253
 tricyclic
 antitumor activity, 4947
- Fas**
 apoptosis
 inhibition by Ras, 3391
 resistance, colon carcinoma, 526
 TGF- β 1 and, glioma, 302
 caspase-mediated NF- κ B cleavage, 882
 expression
 esophageal carcinoma, 2057
 Ewing's sarcoma, 5842
 pancreatic adenocarcinoma, 1741
 tumor-infiltrating lymphocytes, renal cell carcinoma, 2078
 ligand
 expression, esophageal carcinoma, 2057
 expression, Ewing's sarcoma, 5842
 expression, pancreatic adenocarcinoma, 1741
- Fat**
 and estrogen receptor, 654
 and protein kinase C activity, 654
- Fatty acid synthase inhibitors**
 DNA replication inhibition, tumor cells, 5919

- antitumor effects, melanoma and lymphoma, 380
- Focal adhesion kinase**
MMP-9 activation by fibronectin, ovarian cancer, 900
- Folate**
receptors
antibody, scFv/IL-2 fusion protein, 4146
uptake regulation by actin cytoskeleton disruption, 2952
- Fostriecin**
G₂-M phase growth arrest, 3611
- Fractionated radiotherapy**
tumor responses
apoptosis and, 1779
- Fragile histidine triad (FHIT) gene**
alterations, pancreatic carcinoma, 1583
5' CpG island methylation, esophageal squamous cell carcinoma, 3429
deletions
and survival, non-small cell lung cancer, 2533
expression
acute leukemias, 5182
clear cell renal cell carcinoma, 2946
stage I non-small cell lung cancer, 5478
expression loss, gastric carcinoma, 4708
functional loss, lung cancer and preinvasive bronchial lesions, 5032
murine
isolation and mapping, 3409
locus, 3401
- Fructose**
intake
and prostate cancer risk, 442
- $\alpha 1 \rightarrow 2$ Fucosyltransferase**
activity, choriocarcinoma, 4301
- Fumitremorgin C**
multidrug resistance reversal, colon carcinoma, 5850
- Fusion genes**
leukemia
induction by ionizing radiation, 421
NUP98-HOXD13, therapy-related acute myelogenous leukemia, 4269
- Fusion proteins**
antifolate receptor scFv/IL-2 fusion protein, 4146
IL-2-IgG
tumor rejection induction, 2707
PAX3-FKHR
rhabdomyosarcoma oncogenesis, 4426
target gene analysis, alveolar rhabdomyosarcoma, 3542
- Fv molecules**
disulfide-stabilized fragments
renal uptake blockade by aminosyn II, 2612
single-chain
antifolate receptor scFv/IL-2 fusion protein, 4146
anti-HMW-melanoma-associated antigen, characterization, 2417
anti-MUC1, phage antibody libraries, 4324
Bcl-2 modulation, cytotoxicity and, 2134
HPV16 E7 downregulation, 1893
tumor delivery, affinity increase and, 485
VEGF inhibition, 3209
- G**
- Galectin-3**
thyroid fine-needle aspiration biopsy, 3015
- Ganciclovir**
combined with HSV-tk
G₂-M arrest, 3855
prostate cancer therapy, 3221
- multilog cytotoxicity mediation, 3873
- Gangliosides**
GD2
antibodies, micrometastases eradication, 2844
neuroblastoma-derived
hemopoiesis inhibition, 4840
- Gastric adenocarcinoma**
H. pylori infection and, 588
- Gastric carcinogenesis**
H. pylori infection, Mongolian gerbil, 2067
MNNG-induced
dendritic cell response, 4107
- Gastric carcinoma**
DNA copy number changes, 34
families
E-cadherin mutations, 4086
FHIT expression loss, 4708
H. pylori-induced, Mongolian gerbils, 4255
KAI1, 753
replication errors, 1494
S. anginosus, 2991
survivin expression, 1808
- Gastrinoma**
p16/MTS1 inactivation, 237
- Gastrin-releasing peptide**
expression, Ewing tumors, 2469
- Gastro-esophageal junction adenocarcinoma**
DNA copy number changes, 34
- Gastrointestinal carcinoma**
metastasis to liver
basement membrane invasion and, 3727
- Gastrointestinal injury**
chemotherapy and radiation treatment
keratinocyte growth factor effects, mice
mucositis models, 933
- Gastrointestinal tissues**
IGFBP-3 sequence alterations, 4802
- Gastrointestinal tumors**
sporadic
BLM and CBL microsatellite instabilities, 3777
- GBX2**
expression, prostate carcinoma, 1391
- Gelatinase A**
deficiency
angiogenesis and tumor progression, mice, 1048
- Gelsolin**
expression, non-small cell lung cancer, 322
- Gemcitabine**
cytotoxicity
and nucleoside transporters, 4349
- Gene expression profiling**
cDNA microarray, alveolar rhabdomyosarcoma, 5009
- Gene markers**
micrometastasis, 2440
- Genes: see also Fusion genes; Oncogenes; specific genes**
amplification
chronic oxidative stress-induced, 3986
anti-angiogenic
adeno-associated virus-mediated delivery, 5673
antigen-processing
expression decrease by tumor cells, 3660
complementation
hPMS2, HEC-1-A endometrial carcinoma cells, 2978
differentially expressed, prostate cancer, 3732
DNA mismatch repair
somatic frameshift mutations, hereditary nonpolyposis colorectal carcinoma, 997
DNA repair
polymorphic amino acid substitutions, 604
- early growth response
expression, prostate carcinoma, 2461
growth factor dependency
chromosome 21, 2863
metastasis-suppressor
chromosome 12 region, identification, 3561
NO response, 3435
proapoptosis
somatic frameshift mutations, hereditary nonpolyposis colorectal carcinoma, 997
p53 target
regulation by p73, 5061
recurrent breast carcinoma, 2081
reporter
expression, PET imaging, 4333
serial analysis of gene expression
non-small cell lung cancer, 5690
tumor suppressor
chromosome 3p12, renal cell carcinoma, 3533
chromosome 18q locus, lung carcinoma, 3700
- Gene therapy**
combination TNF- α and HSV-tk, 5731
combination TNF-R55 and mitein TNF, pancreatic cancer, 1677
CYP2B6-based, 4391
glial-specific adenovirus vector, 3504
heat-inducible, prostate carcinoma, 1358
IL-12
MHC-negative murine melanoma metastases, 1225
to overcome SFU resistance, 1936
suicide, chemically induced mammary tumor, 3529
viral vector-targeted antiangiogenic, 3362
- Gene transfer**
adenoviral
EGFR-targeted, glioma cells, 5738
modified, dendritic cells, 956
adenoviral anti-angiogenic gene, 5673
CE
CPT-11 resistance reversal, lung carcinoma, 4368
high-efficiency
GFP-expressing retrovirus, 14
retroviral CPP32 β , malignant glioma, 962
TNF- α -mediated *in vivo*, 5725
- Genistein**
cell growth stimulation *in vivo*, breast carcinoma, 3833
suppressive effects, breast carcinoma cells, 4851
- Genomes**
alterations
Fallopian tube carcinoma, 4274
instability
chronic oxidative stress-induced, 3986
- Genome surveillance processes**
mammalian cells, 4733
- Genotypes**
heterogeneity, prostate cancer, 23
mEH
and lung cancer, 5291
- Germ cell tumors**
cisplatin-resistant
chromosomal amplification, 4260
ovarian
comparative genomic hybridization analysis, 3105
- Glial cell line-derived neurotrophic factor**
differentiation, neuroblastoma, 2158
- Glioblastoma**
chemoresistance by WAF1/Cip1, 1538
IL-4 toxin antitumor activity, 3649
neoplastic phenotype reversion by cx43,

5089
PTEN mutations, 29
 radiation sensitivity
 p53 and, 1793
 tumorigenicity inhibition by *MMAC1/PTEN*, 2331

Glioma
 adenovirus vector, gene therapy, 3504
 Akt activation inhibition by *MMAC/PTEN*, 5285
 anoikis induction by *MMAC/PTEN*, 5285
 chemotherapy-induced apoptosis
 inhibition by radiation, 3819
 chlorotoxin targeting, 4871
 CNS myelin, human and rat, 149
 EGFR-targeted adenoviral gene transfer, 5738
 Fas-mediated apoptosis
 TGF- β 1 and, 302
 growth inhibition
 angiostatin, 4654
 mediation by *PTEN*, 5002
 intratumoral cytogenetic heterogeneity, 4694
 invasion
 brain slice culture model, 2935
 neural cell adhesion molecule effects, rat, 2020
 lactate turnover, NMR spectroscopy, 5083
 malignant
 retroviral *CPP32 β* therapy, 962
 MGMT activity, 1068
 NMR diffusion spectroscopy, rat brain, 3791
 selective killing, 4577

Glucocorticoid
 receptor mutants
 cell transformation suppression, 867
 -resistant leukemic cells
 killing by GC-PKA synergism, 3684
 synergy with protein kinase A
 resistant leukemic cell killing, 3684

β -Glucuronidase
 prodrug activation, 1195

Glutathione S-transferase
 doxorubicin resistance role, colon cancer cells, 947

Glutathione S-transferase μ
GSTM1
 polymorphisms, breast carcinoma and, 65
 polymorphisms, lung cancer association, 4858

Glutathione S-transferase π
GSTP1
 inactivation, 4515
 GST-P1-1-transfected MCF-7 cells
 thiotepe and, 4616
 human hGSTP1-1
 allelic variants, 5340

Glutathione S-transferase θ
GSTT1
 polymorphisms, breast carcinoma and, 65

Glycolipid sulfotransferase gene
 expression, renal cell carcinoma, 3800

Glycoprotein 75
 expression, renal cell carcinoma, 4090

Glycoprotein 100
 genetic vaccination, 2509

Glycosylation
 CD44
 and hyaluronan binding states, 3736
 MUC1 antigenicity enhancement, 2541

Gonadal regression-cytoprotection hypothesis
 test, 5105

Gonadotropin-releasing hormone
 receptors, 4558

Granulocyte colony-stimulating factor
 receptor
 prognosis and, oral and mesopharyngeal carcinoma, 794

Granulosa cell tumorigenesis
 ovarian
 multigenic/imprinting control, 3694

Granulosa cell tumors
 erbB receptor signaling, 1773

Green fluorescent protein
 expression
 bone metastasis visualization, 4217
 retrovirus, 14

Growth factors: see also specific factors
 dependency gene
 chromosome 21, 2863
 and oncogenes, hepatocarcinogenesis, 3590

Guided selection
 Fab isolation by panning phage Ab libraries, ovarian carcinoma cells, 991

H

Hamartin
 subcellular localization, 4766

Hammerhead ribozymes
 telomerase activity attenuation, 5406

Haplotypes
 vitamin D receptor
 prostate carcinoma and, African-Americans, 1620

Harvey ras
 expression, mammary carcinoma, 5097

Head and neck carcinoma
 chromosome 1 alterations, characterization, 5859
 squamous cell
 combined with retinoic acid and IFN- α treatment, 5551
 cytokine expression, 3132
 KILLER/DR5 mutation, 3513
 pRB-defective, HPV, 5

Health professionals
 male
 physical activity and prostate cancer study, 5117

Heat
 apoptosis, acidic environments, 2504
 -inducible gene therapy, prostate carcinoma, 1358

Heat shock protein
 hsp27
 tumorigenicity effects, colon carcinoma cells, 5495
 hsp70/Hsc-binding anti-apoptotic protein BAG-1
 expression, tissues and tumors, 3116
 malignant Hodgkin's disease cells, 5507

HEC-1-A endometrial carcinoma cells
hPMS2 gene complementation, 2978

Helicobacter pylori
 gastric carcinoma, Mongolian gerbils, 4255
 infection
 gastric adenocarcinoma and, 588
 stomach carcinogenesis, Mongolian gerbil, 2067

Helix-loop-helix protein Id2
 overexpression, pancreatic carcinoma, 3769

Hemangioblastoma
 sporadic cerebellar, 504

Hemangioma
 growth inhibition by cidofovir, 2562

Hematopoietic cells
 drug-induced apoptosis
 inhibition by VEGF, 5565
 growth inhibition
 vitamin D $_3$ analogs, 3370
 progenitor cells
 selection, GFP-expressing retrovirus, 14

Hemopoiesis
 inhibition by neuroblastoma-derived gangliosides, 4840

Hepatic tumors
 progression
 GlcNAc-TIII and, 2881

Hepatitis
 chronic
 RNA-dependent protein kinase aberrant expression, 4434

Hepatitis B virus
 preS1
 TGF- α gene transactivation, 1813
 X protein
 transcription activation, 3566

Hepatoblastoma
 risk, low-birth-weight children, 3032

Hepatocarcinogenesis
 growth factors and oncogenes, 3590
 inhibition
 PBN, CDAA diet-fed rats, 4548
 phenobarbital, mice, 1665
 pRb/E2F pathway, 123

Hepatocellular carcinoma
 angiogenesis
 hypoxia-induced IGF-II, 348
 β -catenin mutations, 2524
 cell growth
 methionine adenosyltransferase expression effects, 1444
 human *RhoGAP* gene deleted in (*DLC-1*), 2196
 plasminogen activators, 2234
 recurrence
 cyclin A overexpression and, 985
 RNA-dependent protein kinase aberrant expression, 4434

Hepatocytes
 generation from oval cell precursors in culture, 5514
 RNA-dependent protein kinase aberrant expression, 4434

Hepatoma
 angiogenesis and growth inhibition by TNF470, 3751

Herceptin
 paclitaxel and doxorubicin activity enhancement, 2825

Hereditary nonpolyposis colorectal carcinoma
 mouse models, 248
 somatic frameshift mutations, 997

Hereditary ovarian carcinoma
 comparative genomic hybridization changes, 2715
 molecular genetics, 3193

Hereditary papillary renal carcinoma
 MET mutations, 1719

Her-2/neu
 anti-HER2 antibody, recombinant humanized paclitaxel and doxorubicin activity enhancement, 2825
 -expressing mammary tumors
 protective immunity against, 1965
 hydrophobized polysaccharide/HER2 complex, 3385
 mammary tumorigenesis
 genetic modulation, 2675
 NH $_2$ -terminally truncated, breast cancer, 5123
 peptide reactivity, 4902
 peptides, colon and renal cell carcinoma, 732
 receptor
 recombinant specific toxin, pulmonary metastases inhibition, 2661

Herpes simplex virus-thymidine kinase
 astrocyte-specific expression
 selective glioma cell killing, 4577
 combined with ganciclovir
 G $_2$ -M arrest, 3855

- prostate cancer therapy, 3221
combined with TNF- α gene therapy, 5731
gene transfer and expression, PET imaging, 4333
G₂-M arrest, 3855
- Hevin/MAST9**
down-regulation, metastatic prostate adenocarcinoma, 232
expression, non-small cell lung cancer, 626
- Hexamethylenebisacetamide**
JAK2 activation, murine erythroleukemia cells, 556
- High mobility group I HMGI(Y)**
expression, uterine cervix lesions, 426
thyroid neoplasias, detection, 4193
- High molecular weight-melanoma-associated antigen**
anti-HMW-MAA human scFv antibodies, characterization, 2417
- High-resolution magic angle spinning proton magnetic resonance spectroscopy**
brain tumors, 1825
- HIP gene**
overexpression, thyroid carcinoma, 4745
- Histone deacetylase I**
pRb2/p130 binding, 5049
- HL-60 cells**
apoptosis
AN34, 2576
promotion by Apaf-1 overexpression, 4561
edelfosine sensitivity
oxidative basis, 2809
topo II expression, 5298
- HMT-3422S1 cells**
ER Δ E5 splice variant dominant negative activity, 4264
- Hodgkin's disease**
malignant
heat shock proteins, 5507
solid tumors
infarction by tissue factor targeting to tumor vasculature, 4646
- Hollow fiber tumors**
blood vessel development, 5263
- Homeobox**
GBX2 gene expression, prostate carcinoma, 1391
NUP98-HOXD13 gene fusion, therapy-related acute myelogenous leukemia, 4269
- H-Ras**
transformation
ornithine decarboxylase induction, 2748
- HT-1080 cells**
cohesion
dexamethasone effects, 3586
- Human chorionic gonadotropin**
Comexin 26 gene modulation, rat mammary glands, 1498
- Human ether-a-go-go-related gene (*herg*)**
cloning, tumor cells, 815
K⁺ channels, 815
- Human leukocyte antigen**
A2
loss, melanoma, 2149
class I
downregulation, breast carcinoma, 737
localization on shed vesicles, breast carcinoma cells, 4468
HLA-A68.2-restricted squamous cell carcinoma of lung
mutated *elongation factor 2* gene, 5144
- Human papillomavirus**
cell cycle regulation, cervical neoplasia, 2941
pRB-defective tonsillar squamous cell carcinoma, 5646
and VEGF expression, squamous cell carcinoma, 3765
- Hypoxia inducible factor-1 α**
expression, prostate carcinoma, 5280
induction by hypoxia, 5678
- I**
- Id2**
overexpression, pancreatic carcinoma, 3769
- Idiotypic**
anti-idiotypic antibody
-derived peptides, CEA mimicry, 1217
- Immunity**
MUC1 transgenic mouse, 315
against neu-expressing mammary tumors, 1965
p53
induction by anti-p53 antibodies, 5447
T-cell
tyrosinase nonmutated peptide, 296
tumor-protective
cytokine-induced, colon carcinoma metastases, 3918
- Immunization**
rmIL-12 effects, 491
- Immunodeficiency**
severe combined
lymphomagenesis, mice, 3111
- Immunoglobulin G**
chimeric antibodies
half-life, 3905
IL-2 fusion protein
tumor rejection induction, 2707
- Immunoglobulin G2a**
tumor cell vaccine
metastases eradication, 5812
- Immunoglobulin M**
membrane
cell cycle arrest, CDK inhibitors, 691
- Immunoliposomal doxorubicin**
targeting to B lymphocytes, 3320
- Immunology**
tumor
nonclassical MHC class I and, 4682
- Immunotherapy**
adoptive
p53 targeting, 2601
SEA-conjugated antibody, 2838
endogenous IL-12 production, 3073
- Immunotoxins**
anti-CD7-saporin
ADCC additivity, 5787
recombinant
tumor accumulation *in vivo*, 968
- Imprinting**
ovarian granulosa cell tumorigenesis control, 3694
- Incadronate**
mevalonate inhibition, myeloma cells, 5294
- Indium-111**
-labeled somatostatin analogues, evaluation, 437
- Infantile leukemia**
apoptosis by antisense ODN against *MLL-LTG19*, 3773
- Infection**
H. pylori
gastric adenocarcinoma and, 588
stomach carcinogenesis, Mongolian gerbil, 2067
human cytomegalovirus
drug resistance induction, neuroblastoma cells, 367
- Inflammation**
proinflammatory cytokines, squamous cell carcinoma, 3668
- noma, 5
type 16
variants, anal carcinoma *in situ* risk and, 3839
type 16 E6
nucleotide excision repair effects, 599
variants, cervical carcinoma, 829
type 16 E7
downregulation by scFv, 1893
-specific CTLs, tumor protection, 724
Th responses, cervical neoplasia, 1700
- Hyaluronan**
CD44 binding states
glycosylation and, 3736
prognostic factor, colorectal cancer, 342
- Hyaluronate**
-independent metastasis inhibition by CD44, 2350
- Hybrid cells**
nontumorigenic, 4930
- Hydrophobized polysaccharides**
HER2 complex vaccine, 3385
(S)-1-(3-Hydroxy-2-phosphonyl-methoxypropyl) cytosine: *see* Cidofovir
- 7-Hydroxystaurosporine**
clinical pharmacology, 3248
- Hydroxysteroid (alcohol) sulfotransferase a**
 α -hydroxytamoxifen-derived DNA adduct formation, 647
- 11 β -Hydroxysteroid dehydrogenase**
NNK carbonyl reduction, lung microsomes, 2996
- α -Hydroxytamoxifen**
DNA adducts
hydroxysteroid (alcohol) sulfotransferase a, 647
- Hypericin**
photoactivated
energy metabolism effects, 5777
- Hypermethylation**
FHIT, esophageal squamous cell carcinoma, 3429
hMLH1 promoter, colon cancer, 3455
p16^{ink4a} allele silence, 591
p16^{INK4a} promoter, ulcerative colitis, 3942
- Hyperoxia**
respiratory, combined with xanthine oxidase during hyperthermia
oxidative cell injury, 2693
- Hyperplasia**
atypical adenomatous
allelic imbalance, prostate, 389
atypical lobular
breast, comparative genomic hybridization analysis, 4721
complex atypical
PTEN mutations and microsatellite instability, 3254
endometrial
PTEN mutations, 2500
squamous cell hyperplastic foci, SENCAR mice, 4314
- Hyperthermia**
oxidative cell injury
enhancement with combination respiratory hyperoxia and xanthine oxidase, 2693
- Hypoxanthine phosphoribosyltransferase**
hprt gene
mutations, internal XPA-deficient mice tissue, 2850
- Hypoxia**
cell proliferation and, 3547
HIF-1 α induction, 5678
IGF-II
angiogenic activity, hepatocellular carcinoma, 348
NO-mediated radiosensitization, EMT-6 cells, 5646
and VEGF expression, squamous cell carcinoma, 3765

INK4

germ-line deletion, melanoma and nervous system tumors, 2298

In situ aromatization

breast tumor estradiol levels and cellular proliferation and, 927

Insulin

transendothelial leakiness
TPA-induced, 1641

Insulin-like growth factor

binding protein 3
sequence alterations, gastrointestinal tissues, 4802

binding protein 6
neuroblastoma growth arrest and, 1670

Insulin-like growth factor I

inhibition
metastasis inhibition, breast cancer, 3353

receptor
activity, breast carcinoma, 1159
COOH terminus, tumorigenesis inhibition and apoptosis induction, 2477

C terminus, tumor cell survival modulation, 570

inhibition, Ewing's sarcoma growth inhibition, 4127

inhibition, neuroblastoma regression, 5432

MMP-2 regulation, 3243

Src and, pancreatic carcinoma, 3551

recombinant human

tumor growth stimulation, 3021

VEGF regulation, colon carcinoma, 4008

Insulin-like growth factor II

hypoxia-induced
angiogenic activity, hepatocellular carcinoma, 348

rhabdomyosarcoma oncogenesis, 4426

Insulin receptor substrate-2

expression, pancreatic carcinoma, 4250

Integrins

$\alpha_2\beta_1$
mammary gland morphogenesis, 2224

$\alpha_3\beta_1$
expression, small cell lung cancer, 5537

α_5
fibronectin interactions, tumorigenesis, 848

$\alpha_6\beta_4$
mammary gland morphogenesis, 2224

β_1
-knockout lymphoma, metastasis, 1569

localization on shed vesicles, breast carcinoma cells, 4468

$\alpha 1\text{Ib}$
truncated, cancer, 4771

$\alpha_3\beta_3$
peptidomimetic antagonist, tumor growth inhibition, 1930

Intercellular adhesion molecule-1

MUC1 binding, molecular requirements, 5577

Interferon

type I
Stat1 signaling, 1914

Interferon α

bFGF inhibition, 808

expression
T-cell proliferation and, 5795

recombinant, properties and applications, 2489

Stat1 signaling, 1914

synergy with retinoic acid, head and neck squamous cell carcinoma treatment, 5551

Interferon β

Stat1 signaling, 1914

Interferon γ

apoptosis induction, 2832

IL-12 tumor therapy roles, 2426

signaling pathway, malignant mesothelioma cells, 840

Interleukin 1

IL-6 secretion regulation, oral squamous cell carcinoma, 3142

Interleukin 2

antifolate receptor scFv/IL-2 fusion protein, 4146

IgG fusion protein

tumor rejection induction, 2707

tumor microenvironment changes, 1478

Interleukin 4

apoptosis induction, breast carcinoma, 4199

toxin

antitumor activity, glioblastoma, 3649

Interleukin 6

androgen receptor activation, prostate carcinoma, 4640

dependency gene

chromosome 21, 2863

regulation by IL-1, oral squamous cell carcinoma, 3142

Interleukin 8

expression

regulation, melanoma, 1532

Tax-induced, 3993

Interleukin 10

modulation by tumor COX-2, 1208

Interleukin 12

endogenous production, immunotherapy, 3073

gene therapy

MHC-negative murine melanoma metastases, 1225

modulation by tumor COX-2, 1208

recombinant murine

immunization effects, 491

tumor cell vaccines

IgG2a, metastases eradication, 5812

tumor therapy

IFN- γ roles, 2426

Interleukin 15

Fura/LV interactions, colorectal carcinoma, 1695

protective effects against CPT-11-induced intestinal toxicity, 3270

Interleukin 1 β -converting enzyme

activation by BaP, 2102

expression, pancreatic adenocarcinoma, 2703

Internal tumors

XP-C, 4402

International criteria

microsatellite instability, colorectal carcinoma

meeting report, 5248

International Workshop on Microsatellite

Instability and RER Phenotypes in Cancer Detection and Familial Predisposition

meeting report, 5248

Intestinal epithelia

5-FU-induced histopathology

apoptosis induction and, murine, 5453

Intestinal polyps

Pms2^{-/-}; *Min* mice, 1087

Intestinal toxicity

CPT-11-induced

IL-15 protective effects against, 3270

Intraepithelial lesions

squamous

cervix, cell cycle regulation by HPV, 2941

uterine cervix

HMGI(Y) protein expression, 426

Intraepithelial neoplasia

prostatic

telomerase activity, 619

5923

Invasion

basement membrane

and liver metastases, gastrointestinal carcinoma, 3727

bladder carcinoma

MUC7 gene expression, 5662

glioma, brain slice culture model, 2935

inhibition

Ets-2 mutant, breast carcinoma, 1027

SB 203580, 1135

TIMP-3, melanoma cells, 2310

lobular breast carcinoma

cyclin D1 overexpression, 2876

matrix metalloproteinase role, 5221

neural cell adhesion molecule effects, rat CNS-1 glioma, 2020

phenotype

inhibition by maspin, 5681

uterine cervix

HMGI(Y) protein expression, 426

3-(Iodoacetamido)-benzoylurea

anticancer effects, 5389

Iododeoxyuridine

intraperitoneal, advanced malignancy treatment, 2793

Ionization

matrix assisted laser desorption ionization-post source decay

renal cell carcinoma tumor peptides, 5803

Ionizing radiation

anti-tumor effects

potentiation by angiostatin, 5686

apoptosis induction, 4277

caspase-3 activation, 4277

cell cycle checkpoint responses, Nijmegen breakage syndrome cells, 2316

ribonucleotide reductase regulation after, cervical carcinoma, 2245

Irinotecan

activation by rabbit carboxylesterase, 20

biliary excretion mechanism, 5137

intestinal toxicity

IL-15 protective effects against, 3270

metabolism

CYP3A, 468

rabbit carboxylesterase, 3627

resistance

reversal by CE gene transfer, lung carcinoma, 4368

Iron

asbestos mutagenicity, 1144

chelation

neuroblastoma xenografts, 473

Isogranulatimide

G2 checkpoint inhibition, 5701

Isothiocyanates

anticarcinogenic phase 2 enzyme inducer

potencies, 4632

chemopreventive

apoptosis induction, 402

J

Janus-activated kinase 2

activation by chemical inducers, murine erythroleukemia cells, 556

Japanese patients

p53 polymorphism and cervical cancer, 4585

Jennifer Jones Simon Foundation

UCLA Symposium on Prostate Cancer and Epithelial Cell Biology

meeting report, 2895

JNK: see Stress-activated protein kinase

K

KAI1

esophageal and gastric cancer, 753

Kaposi's sarcoma
vascular endothelial growth factor receptor-3, 1599

K562 cells
edelfosine sensitivity
oxidative basis, 2809

Keratinocyte growth factor
mucositis model effects, mice, 933

Keratinocytes
eicosanoids and, 4624
neoplastic progression suppression, 2200

Kidney
dsFv uptake
blockade by aminosyn II, 2612

KILLER/DR5 gene
mutations, head and neck squamous cell carcinoma, 3513
regulation, 1593

Kinesin heavy chain
ubiquitous
drug resistance domain, 3423

Ki-ras
mutations, colorectal carcinoma, 1149

Kirsten ras
expression, mammary carcinoma, 5097

K-ras
mutations
codon 12, polypoid colorectal carcinoma, 3289

KRN7000
antiliver metastatic effects, 1202

L

LacI gene
genetic control of mutagenesis, 1616

Lactate
turnover, rat glioma, 5083

Lactone
topotecan
DNA binding, topo I absence, 3782

LacZ gene
-tagged DBA/2 lymphoma
dormancy, bone marrow and lymph nodes, 5439

β -Lapachone
apoptosis induction, MCF-7:WS8 breast carcinoma cells, 1876

Large bowel tumorigenesis
inhibition by auraptene, rat, 2550

Laser medicine
matrix assisted laser desorption ionization-post source decay
renal cell carcinoma tumor peptides, 5803

Lectures
Nineteenth Cornelius P. Rhoads Memorial Award Lecture 5633
Seventeenth Bruce F. Cain Memorial Award Lecture, 4211

Letters to the Editor
re: J. Benítez *et al.*, 4480
re: L. G. Boros *et al.*, 3188
re: M. Tresini *et al.*, 4980
re: S. Fulda *et al.*, 5876
re: Y. E. Shi *et al.*, 4015

Leucovorin
combined with FUra
IL-15 interactions, colorectal carcinoma, 1695

Leukemia
acute
FHIT gene expression, 5182
fusion genes
induction by ionizing radiation, 421
glucocorticoid-resistant
cell killing by GC-PKA synergism, 3684
infantile
apoptosis by antisense ODN against *MLL-LTG19*, 3773

T-cell
apoptosis inhibition by ectopic *TALI/SCL* expression, 2680
ataxia-telangiectasia and, 2293
ATM gene and, 2293
telomerase
properties, 1909
TNF- α and TNF receptors, Mo7e cells, 2217
tumor antigen peptide vaccination, murine, 1960

Leukemia, acute lymphoblastic
ALL1 (MLL) gene
fusion transcripts, detection in normal donors, 790
rearrangement, acute myeloid leukemia, 55
childhood
chromosome 6q loss of heterozygosity, 2618

Leukemia, acute myelogenous
therapy-related
NUP98-HOXD13 gene fusion, 4269

Leukemia, acute myeloid
ALL1 (MLL) gene rearrangement, 55
high-dose cytarabine therapy
remission duration, 4173
remission
high-dose cytarabine therapy, 4173
STAT expression, blasts, 3173

Leukemia, acute promyelocytic
CRABP-II expression, 5770

Leukemia, chronic lymphocytic
B-cell
ATM gene, 4552
chlorambucil cytotoxicity, 1789
telomerase activity, 4918
telomere length, 4918

Leukemia, myeloid
apoptosis promotion by mutant *RAS*, 2029

Lewis antigens
lung adenocarcinoma cell adhesion, 1544

Lewis gene
dosage effects, CA19-9 and DU-PAN-2 serum levels, 512

Leydig cell tumors
growth inhibition
 $\alpha_{v\beta_3}$ integrin peptidomimetic antagonist, 1930

LGD1069
mammary carcinoma regression, 479

Ligands
protein kinase C δ selectivity, 1423

Light
solar-simulated
melanocytic nevi augmentation, guinea pigs, 5361

Limb perfusion
TNF-based
melanoma metastasis after, 4880

Lipid-mobilizing factor
biological effects, 2359
purification and characterization, 2353

Lipids
ether
sensitivity, oxidative basis, 2809

Lipolysis
inhibition by eicosapentaenoic acid, 4827

12-Lipoxygenase
platelet-type
angiogenesis and tumor growth stimulation, prostate carcinoma, 4047

Lithotripter shock waves
melanoma transfection, 219

Liver
17-(allylamino)-17-demethoxygeldanamycin metabolism, 2385
colon adenocarcinoma metastasis

inhibition by KRN7000, 1202
dimers reduction, rat, 4358
doxorubicin disposition
multidrug resistance modulators and, 3641
gastrointestinal carcinoma metastasis
basement membrane invasion and, 3727
neuroblastoma metastasis
inhibition by targeted calicheamicin θ^1 , 2925
rabbit carboxylesterase
cDNA, isolation, 2646
CPT-11 activation, 20
regeneration
AFP mRNA expression, 5825

LKB1 gene
mutations
colorectal and testicular tumors, 2087
sporadic breast carcinoma, 1384

LNCAp cells
apoptosis, 76
induction by NS398, 4245
mediation by ceramide synthase, 2260
biochanin A effects, 2379
death decrease by prostatic fibroblasts, 4525
genes differentially expressed, 3732
PSM' protein identification, 4787

Lobular breast carcinoma
invasive
cyclin D1 overexpression, 2876

Lobular breast carcinoma in situ
comparative genomic hybridization analysis, 4721

Lobular hyperplasia
atypical breast
comparative genomic hybridization analysis, 4721

Loss of heterozygosity
breast tumors, BRCA2 999del5 mutation-carriers, 4421
chromosome 1p32, meningioma, 3226
chromosome 6q, childhood acute lymphoblastic leukemia, 2618
chromosome 17, breast carcinoma, 1004
VHL
sporadic cerebellar hemangioblastoma, 504

Lovastatin
apoptosis, prostate cancer cells, 76

Low-birth-weight children
hepatoblastoma risk, 3032

Lumican
expression, breast carcinoma, 1348

Lung
epithelial cells
ambient particulate matter, 4543
metastases
inhibition by recombinant erbB-2 receptor-specific toxin, mice, 2661
NNK carbonyl reduction by 11 β -HSD, mouse microsomes, 2996

Lung adenocarcinoma
cell adhesion
Lewis antigens, 1544

Lung cancer susceptibility (*Sluc*) genes
Sluc5 mapping to *Sluc14*, 4794

Lung carcinogenesis
inhibition by black tea and caffeine, 4096
MUC1 expression, 5582

Lung carcinoma
chromosome 3p14 alterations, 1804
chromosome 18q tumor suppressor locus, 3700
circulating cells, detection, 2761
COX-2 expression, 3761, 4997
CPT-11 resistance reversal by *CE* gene transfer, 4368
FHIT functional loss, 5032

- immunogenic antigen
 - chromosome 3p21.3, 1034
- mEH genotypes and, 5291
- metastasis
 - growth inhibition, 4761
- non-small cell
 - cdc25* overexpression, 4082
 - chromosome 3 duplications, 4701
 - COX-2, IL-10 and IL-12 modulation, 1208
 - FHIT* deletions and survival, 2533
 - gelsolin expression, 322
 - MAST9/Hevin expression, 626
 - p27^{KIP1} expression, 1042
 - serial analysis of gene expression, 5690
 - stage I, CD44v6 expression, 1108
 - stage I, *Fhit* protein expression, 5478
 - p27^{KIP1} expression, 1042
 - p73, 1380
 - p73 expression, 2347
 - polymorphism associations, 4858
 - predisposition
 - BPDE-induced, 1605
 - small cell
 - cell proliferation mediation by PI 3-kinase, 5239
 - c-myc* overexpression, 5537
 - growth blockade by inhibitory PLC β , 910
 - growth inhibition by PP1, 4660
 - α 3 β 1 integrin expression, 5537
 - p27^{KIP1} expression, 1042
 - p19^{ARF} protein absence, 3926
 - squamous cell
 - HLA-A68.2-restricted, mutated *elongation* factor 2 gene, 5144
 - p53 mutations, Taiwan, 328
- Lung tumorigenesis**
 - prevention by acetylsalicylic acid and NS-398, A/J mice, 5354
- Lymphatic vessels**
 - vascular endothelial growth factor receptor-3, 1599
- Lymph nodes**
 - EblacZ tumor dormancy, 5439
 - sentinel
 - polymerase chain reaction markers, 4581
- Lymphoblastoid cells**
 - autologous EBV-immortalized
 - nontumorigenic malignant Burkitt's lymphoma hybrid cells, 4930
- Lymphocytes**
 - activated
 - solid tumor inaccessibility, 4673
 - antitumor
 - self-peptide ligands, 2433
 - tumor-infiltrating
 - adhesion to stromal cells, 4138
 - Fas expression, renal cell carcinoma, 2078
 - villous, splenic lymphoma with chromosome 13q14 deletions, 1736
- Lymphoid cells**
 - radiosensitivity, 2817
- Lymphoid tumors**
 - inhibition
 - farnesyl transferase inhibitors, 1253
- Lymphoma**
 - brain
 - p16 abnormalities, 1231
 - Burkitt's
 - malignant, nontumorigenic EBV-immortalized B-cell hybrids, 4930
 - proteasome inhibitor-induced tumor
 - growth inhibition, 4342
 - cell growth inhibition by FLT3 ligand, 380
 - β 1 integrin-knockout
 - metastasis, 1569
 - lacZ* tagged DBA/2
 - dormancy, bone marrow and lymph nodes, 5439
 - non-Hodgkin's
 - cdc25*, 1762
 - c-myc* expression, 1762
 - pyothorax-associated
 - p53 mutations, 1105
 - splenic, with villous lymphocytes
 - chromosome 13q14 deletions, 1736
 - thymic
 - truncating *Brca2* mutation, mice, 1338
 - Lymphomagenesis**
 - SCID mice, 3111
 - Lysosomal membrane glycoproteins 1 and 2**
 - homologous TSC403, characterization, 3499
 - Lysosomal protease**
 - tumor cell proliferation regulation, 904
 - Lysyl oxidase**
 - mRNA levels, prostate cancer, 1285

M

- Macrophages**
 - iNOS and COX-2 inhibition by triterpenoids, mouse, 717
- Madin-Darby canine kidney cells**
 - Moloney sarcoma virus-transformed variants
 - β -actin expression, 1631
 - MT1-MMP induction by v-src, 2240
- Magnetic resonance imaging**
 - dynamic
 - tumor angiogenesis assessment, uterine cervical carcinoma, 3598
 - 5-fluorocytosine activation detection, 4075
- Magnetic resonance spectroscopy**
 - 5-fluorocytosine activation detection, 4075
 - high-resolution magic angle spinning proton brain tumors, 1825
- Major histocompatibility complex**
 - class I
 - downregulation, tumor cells, 3660
 - MUC1 motifs, definition, 5151
 - nonclassical, and tumor immunology, 4682
 - class II
 - spontaneous metastases reduction, 1486
 - negative melanoma metastases
 - IL-12 gene therapy, 1225
- Male health professionals**
 - physical activity and prostate cancer study, 5117
- Maleic anhydride**
 - divinyl ether copolymer
 - TNF- α conjugate antitumor activity, solid tumors, 290
- Malignancy**
 - adenoma
 - chromosome 19p deletion, 1140
 - advanced
 - intraperitoneal iododeoxyuridine treatment, 2793
 - ascites tumors
 - VEGF expression, mouse, 2652
 - brain lymphoma
 - p16 abnormalities, 1231
 - Burkitt's lymphoma
 - nontumorigenic EBV-immortalized B-cell hybrids, 4930
 - centrosome defects, 3974
 - conversion
 - Bcl-x_L, skin papilloma, 2111
 - genetic instability, 3974
 - glioma
 - growth inhibition by angiostatin, 4654
 - retroviral CPP32 β therapy, 962
 - Hodgkin's disease
 - heat shock proteins, 5507
 - melanoma
 - comparative genomic hybridization, 2170
 - IL-8 expression regulation, 1532
 - induction by c-Met autocrine activation, 5157
 - mesothelioma
 - IFN- γ signaling pathway, 840
 - SV40, 4505
 - ovarian cystic fluid
 - cleaved su-PAR, 3294
 - plasma cell
 - translocations t(11;14)(q13;q32) and t(4;14)(p16;q32), 5640
 - prostate tumor
 - growth inhibition by FGFR2, 1509
 - T-cell
 - multiple copies in a T-cell malignancy (*MCT-1*) gene, 4233
- Malignancy-associated gene (MAG)**
 - tumors and tumor preexisting conditions, 4475
- Mammary carcinoma: see also Breast carcinoma**
 - allogeneic cell therapy, murine, 3891
 - collagen degradation regulation, 4970
 - Harvey vs Kirsten *ras* expression, 5097
 - regression by LGD1069, 479
 - spontaneous metastases
 - reduction by class II and B7.1, 1486
- Mammary-derived growth inhibitor-related gene MRG**
 - antitumor activity, 4015
- Mammary ductal carcinoma in situ**
 - p53 mutations, 785
- Mammary epithelial cells**
 - CYP1B1 and CYP1A1 expression, 2366
 - p16^{INK4} expression loss by methylation, 3508
 - p27^{KIP1} overexpression, 3448
- Mammary gland**
 - Connexin 26* gene modulation by hCG, rat, 1498
 - morphogenesis
 - α 2 β 1 and α 6 β 3, 2224
 - morphology
 - fat and, 654
- Mammary tumorigenesis**
 - early-stage
 - matrilysin effects, 5500
 - neu-induced
 - genetic modulation, 2675
- Mammary tumors**
 - chemically induced
 - suicide gene therapy, 3529
 - inhibition by farnesyl transferase inhibitors, 1253
 - neu-expressing
 - protective immunity against, 1965
- THE MARCH Research Task Force**
 - report, 5590
- Maspin**
 - invasive phenotype inhibition, 5681
- MAST9/Hevin**
 - down-regulation, metastatic prostate adenocarcinoma, 232
 - expression, non-small cell lung cancer, 626
- Matrilysin**
 - early-stage mammary tumorigenesis effects, 5500
- Matrix assisted laser desorption ionization-post source decay**
 - renal cell carcinoma tumor peptides, 5803
- Matrix metalloproteinase**
 - carcinoma invasion role, 5221
 - membrane-type 1
 - induction by v-src, MDCK cells, 2240
 - urine, 1395
- Matrix metalloproteinase 1**
 - promoter

- single nucleotide polymorphism, Ets binding site, 5321
- Matrix metalloproteinase 2**
- activation
 - cell-mediated extracellular matrix remodeling, 3743
 - induction by SPARC, breast carcinoma cells, 5529
 - degradation by plasmin
 - protection by TIMP-2, 2957
 - expression, neuroblastoma, 2209
 - regulation by IGF-IR, 3243
- Matrix metalloproteinase 9**
- activation by fibronectin, ovarian cancer, 900
 - activity, prostate carcinoma, 4288
 - expression, neuroblastoma, 2209
 - localization on shed vesicles, breast carcinoma cells, 4468
 - secretion inhibition by SB 203580, 1135
- Maturation factor**
- neuroleukin/phosphohexose isomerase/MF tumor cell expression, 2667
- MCF-7 cells**
- apoptosis susceptibility, 4940
 - FGF-1-transfected
 - FGFR1 overexpression, 352
 - growth stimulation *in vivo* by genistein, 3833
 - GST-P1-1-transfected
 - thiotepe and, 4616
 - invasive properties
 - melatonin effects, 4383
- MCF-7:WS8 cells**
- apoptosis induction by β -lapachone, 1876
- Medullary breast carcinoma**
- BRCA1* mutations, 1588
- Medulloblastoma**
- β -catenin mutations, 896
- Meeting reports**
- International Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection and Familial Predisposition, 5248
 - Seventh International Workshop on A-T, 3480
 - UCLA/Jennifer Jones Simon Foundation Symposium on Prostate Cancer and Epithelial Cell Biology, 2895
- Melanocyte lineage-specific antigens**
- gp100
 - genetic vaccination, 2509
- Melanocytes**
- response to UVB light
 - mediation by cAMP, 47
- Melanocytic nevi**
- augmentation by solar-simulated light, guinea pigs, 5361
- Melanogenic protein**
- levels, mouse melanoma, 1521
- Melanoma**
- apoptosis induction by TIMP-3, 2310
 - cell growth
 - inhibition by FLT3 ligand, 380
 - modulation by thrombospondin 1, 3154
 - chemotherapy
 - c-myc* antisense oligodeoxynucleotides and cisplatin, 283
 - choroidal
 - MARCKS expression, 1429
 - germ-line *INK4* deletion, 2298
 - HLA-A2 antigen loss, molecular analysis, 2149
 - IL-8 expression regulation, 1532
 - invasion inhibition by TIMP-3, 2310
 - malignant
 - comparative genomic hybridization, 2170
 - induction by c-Met autocrine activation, 5157
 - melanogenic protein levels, mouse, 1521
 - metastasis
 - Melastatin* loss of expression, 1515
 - MHC-negative, IL-12 gene therapy, 1225
 - procathepsin-L, 2733
 - after TNF-based perfusion, 4880
 - UVR-treated transgenic mice, 4061
 - motility
 - modulation by thrombospondin 1, 3154
 - skin age and site factors, mouse, 630
 - transfection by lithotripter shock waves, 219
 - Melanoma antigen-encoding gene (*MAGE*)**
 - tumor-specific expression, representational difference analysis, 743
 - Melanoma-associated antigen**
 - high molecular weight
 - anti-HMW-MAA human scFv antibodies, characterization, 2417
 - Melanoma/melanocyte epitope MART1**
 - CD4+ and CD8+ T-cells, 5305
 - CD8+ T-cell clones
 - self-peptide ligands, 2433
 - α -Melanotropin**
 - cAMP activation
 - melanocyte response to UVB light mediation, 47
 - Melastatin**
 - gene expression loss, melanoma metastases, 1515
 - Melatonin**
 - tumor invasion effects, MCF-7 breast cancer cells, 4383
 - Melphalan**
 - monoadducts
 - nucleotide excision repair, 5196
 - Membrane antigens**
 - localization on shed vesicles, breast carcinoma, 4468
 - Meningioma**
 - chromosome 1p32 loss of heterozygosity, 3226
 - PTEN* gene, 29
 - Merkel cell carcinoma**
 - comparative genomic hybridization analysis, 1503
 - Mesentery vascular endothelium**
 - vascular permeability factor/vascular endothelial growth factor signaling, mouse, 1278
 - Mesoblastic nephroma**
 - histogenetic link with congenital fibrosarcoma, 5046
 - Mesopharyngeal carcinoma**
 - prognosis
 - G-CSFR and, 794
 - Mesothelial cells**
 - AP-endonuclease inducibility, 189
 - Mesothelioma**
 - malignant
 - IFN- γ signaling pathway, 840
 - SV40, 4505
 - MET**
 - mutations, hereditary papillary renal carcinoma, 1719
 - Metabolic capacity**
 - rhEPO protective effects, 5374
 - Metallothionein**
 - deficiency
 - carcinogenesis promotion, mouse skin, 4044
 - NF κ B activation, 2335
 - Metastasis**
 - expression
 - inverse E-cadherin levels, 4587
 - Metastasis**
 - bone
 - visualization by GFP expression, 4217
 - breast cancer
 - inhibition by IGF-I inhibition, 3353
 - T β R-1* mutants, 4805
 - colon adenocarcinoma to liver
 - inhibition by KRN7000, 1202
 - colon carcinoma
 - cytokine-induced tumor-protective immunity, 3918
 - promotion by Ω -3 PUFAs, 3312
 - colorectal tumor
 - and antisense CD44v6, 3719
 - eradication by tumor cell vaccine-induced IgG2a, 5812
 - gastrointestinal carcinoma to liver
 - basement membrane invasion and, 3727
 - hepatic
 - inhibition by KRN7000, 1202
 - inhibition by CD44
 - hyaluronate-independent, 2350
 - β 1 integrin-knockout lymphoma, 1569
 - living intact metastatic tumors
 - cell motility, 2528
 - lung cancer
 - growth inhibition, 4761
 - melanoma
 - Melastatin* loss of expression, 1515
 - MHC-negative, IL-12 gene therapy, 1225
 - procathepsin-L, 2733
 - after TNF-based perfusion, 4880
 - UVR-treated transgenic mice, 4061
 - micrometastasis
 - eradication by anti-GD2 mAb 3F8, 2844
 - gene marker, 2440
 - prostate carcinoma, suppression *in vivo*, 4963
 - neuroblastoma to liver
 - inhibition by targeted calicheamicin θ^1 , 2925
 - osteolytic bone
 - inhibition by TNF-470, breast cancer, 462
 - prostate adenocarcinoma
 - Hevin* down-regulation, 232
 - prostate cancer
 - BCH-4556 effects, 3461
 - inhibition by chromosome 16, 4572
 - PTEN/MMAC1* gene alterations, 204
 - pulmonary
 - inhibition by recombinant erbB-2 receptor-specific toxin, mice, 2661
 - semaphorin expression, mouse tumor cells, 1238
 - solid-type papillary thyroid carcinoma
 - RET/PTC3* gene, murine model, 5523
 - spontaneous mammary carcinoma
 - reduction by class II and B7.1, 1486
 - Metastasis-suppressor genes**
 - chromosome 12 region, identification, 3561
 - Methioninase**
 - recombinant
 - anticancer efficacy and synergy with 5-FU, 2582
 - Methionine adenosyltransferase**
 - growth effects, hepatocellular carcinoma cells, 1444
 - Methotrexate**
 - kinetics, breast carcinoma, 2982
 - 2-Methoxyestradiol**
 - breast carcinoma inhibition, 2269
 - 3-Methyladenine DNA glycosylase**
 - mammalian
 - protective effects against chemotherapeutics, 3965
 - O⁶-Methylguanine-DNA methyltransferase**
 - activation by AP-1, 3950
 - activity, glioma, 1068
 - N-Methyl-N'-nitro-N-nitrosoguanidine**
 - mutations, mitochondrial DNA, 2857

stomach carcinogenesis
 dendritic cell response, 4107

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
 carbonyl reduction by 11 β -HSD, lung microsomes, 2996
 dosimetry, airway mucosa, 1417

Methylnitrosourea
 breast cancer
 modulation by dehydroepiandrosterone, 921

MG-132: see Carbobenzoxy-leucyl-leucyl-leucinal

Microarrays
 complementary DNA
 alveolar rhabdomyosarcoma gene expression profiling, 5009

Microenvironment
 tumor
 IL-2-mediated changes, 1478

Micrometastasis
 eradication by anti-GD2 mAb 3F8, 2844
 gene marker, 2440
 prostate carcinoma
 AT6.1, suppression *in vivo*, 4963

Microsatellites
 alterations, clear cell renal carcinoma, 4728
 instability
 -associated mutations, gastric cancer, 1494
 BLM gene, sporadic gastrointestinal tumors, 3777
 CBL proto-oncogene, sporadic gastrointestinal tumors, 3777
 colorectal carcinoma, 1713
 colorectal carcinoma, international criteria, meeting report, 5248
 complex atypical hyperplasia, 3254
 International Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection and Familial Predisposition, meeting report, 5248
 mutation rate, normal human fibroblasts, 3946

Microtubules
 assembly inhibition by 3-bromoacetylaminobenzoylurea, 2126
 disruption
 Bcl-x_L phosphorylation after, 3331

Minimal residual disease
 quantitative real-time PCR, 3957

Mitochondria
 DNA interstrand cross-links, 1400
 membrane potential
 proliferation and apoptosis, colonic carcinoma, 2869
 MKT-077 phototoxicity, 71
 mutations
 chemically induced, 2857
 spectra, smoking vs nonsmoking, 1268

Mitogen-activated protein/extracellular signal-regulated kinase
 retinoic acid-induced MAPK activation, 3163

Mitogen-activated protein kinase
 activation
 retinoic acid-induced MEK-dependent, 3163
 activity, estrogen-nonresponsive breast carcinoma, 4071
 5-aminolevulinic photodynamic therapy effects, 4297

Mitogen-activated protein kinase kinase 4
 gene alterations
 pancreatic, biliary, and breast carcinoma, 2339

Mitogenesis
 E2F4 activity regulation, 1325

Mitomycin C
 DNA adducts
³²P-postlabeling *in vivo*, 453

MKT-077
 mitochondrial phototoxicity, 71

MLL-LTG19
 antisense oligodeoxynucleotide
 apoptosis, infantile leukemia cells, 3773

MMAC1/PEN gene
 Akt activation inhibition, glioma cells, 5285
 alterations
 aerodigestive tract tumors, 509
 metastatic prostate cancer, 204
 anoikis induction, glioma cells, 5285
 cell death, 5667
 glioblastomas, 29
 growth inhibition mediation, glioma, 5002
 meningiomas, 29
 mutations
 Bannayan-Riley-Ruvalcaba syndrome, 2724
 complex atypical hyperplasia, 3254
 endometrial hyperplasia, 2500
 ovarian tumors, 2095
 prostate carcinoma, 2720
 tumorigenicity inhibition, glioblastoma, 2331

MNNG: see N-Methyl-N'-nitro-N-nitrosoguanidine

Mo7e cells
 TNF- α and TNF receptors, 2217

Molecular epidemiology
 human cancer, 4023

Moloney sarcoma virus-MDCK cell variants
 β -actin expression, 1631

Monoadducts
 melphalan
 nucleotide excision repair, 5196

Monoclonal antibodies
 anti-GD2 3F8
 micrometastases eradication, 2844
 anti-MUC1 BCP8
 MHC class I-associated MUC1 motif definition, 5151
 thymidylate synthase
 epitope mapping, 2606

Monolayers
 G₁ regulation, 1305

Mucins
 gene expression, ovarian carcinoma, 5546
 MUC1
 antigenicity, enhancement by glycosylation, 2541
 anti-MUC1 mAb BCP8, MHC class I-associated MUC1 motif definition, 5151
 anti-MUC1 scFv antibodies, phage libraries, 4324
 CD4+ T-cell priming, 5066
 expression, activated T cells, 4079
 expression, cell adhesion and, 2014
 expression, lung carcinogenesis, 5582
 ICAM-1 binding, molecular requirements, 5577
 tolerance and immunity, transgenic mouse, 315

MUC7
 expression, invasive bladder carcinoma, 5662

Mucosa
 airway
 NNK dosimetry, 1417
 colorectal
 age-related DNA methylation, 5489

Mucositis
 keratinocyte growth factor effects, mice models, 933

Multidrug resistance
 ABCP role, 5337

modulators
 hepatobiliary doxorubicin disposition and, 3641
 reversal by fumitremorgin C, colon carcinoma, 5850

Multidrug resistance protein
 gene expression inhibition by p53, 5762
 vincristine transport, 5130

Multifocal urothelial cancer
 genetic analysis, 5835

Multiminucleation
 paclitaxel-associated, 4667

Multiple copies in a T-cell malignancy (MCT-1) gene
 cell cycle progression, 4233

Multiple endocrine neoplasia type 1
 MEN1 gene, endocrine pancreatic tumors, 377
 MENIN gene, sporadic pancreatic endocrine tumors, 4417

Multiple myeloma
 BCL-X expression, 256
 minimal residual disease
 quantitative real-time PCR, 3957

Multispecific organic anion transporter
 MOAT-B, isolation, 2741

Murine double minute 2 gene (mdm2)
 variants, astrocytic tumors, 609

Muscle cells
 adenosine
 growth inhibition, 3181

Mutagenesis
 genetic control
 lacI gene, 1616
 nondimer photoproducts, trichothiodystrophy cells, 102
 random sequence
 DNA alkyltransferase, 1013

Mutagenicity
 asbestos
 iron and nitric oxide, 1144

Mutagenic replication
 BPDE-adducted DNAs, cell extract, 887

Mutations
 APC/ β -catenin/Tcf pathway, colorectal carcinoma, 1130
 chemically induced, mitochondrial DNA, 2857
 microsatellite instability-associated, gastric cancer, 1494
 microsatellite rate, normal human fibroblasts, 3946
 mitochondrial spectra, smoking vs nonsmoking, 1268
 somatic frameshift
 hereditary nonpolyposis colorectal carcinoma, 997
 T4 type II DNA topoisomerase, 1260

Mutator phenotypes
 colorectal carcinoma, 1713

MutL homologue
 MLH1
 G₂-M arrest role, 767
 human hMLH1, colorectal carcinoma, 1713
 human hMLH1 promoter, hypermethylation, 3455

MutS homologue
 human hMSH2
 exonuclease I interactions, 4537
 refined chromosomal localization, 5023
 human hMSH3
 mutations, colorectal cancer, 594
 human hMSH6
 refined chromosomal localization, 5023

MX781
 antitumor activity, breast cancer, 4607

- Myelin**
central nervous system
glioma cells, human and rat, 149
- Myelin basic protein kinase**
36-kDa
activation during apoptosis, 4888
- Myeloma**
mevalonate inhibition by incadronate, 5294
multiple
BCL-X expression, 256
minimal residual disease, quantitative real-time PCR, 3957
- Myristoylated alanine-rich C kinase substrate**
expression, choroidal melanoma cells, 1429
- N**
- NADPH-cytochrome P450 reductase**
Salmonella harboring, 1833
- Nasopharyngeal carcinoma**
antigen processing, 310
inhibition by cidofovir, 384
senescent-like growth arrest, 5019
- National Cancer Institute**
International Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection and Familial Predisposition, meeting report, 5248
- NB4 cells**
differentiation induction by 4-oxoretinol, 2007
- Neoplasia: see also Tumors; specific sites**
cervical
cell cycle regulation by HPV, 2941
HPV-16 E7 Th responses, 1700
colorectal
APC *II307K* somatic instability, 4040
multiple endocrine, type 1
MEN1 gene mutations, endocrine pancreatic tumors, 377
progression
suppression, keratinocytes, 2200
prostatic intraepithelial
telomerase activity, 619
thyroid
HMGI(Y) protein, detection, 4193
- Neoplastic phenotype**
normal cell-mediated modulation, 4445
reversion by cx43, glioblastoma cells, 5089
- Nephroma**
mesoblastic
histogenetic link with congenital fibrosarcoma, 5046
- Nervous system tumors**
germ-line *INK4* deletion, 2298
- NES1: see Normal epithelial specific-1**
- neu: see Her-2**
- Neural cell adhesion molecule**
invasiveness effects, rat CNS-1 glioma, 2020
polysialic acid
and polysialyltransferases, neuroblastoma, 779
- Neuregulin**
ErbB signaling network
cerebellar development, 3932
- Neuroblastoma**
apoptosis
drug-induced, molecular ordering, 4453
CDK6 mutation, 2624
differentiation
glial cell line-derived neurotrophic factor/neurturin-induced, 2158
Down syndrome, 448
drug resistance
induction by human CMV infection, 367
patterns, 5396
growth arrest
IGFBP-6 and, 1670
- growth promotion by polysialic acid, 779
hemopoiesis inhibition, 4840
iron chelation, xenografts, 473
metastasis to liver
inhibition by targeted calicheamicin θ^1 , 2925
MMP-2 and MMP-9 expression, 2209
polysialic acid and polysialyltransferases, 779
regression
IGF1R inhibition, mice, 5432
Schwann cell effects, 4602
- Neuroectodermal tumors**
apoptosis induction by betulinic acid, 5876
- Neuroleukin/phosphohexose isomerase/maturation factor**
tumor cell expression, 2667
- Neurturin**
differentiation, neuroblastoma, 2158
- Nevi**
melanocytic
augmentation by solar-simulated light, guinea pigs, 5361
- Nickel**
-specific gene *Cap43*, 2182
- Nijmegen breakage syndrome**
cell cycle checkpoint responses, 2316
- Nimesulide**
chemopreventive effects, bladder carcinoma, 3028
- Nitric oxide**
asbestos mutagenicity, 1144
generation, phthalocyanine photodynamic therapy, 1785
radiosensitization, hypoxic cells, 5646
sublethal
genetic response, 3435
- Nitric oxide scavenger**
tumor vascular permeability modulation, 159
- Nitric oxide synthase**
inducible
expression, Barrett's esophagus, 2929
inhibition by triterpenoids, mouse macrophages, 717
- Nitric oxide synthase-2**
expression, colon adenomas, 334
- 4-Nitrobenzylidene malononitrile**
protective effects against chemotherapy toxicity, 2397
- 4-Nitroquinoline 1-oxide**
tongue carcinogenesis
genetic susceptibility, rat, 1660
- nm23**
angiogenesis
node-negative breast carcinoma and, 2766
- Non-Hodgkin's lymphoma**
cdc25, 1762
c-myc expression, 1762
- Normal epithelial specific-1 (NES1)**
tumor suppressor role, 4782
- NS398**
apoptosis induction, LNCaP cells, 4245
lung tumorigenesis prevention, A/J mice, 5354
- NSC 330507: see 17-(Allylamino)-17-demethoxygeldanamycin**
- Nuclear factor κ B**
activation
drug resistance, 3059
metallothionein, 2335
caspase-mediated cleavage
CD95-induced, 882
dominant negative genetic construct
radiation-induced CAM expression inhibition, 5484
RelA
p53-mediated repression, 4531
- O**
- Nuclear magnetic resonance spectroscopy**
lactate turnover, rat glioma, 5083
rat brain glioma, 3791
- Nucleophosmin-anaplastic lymphoma kinase**
nucleolar localization, 1057
- Nucleosides**
cytotoxic analogues
G₂-M arrest, 3855
transporters
gemcitabine cytotoxicity and, 4349
- Nucleotide excision repair**
HPV E6 gene effects, 599
impairment by apoptosis, 1978
melphalan monoadducts, 5196
- NUP98-HOXD13 gene fusion**
therapy-related acute myelogenous leukemia, 4269
- Oligodeoxynucleotides**
c-myc antisense
cisplatin and, melanoma chemotherapy, 283
- Oligodeoxyribonucleotides**
MLL-LTG19 antisense
apoptosis, infantile leukemia cells, 3773
- Oligopeptide transporter**
expression, pancreatic carcinoma, 519
- Oligosaccharides**
 β 1,6-branched
prognostic value, colorectal carcinoma, 5559
- Oncogenes: see also Genes; specific genes**
growth factors and, hepatocarcinogenesis, 3590
R2 and, cell transformation, 1650
- Oncogenesis**
IGF-II and PAX3-FKHR, rhabdomyosarcoma, 4426
liver
pRb/E2F pathway, 123
- Oral carcinoma**
prognosis
G-CSFR and, 794
squamous cell
IL-6 secretion regulation by IL-1, 3142
retinol metabolism, 166
synchronous
origin, 2003
T-cell ζ chain expression, 5344
- Ornithine decarboxylase**
induction, H-Ras and RhoA transformation, 2748
- Osteolytic bone metastasis**
inhibition by TNP-470, breast cancer, 462
- Osteopontin**
squamous cell carcinoma progression role, 5206
- Oval cell precursors**
hepatocyte generation, culture, 5514
- Ovarian carcinogenesis**
ER- α and ER- β mRNA expression, 5367
- Ovarian carcinoma**
c-Mos induction and activation by paclitaxel, SKOV3 cells, 3633
cystic fluid
cleaved su-PAR, 3294
drug resistance
ABC2 gene amplification and, 1332
endometrioid
CTNNB1 mutations, 1344
endometriosis and, 1707
epithelial
AKT2 activation, 2973
ets-2 activation by *ras* signaling, 2253
Fab isolation by panning phage Ab libraries, 991

- hereditary
 - comparative genomic hybridization changes, 2715
 - molecular genetics, 3193
- MMP-9 activation by fibronectin, 900
- mucin gene expression, 5546
- PTEN/MMAC mutations, 2095
- risk
 - H307K APC* allele and, Ashkenazi Jews, 2919
- sporadic
 - comparative genomic hybridization changes, 2715
 - TBR-II* mutations, 4227
 - uPAR serum levels, 1843
- Ovarian granulosa cell tumorigenesis**
 - multigenic/imprinting control, 3694
- Ovarian tumors**
 - borderline
 - advanced, multifocal origin, 2328
 - germ cell
 - comparative genomic hybridization analysis, 3105
- Oxidative cell injury**
 - hyperthermia
 - enhancement with combination respiratory hyperoxia and xanthine oxidase, 2693
- Oxidative stress**
 - apurinic endonuclease induction, 4410
 - chronic
 - gene amplification, 3986
 - inhibition by ACA, mouse skin, 4832
- 4-Oxoretinol**
 - cell differentiation, NB4 cells, 2007
- Oxythiamine**
 - ribose and cell proliferation inhibition, 3188

P

- p16**
 - abnormalities, brain lymphoma, 1231
 - CDK4* binding region
 - mutations, 109
 - expression
 - DNA methylation role, bladder carcinoma, 1245
 - inactivation
 - gastrinoma, 237
 - pancreatic duct lesions, 4740
- p16^{INK4A}**
 - expression loss by methylation, mammary epithelial cells, 3508
- p16^{INK4A}**
 - alleles
 - silence by hypermethylation, 591
 - promoter
 - hypermethylation, ulcerative colitis, 3942
- p19**
 - expression
 - DNA methylation role, bladder carcinoma, 1245
- p19^{ARF}**
 - protein absence, small cell lung cancer, 3926
- p21^{WAF1}**
 - induction by *Smad4/DPC4*, carcinoma, 5656
- p21^{WAF1/CIP1}**
 - mutations
 - cyclin D/*CDK4(6)* complex promotion, 5053
- p27**
 - subcellular localization, Barrett's associated adenocarcinoma, 1730
- p27^{KIP1}**
 - colorectal carcinogenesis, 114
 - expression, lung cancers, 1042
 - loss
 - prognostic factor, prostate adenocarcinoma, 542

- overexpression, mammary epithelial cells, 3448
- p36**
 - myelin basic protein kinase
 - activation during apoptosis, 4888
- p53**
 - alterations
 - retinoblastoma protein and, bladder cancer, 1090
 - antibodies
 - p53 immunity induction, 5447
 - apoptosis
 - antioxidants, 1723
 - intestinal histopathology and, murine epithelia, 5453
 - hinge domain mutants, apoptotic response, 2190
 - immunity
 - induction by anti-p53 antibodies, 5447
 - inactivation via novel *Alu* rearrangement, 5333
 - induction
 - cisplatin vs X-rays, 698
 - hypoxia, 5678
 - ionizing radiation-induced caspase-3 activation and apoptosis, 4277
 - knockout mice
 - urinary bladder carcinogenesis, 3807
 - lymphomagenesis, SCID mice, 3111
 - MRP gene expression inhibition, 5762
 - mutant
 - topoisomerase I activation, 2091
 - mutational hot spots
 - CpG carcinogen binding, 2070
 - mutations
 - mammary ductal carcinoma *in situ*, 785
 - primary breast carcinoma, 859
 - prognostic value, breast carcinoma, 1451
 - pyothorax-associated lymphoma, 1105
 - skin tumors, *XPA*-deficient mice, 641
 - squamous cell lung cancer, Taiwan, 328
 - thyroid cell growth and differentiation effects, 2888
 - xeroderma pigmentosum, 2449
 - NF- κ B *RelA* repression, 4531
 - overexpression, colorectal carcinoma, 1149
 - PARP interactions, apoptosis, 5075
 - PEITC-induced apoptosis role, 4102
 - polymorphism
 - and cervical cancer, Japanese patients, 4585
 - ψ p53 recombination, radiation-induced tumor, 5649
 - radiation sensitivity and, glioblastoma, 1793
 - RTP/rit42* responsiveness, 4439
 - signaling
 - DNA replication and, UV-irradiated fibroblasts, 1993
 - target genes
 - regulation by p73, 5061
 - targeting, adoptive T-cell immunotherapy, 2601
 - tumor cells
 - G₁-S arrest, 2036
 - VEGF regulation, 2288
 - Wee1 expression downregulation, 3231
- p60^{src}**
 - MT1-MMP induction, MDCK cells, 2240
- p73**
 - expression, lung carcinoma, 2347
 - lung carcinoma, 1380
 - mutations, prostate carcinoma, 2076
 - p53 target gene regulation, 5061
- p130**
 - HDAC1 binding, 5049
- p369**
 - HER-2/neu
 - peptide reactivity, 4902

- P829**
 - ^{99m}Tc-labeled
 - binding properties, 1850
- PA28 α**
 - B-Raf binding, 2986
- Paclitaxel: see also Taxol**
 - antitumor activity
 - enhancement by rhuMab HER2, 2825
 - c-Mos induction and activation, ovarian carcinoma, 3633
 - intracellular
 - BAX and, 4776
 - JNK/AP-1 pathway stimulation, 241
 - multiminucleation, 4667
 - pharmacodynamics, 2141
- Pancreas**
 - DNA adducts, 38
- Pancreatic adenocarcinoma**
 - caspase-1 expression, 2703
 - Fas and Fas ligand expression, 1741
 - TGF β receptor gene alterations, 5329
- Pancreatic carcinogenesis**
 - DNA adduct role, 38
- Pancreatic carcinoma**
 - chromosome 12q allelic loss, 2456
 - DPC4/Smad4* gene
 - mutations, biliary tract carcinoma, 1124
 - factor VIIa-tissue factor system, 4461
 - FHIT* alterations, 1583
 - gene therapy
 - combination TNF-R55 and mutein TNF, 1677
 - Id2 overexpression, 3769
 - IRS-2 expression, 4250
 - MKK4* alterations, 2339
 - peptide transport, 519
 - Src and IGF-I receptors, 3551
- Pancreatic duct lesions**
 - p16 inactivation, 4740
- Pancreatic tumorigenesis**
 - ductal
 - early diagnosis by FISH, 4222
- Pancreatic tumors**
 - endocrine
 - allelotyping, 3706
 - MEN1* gene mutations, 4417
 - MEN1* mutations, 377
- Papillary renal carcinoma**
 - hereditary, MET mutations, 1719
- Papillary thyroid carcinoma**
 - metastatic solid-type
 - RET/PTC3* gene, murine model, 5523
 - PTC5*
 - thyroid carcinoma, 198
- Papilloma**
 - skin
 - reduction by topical retinoic acid, 1435
- Parathyroid hormone-related protein**
 - breast carcinoma and eucalcemia, 4113
- Particulate matter**
 - ambient
 - lung epithelial cells, 4543
- PAX3-FKHR fusion protein**
 - rhabdomyosarcoma oncogenesis, 4426
 - target gene analysis, alveolar rhabdomyosarcoma, 3542
- PC-3 cells**
 - genes differentially expressed, 3732
- Pentose phosphate**
 - pathways
 - and tumor proliferation, 3188
- Peptides**
 - anti-idiotypic antibody-derived, CEA mimicry, 1217
 - doxorubicin-peptide prodrugs
 - activation by prostate-specific antigen, 2537

- HER-2/neu p369 reactivity, 4902
 internalization sequence-fused c-Myc helix
 I-type Int-H1-S6A,F8A
 growth and transcription inhibition, 3654
 self-protein
 antitumor lymphocyte ligands, 2433
 transport, pancreatic carcinoma, 519
 tumor
 renal cell carcinoma, MALDI-PSD, 5803
 tyrosinase nonmutated
 T-cell immunity, 296
- Perfusion**
 TNF-based
 melanoma metastasis after, 4880
- Perillyl alcohol**
 UVB tumorigenesis and AP-1 inhibition, 711
- Peripheral blood**
 circulating lung cancer cells, detection, 2761
- Peritoneal cavity**
 advanced malignancies
 intraperitoneal iododeoxyuridine treatment, 2793
- Permeability**
 bradykinin
 mediation by cyclic GMP, 914
 vascular
 modulation, 159
- Peroxisome proliferator-activated receptor γ**
 antitumor effects, prostate carcinoma, 3344
- Peutz-Jeghers syndrome**
 adenocarcinoma pathogenesis, 5267
LKB1 gene
 mutations, sporadic breast carcinoma, 1384
STK11 mutations, 4799
 somatic, left-sided colon carcinoma, 3787
- P-glycoprotein**
 antigen presentation role, 4688
 sister gene, cloning and function, 4160
 transport inhibition, 276
- pH**
 intracellular
 heterogeneity, 1901
- Phage antibody libraries**
 anti-MUC1 scFv, 4324
 panning
 Fab isolation, ovarian carcinoma cells, 991
- Phenethyl isothiocyanate**
 apoptosis
 p53 role, 4102
- Phenobarbital**
 hepatocarcinogenesis inhibition, mice, 1665
- Phenotypes**
 invasive
 inhibition by maspin, 5681
 mutator
 colorectal carcinoma, 1713
 neoplastic
 normal cell-mediated modulation, 4445
 reversion by cx43, glioblastoma cells, 5089
 replicative error
 International Workshop on Microsatellite Instability and RER Phenotypes in Cancer Detection and Familial Predisposition, meeting report, 5248
 Werner syndrome
 complementation, 5188
- Phenyl *N*-tert-butyl nitron**
 liver carcinogenesis inhibition, CDAA diet-fed rats, 4548
- Phosphosine**
 cyclin D1 and pRb effects, 704
- Phosphohexose isomerase**
 neuroleukin/PHI/maturation factor
 tumor cell expression, 2667
- Phosphoinositide 3-kinase**
 cell proliferation mediation, small cell lung cancer, 5239
 senescence induction, diploid fibroblasts, 1, 4980
- Phosphoinositide 3-kinase related kinases**
 inhibition by wortmannin, 4375
- Phospholipase A_2**
 cytosolic
 inactivation by 1,25(OH) $_2$ D $_3$, TNF resistance, 633
 and keratinocytes, 4624
 secretory
 overexpression, colorectal adenoma, 500
- Phospholipase CB**
 inhibitory
 cell growth blockade, small cell lung cancer, 910
- Phospholipase CB_1**
 nuclear
 differentiation inhibition, erythroleukemia cells, 5057
- Phosphorylation**
 Bcl2 site, 1609
 Bcl-x $_1$, after microtubule disruption, 3331
- Photoactivation**
 hypericin
 energy metabolism effects, 5777
- Photodynamic therapy**
 5-aminolevulinic
 mitogen-activated protein kinase effects, 4297
 benzoporphyrin derivative, orthotopic prostate cancer, 5425
 PARP cleavage response, 940
 phthalocyanine
 nitric oxide generation, 1785
- Photoproducts**
 nondimer
 mutagenesis, trichothiodystrophy cells, 102
- Photosensitization**
 tolporphin, 3571
- Phototoxicity**
 MKT-077, mitochondria, 71
- Phthalocyanine photodynamic therapy**
 nitric oxide generation, 1785
- Physical activity**
 and prostate cancer, male health professionals, 5117
- PINCO**
 green fluorescence protein-expressing retrovirus, 14
- Pituitary adenoma**
 pluripotent tumor cells, 4715
- Placental alkaline phosphatase gene (PLAP)**
 expression, seminoma, 5079
- Placenta-specific adenosine triphosphate-binding cassette gene (ABCP)**, 5337
- Plasma cell malignancies**
 translocations t(11;14)(q13;q32) and t(4;14)(p16;q32), 5640
- Plasmacytoma**
 growth
 disseminated, murine, 535
- Plasmid vector backbone**
 CTL epitopes, 3087
- Plasmin**
 MMP-2 degradation
 protection by TIMP-2, 2957
- Plasminogen activator**
 carcinoma invasion role, 5221
- Platelet-derived endothelial cell growth factor**
 expression, colon carcinoma, 1551
- Platelet-derived growth factor B-chain**
 recombinant retrovirus
 brain tumor induction, mice, 5275
- Platinum**
 DNA adducts
 replicative bypass, mismatch repair-defective cells, 3579
- Pleiotropic defect**
 cisplatin-resistant cells, 268
- Pleural cells**
 AP-endonuclease inducibility, 189
- Pluripotent tumor cells**
 pituitary adenoma, 4715
- PMS2**
 human *hPMS2*
 gene complementation, HEC-1-A endometrial carcinoma cells, 2978
Pms2 $^{-/-}$; *Min* mice
 intestinal polyps, 1087
- Poly(ADP)ribose polymerase**
 cleavage, photodynamic treatment response, 940
 cleavage product
 DNA end binding, 3495
 p53 interactions, apoptosis, 5075
- Polyamines**
 analogues
 apoptosis induction, prostate carcinoma cells, 4864
 lysosomal sequestration, 3883
 skin carcinogenesis and, mouse, 1654
- Poly(L-glutamic acid)-paclitaxel conjugate**
 tumor regression, 2404
- Polyglutamine**
 expression
 prostate-specific amplification, 2282
- Polyglutamylase**
 super synergy role, 3036
- Poly(L-lysine)**
 adenoviral conjugates
 modified gene transfer, dendritic cells, 956
- Polymerase chain reaction**
 breast cancer and sentinel node markers, 4581
 quantitative real-time
 minimal residual disease, 3957
 reverse transcription
 nested PSA/PSM assay, prostate carcinoma, 1456
 thyroid carcinoma diagnosis, 4913
- Polymeric chemotherapy delivery**
 monkey brain, 672
- Polymerization**
 tubulin
 induction by eleutherobin, 1111
- Polyoid colorectal carcinoma**
K-ras codon 12 mutations, 3289
- Polyps**
 colon
 fecal water ursodeoxycholic acid, rats, 1684
 intestinal
 Pms2 $^{-/-}$; *Min* mice, 1087
- Polysaccharides**
 hydrophobized
 HER2 complex vaccine, 3385
- Polysialic acid**
 and polysialyltransferases, neuroblastoma, 779
- Polysialyltransferases**
 polysialic acid and, neuroblastoma, 779
- Polyunsaturated fatty acids**
 Ω -3
 colon carcinoma metastasis promotion, 3312
- Positron emission tomography**
 HSV-tk gene transfer and expression imaging, 4333

- prostate cancer xenograft, 3009
reporter gene expression imaging, 4333
- Potassium channels**
herg, 815
- PPI**
growth inhibition, small cell lung cancer, 4660
- ³²P-Postlabeling**
mitomycin C-DNA adducts *in vivo*, 453
- PRAME**
expression, renal cell carcinoma, 4090
- Prenyltransferase**
inhibitors
radiosensitization, 1754
- Preprogalanin gene *GALN***
expression, breast carcinoma, 1353
- Primitive neuroectodermal tumors**
peripheral
gastrin-releasing peptide expression, 2469
*SMO*H mutations, 1798
- Proapoptosis genes**
somatic frameshift mutations, hereditary
nonpolyposis colorectal carcinoma, 997
- Procathepsin-L**
melanoma metastasis, 2733
- Prodrugs**
doxorubicin-peptide
activation by prostate-specific antigen, 2537
 β -glucuronidase-mediated activation, 1195
- Progesterone**
receptor B
downregulation, endometrial carcinoma, 1860
serum levels
CYP17 polymorphism and, 585
- Progestin**
VEGF regulation, breast cancer, 392
- Programmed cell death**
CHENSpm-induced, 2711
- Prolactin**
Stat1 signaling, 1914
- Proliferating cell nuclear antigen**
breast carcinoma, 3264
- 1,N²-Propanodeoxyguanosine**
DNA adducts
smoking-induced DNA damage biomarkers, 581
- Prostaglandin E₂**
apoptosis modulation, colon cancer, 362
- Prostanoids**
adenoma levels, familial adenomatous polyposis, 1750
- Prostate**
atypical adenomatous hyperplasia
allelic imbalance, 389
epithelium
telomerase activity, 619
fibroblasts
LNCaP cell death decrease, 4525
ventral
weight reduction by finasteride, 215
- Prostate adenocarcinoma**
metastatic
Hes1 down-regulation, 232
prognosis
p27^{Kip1} loss and, 542
- Prostate carcinoma**
advanced
chromosome 12p deletions, 5652
androgen action site, 3299
androgen metabolism and, 4497
androgen receptor activation by IL-6, 4640
androgen receptor expression loss, 5310
androgen receptor promoter CpG island methylation, 5310
angiogenesis
stimulation by platelet-type 12-LOX, 4047
apoptosis, 76
androgen withdrawal, blockade by caspase inhibition, 834
and cell survivability, 3466
induction by polyamine analogue BIS, 4864
biochanin A effects, 2379
caspase activation, 5870
 β -catenin mutations, 2520
cell cycle modulation by silymarin, 1920
cell growth
BCH-4556 effects, 3461
inhibition by AN-238, 4132
inhibition by vitamin D₃ analogs, 3370
stimulation by platelet-type 12-LOX, 4047
cell survivability
apoptosis and, 3466
chromosome 7q31 molecular cytogenetics, 759
combination HSV-tk and ganciclovir therapy, 3221
early growth response gene expression, 2461
endothelin-1 expression, 4817
erbB1 signaling modulation by silymarin, 1920
fibroblast growth factor 8 expression, 2053
GBX2 expression, 1391
genes differentially expressed, 3732
genotypic heterogeneity, 23
heat-inducible gene therapy, 1358
HIF-1 α expression, 5280
hSP56, 3150
induction, Wistar-Unilever rats, 3282
lysyl oxidase mRNA levels, 1285
metastasis
BCH-4556 effects, 3461
PTEN/MMAC1 gene alterations, 204
micrometastases
AT6.1, suppression *in vivo*, 4963
MMP-9 activity, 4288
nested PSA/PSM RT-PCR, 1456
orthotopic
benzoporphyrin derivative photodynamic therapy, 5425
p73 gene mutations, 2076
physical activity and, male health professionals, 5117
positron emission tomography, xenografts, 3009
PSM' protein identification, LNCaP cells, 4787
PTEN, 2720
recurrent
androgen receptor expression, 5718
risk
calcium and fructose intake and, 442
telomerase activity, 619
troglitazone antitumor effects, 3344
UCLA/Jennifer Jones Simon Foundation Symposium on Prostate Cancer and Epithelial Cell Biology, meeting report, 2895
vitamin D receptor haplotypes and, African-Americans, 1620
- Prostate-specific antigen**
doxorubicin-peptide prodrug activation, 2537
nested RT-PCR assay, prostate carcinoma, 1456
polyglutamine expression amplification, 2282
- Prostate-specific membrane antigen**
internalization, 4055
nested RT-PCR assay, prostate carcinoma, 1456
- Prostate-specific membrane antigen PSM' protein**
identification, LNCaP cells, 4787
5931
- Prostate tumors**
growth inhibition by FGFR2, 1509
metastasis
inhibition by chromosome 16, 4572
xenografts
drug effects, 2777
- Prostatic intraepithelial neoplasia**
telomerase activity, 619
- Protease**
lysosomal
tumor cell proliferation regulation, 904
- Proteasome**
inhibitors
tumor growth inhibition, Burkitt's lymphoma, 4342
subunits
downregulation, tumor cells, 3660
- Proteinase**
C3-cleaving, melanoma metastasis, 2733
- Protein kinase A**
synergy with glucocorticoid
glucocorticoid-resistant leukemic cell killing, 3684
- Protein kinase C**
activity
fat and, 654
- Protein kinase C α**
cell growth effects, CaCo-2 cells, 1074
- Protein kinase C δ**
ligand selectivity, 1423
- Proteins**
fusion
IL 2-IgG, tumor rejection induction, 2707
Pseudomonas exotoxin-chimeric
apoptotic response modulation, 3215
tumor suppressor
differentiation regulators, 4282
- Pseudomonas* exotoxin**
chimeric protein
apoptotic response modulation, 3215
- ψ p53**
p53 recombination, radiation-induced tumor, 5649
- Psoralen**
DNA interstrand cross-links, mitochondria, 1400
- PTEN/MMAC1* gene**
Akt activation inhibition, glioma cells, 5285
alterations
aerodigestive tract tumors, 509
metastatic prostate cancer, 204
anoikis induction, glioma cells, 5285
cell death, 5667
glioblastomas, 29
growth inhibition mediation, glioma, 5002
meningiomas, 29
mutations
Bannayan-Riley-Ruvalcaba syndrome, 2724
complex atypical hyperplasia, 3254
endometrial hyperplasia, 2500
ovarian tumors, 2095
prostate carcinoma, 2720
tumorigenicity inhibition, glioblastoma, 2331
- Pyothonax-associated lymphoma**
p53 mutations, 1105
- R**
- Rabbit carboxylesterase**
cDNA, isolation, 2646
CPT-11 activation, 20
CPT-11 metabolism, 3627
- Radiation**
apoptosis
Rb-mediated, 3275
cell adhesion molecule expression
inhibition by NF κ B dominant negative genetic construct, 5484

- cell cycle checkpoint activation
amiloride effects, 413
chemotherapy-induced apoptosis inhibition,
glioma, 3819
extrachromosomal DNA loss after, 3845
ionizing: *see* **Ionizing radiation**
P-selectin localization to tumor blood vessel
lumen, 5216
sensitivity
p53 and, glioblastoma, 1793
tumor response potentiation by FMdC, solid
tumor xenografts, 5411
tumors
p53-p53 recombination, 5649
ultraviolet B
melanocyte response mediation by cAMP,
47
- Radiation-induced fibrosarcoma 1**
5-fluorouracil response, 1063, 2904
- Radionuclide therapy**
radiolabeled somatostatin analogues, 437
- Radiosensitivity**
ataxia telangiectasia, 4923
180BR cells, 84
lymphoid cells, 2817
- Radiosensitization**
atm lack, p53 null tissues, 5637
NO-mediated, hypoxic cells, 5646
prenyltransferase inhibitors, 1754
- Radiotherapy**
fractionated
tumor responses, apoptosis and, 1779
gastrointestinal injury
keratinocyte growth factor effects, mice
mucositis models, 933
- Raf**
signals
cell growth and, 1636
- RAGE-1**
expression, renal cell carcinoma, 4090
- Raloxifene**
antiestrogenic mechanism of action, 1872
- Random sequence mutagenesis**
DNA alkyltransferase, 1013
- ras**
antibody-mediated knockout, 1170
Fas-mediated apoptosis inhibition, 3391
mutant
apoptosis promotion, myeloid leukemia,
2029
signaling
ets-2 activation, ovarian carcinoma, 2253
- Receptors: see also specific receptors**
death receptor *KILLER/DR5* gene
mutations, head and neck squamous cell
carcinoma, 3513
regulation, 1593
- Rec2/Rad51B**
human *hREC2/RAD51B* gene
DNA damage sensor, 4733
- Red meat**
intake
and colorectal carcinoma risk, 3307
- Ref-1: see** *Apurinic/apyrimidinic endonuclease*
- Rejection**
tumor
induction by IL-2-IgG fusion protein,
2707
- Renal cell carcinoma**
chromosome 3p12 tumor suppressor gene
locus, 3533
clear cell
FHIT expression, 2946
plasma DNA, 4728
Fas expression, tumor-infiltrating lympho-
cytes, 2078
- glycolipid sulfotransferase gene expression,
3800
- hereditary papillary
MET mutations, 1719
- Her-2/neu-derived peptides, 732
- specific CTLs
usage by T-cell receptor, 3078
- tumor-associated antigen expression, 4090
- tumor peptides, MALDI-PSD, 5803
- VHL* deletion, 2304
- VHL* gene function, spheroids, 4957
- Replication errors**
gastric cancer, 1494
International Workshop on Microsatellite
Instability and RER Phenotypes in Can-
cer Detection and Familial Predisposi-
tion, meeting report, 5248
- Reporter genes**
expression, PET imaging, 4333
- Representational difference analysis**
MAGE gene with tumor-specific expression,
743
- Residual disease**
minimal
quantitative real-time PCR, 3957
- Respiratory hyperoxia**
combined with xanthine oxidase during hy-
perthermia
oxidative cell injury, 2693
- Resveratrol**
CYP1A1 transcription inhibition, 5707
- RET**
metastatic solid-type papillary thyroid carci-
noma, murine model, 5523
rearrangement, thyroid carcinoma, 198
- RET-fused gene *RFG5***
expression, thyroid carcinoma, 198
- Retinoblastoma protein**
apoptosis, 3275
-defective tonsillar squamous cell carcinoma
HPV, 5
E2F pathway, liver oncogenesis, 123
inhibition by phosmidosine, 704
p53 alterations and, bladder cancer, 1090
- Retinoblastoma protein 2**
HDAC1 binding, 5049
- Retinoblastoma protein-interacting zinc fin-
ger**
RIZ1
expression, breast cancer, 4238
- Retinoic acid**
MEK-dependent MAPK activation, 3163
receptor β
differentiation, squamous cell carcinoma,
142
synergy with IFN- α , head and neck squa-
mous cell carcinoma treatment, 5551
topical
skin papilloma reduction, 1435
VIP-R1 regulation, breast carcinoma, 4845
- Retinoids**
receptor antagonist
activity *in vivo*, breast cancer, 4607
response
activation by estrogen receptor, 5110
- Retinoid X**
receptor-selective ligand LGD1069
mammary carcinoma regression, 479
- all-trans-Retinoi**
metabolism, squamous cell carcinoma cells,
166
- Retrovirus**
cDNA library, 3519
green fluorescence protein-expressing, 14
PDGF B-chain, recombinant
brain tumor induction, mice, 5275
- Rhabdomyosarcoma**
alveolar
gene expression profiling with cDNA mi-
croarrays, 5009
growth deregulation, 2042
oncogenesis
IGF-II and PAX3-FKHR, 4426
- RhoA**
transformation
ornithine decarboxylase induction, 2748
- Rhoads Memorial Award**
Nineteenth Lecture, 5633
- RhoGAP gene**
human, deleted in liver cancer, 2196
- Ribonucleotide reductase**
R2
oncogenes and, cell transformation, 1650
regulation after ionizing radiation, cervical
carcinoma, 2245
- Ribozymes**
ErbB-4, 3415
hammerhead
telomerase activity attenuation, 5406
- rit42**
tumor growth inhibition, 4439
- RNA-dependent protein kinase**
double-stranded
aberrant expression, hepatocytes, 4434
- RNP**
hnRNP
expression, colon adenocarcinoma, 5818
- RTP/rit42**
tumor growth inhibition, 4439
- S**
- Saccharomyces cerevisiae EXO1**
human *EXO1* gene, identification, 5027
- Salivary gland carcinoma**
transforming growth factor β -stimulated
clone 22, 549
- Salmonella**
CYP1A2-, reductase-, and OAT-harboring,
1833
- Saporin**
anti-CD7-saporin immunotoxin
ADCC additivity, 5787
- Sarcoma**
Ewing's sarcoma
Fas and Fas ligand expression, 5842
gastrin-releasing peptide expression, 2469
growth inhibition by IGF-IR blockade,
4127
Kaposi's sarcoma
vascular endothelial growth factor recep-
tor-3, 1599
Moloney sarcoma virus-MDCK cell variants
 β -actin expression, 1631
- SB 203580**
invasion and MMP-9 secretion inhibition,
1135
- Scatter factor**
carcinoma invasion
matrix metalloproteinase role, 5221
- SCH 66336**
antitumor activity, 4947
- Schwann cells**
neuroblastoma effects, 4602
- Scintigraphy**
tumor
radiolabeled somatostatin analogues, 437
- Secreted protein acidic and rich in cysteine**
MMP-2 activation, breast carcinoma cells,
5529
- Secretor gene**
dosage effects, CA19-9 and DU-PAN-2
serum levels, 512
- P-Selectin**
radiation-induced localization to tumor blood
vessel lumen, 5216

- Selenium-binding protein**
human *hSP56*, prostate carcinoma, 3150
- Self-peptides**
antitumor lymphocyte ligands, 2433
- Semaphorin**
expression, metastatic mouse tumor cells, 1238
- Seminoma**
alkaline phosphatase gene expression, 5079
- Senescence**
induction by PI-3 kinase, diploid fibroblasts, 1, 4980
- Senescent-like growth arrest**
nasopharyngeal carcinoma cells, 5019
- Sensitivity**
CCNU, MMR⁻ cells, 135
chemosensitivity
E2F-1 role, 4292
edelfosine
oxidative basis, K562 and HL-60 cells, 2809
ether lipid
oxidative basis, K562 and HL-60 cells, 2809
radiosensitivity
ataxia telangiectasia, 4923
180BR cells, 84
lymphoid cells, 2817
- Serial analysis of gene expression**
non-small cell lung cancer, 5690
- Serine-70**
Bcl2 phosphorylation site, 1609
- Serine/threonine kinase 11/Peutz-Jeghers syndrome (STK11) gene**
mutations
Peutz-Jeghers syndrome and sporadic colon cancer, 4799
somatic, left-sided colon carcinoma, 3787
- Serum**
BPDE-DNA adduct antibodies, 4122
colorectal carcinoma, molecular detection, 1405
- Severe combined immunodeficiency**
lymphomagenesis, mice, 3111
- Sialyltransferase**
expression, breast carcinoma, 4066
- $\alpha 2 \rightarrow 6$ Sialyltransferase**
activity, choriocarcinoma, 4301
- Signal transducers and activators of transcription**
expression, acute myeloid leukemia blasts, 3173
Stat1
activation by prolactin, 1914
activation by type I interferons, 1914
- Silymarin**
cell cycle modulation, prostate carcinoma DU145 cells, 1920
erbB1 signaling modulation, prostate carcinoma DU145 cells, 1920
- Simian virus 40**
malignant mesothelioma, 4505
- Sinusoidal endothelial cells**
tumor cell killing, 1524
- Sister gene of P-glycoprotein (Spgp)**
cloning and function, 4160
- Skin**
age and site
melanoma factor, mouse, 630
oxidative stress
inhibition by ACA, mouse, 4832
- Skin carcinogenesis**
polyamines and, mouse, 1654
promotion by metallothionein deficiency, mouse, 4044
- Skin carcinoma**
squamous cell
retinol metabolism, 166
- XP-C, 4402
- Skin papilloma**
malignant conversion
Bcl-x_L, 2111
reduction by topical retinoic acid, 1435
- Skin tumors**
p53 mutations, XPA-deficient mice, 641
- SKOV3 cells**
c-Mos induction and activation by paclitaxel, 3633
- Sluc5**
mapping to *Sluc14*, 4794
- Sluc14**
Sluc5 mapping, 4794
- Smad1**
TGF- β signaling role, breast carcinoma, 4752
- Smad4/DPC4 gene**
dysfunction, cancer cells, 4592
mutations, biliary tract carcinoma, 1124
overexpression, carcinoma cells, 5656
- Small cell carcinoma: see also specific sites**
vasopressin receptor expression, 1866
- SMDH gene**
mutations, sporadic basal cell carcinoma and primitive neuroectodermal tumors, 1798
- Smoke**
cigarette
DNA deletions, 2633
- Smoking**
bladder cancer
N-acetylation polymorphisms, 3603
DNA damage biomarkers, 581
mitochondrial mutational spectra, 1268
- Sodium ascorbate**
tumorigenicity, male rats, 2557
- Solar-simulated light**
melanocytic nevi augmentation, guinea pigs, 5361
- Solid tumors**
activated lymphocyte inaccessibility, 4673
Hodgkin's
infarction by tissue factor targeting to tumor vasculature, 4646
inhibition
DIVEMA-conjugated TNF- α , 290
physiology, 1408
radioresponse
potentiation by FMDC, xenografts, 5411
- Solid-type papillary thyroid carcinoma**
metastatic
RET/PTC3 gene, murine model, 5523
- Somatostatin**
analogues
radiolabeled, evaluation, 437
cytotoxic analogue AN-238
growth inhibition, prostate carcinoma, 4132
receptor subtype 2
antibodies, carcinoid tumors, 2375
- Somatostatin-14**
P829 analogue, ^{99m}Tc-labeled
binding properties, 1850
- Soy isoflavones**
growth inhibition, bladder tumorigenesis, 5231
- SPARC: see Secreted protein acidic and rich in cysteine**
- Spermine analogue**
apoptosis induction, prostate carcinoma cells, 4864
- Spheroids**
G₁ regulation, 1305
- Sphingosine-1-phosphate**
1,25-(OH)₂D₃ and, 1817
- Spindle inhibitors**
G₁ arrest, 396
- Spleen**
mutagenesis
lacI gene genetic control, 1616
- Splenic lymphoma with villous lymphocytes**
chromosome 13q14 deletions, 1736
- Spontaneous metastases: see specific carcinomas, sites**
- Sporadic carcinoma: see specific sites**
- Squalamine**
angiogenesis inhibition, 2784
- Squamous cell carcinoma: see also specific sites**
differentiation by RAR β , 142
hypoxia and VEGF expression, 3765
progression
osteopontin role, 5206
proinflammatory cytokines, 3668
retinol metabolism, 166
- Squamous cell hyperplastic foci**
SENCAR mice, 4314
- Squamous intraepithelial lesions**
cervix
cell cycle regulation by HPV, 2941
HMGI(Y) protein expression, 426
- Src**
IGF-I receptors and, pancreatic carcinoma, 3551
- SR factors**
expression, colon adenocarcinoma, 5818
- Staphylococcus enterotoxin A**
antibody conjugate
adoptive immunotherapy, 2838
- Streptococcus anginosus**
gastric and esophageal cancer, 2991
- Stress**
oxidative
apurinic endonuclease induction, 4410
gene amplification, 3986
inhibition by ACA, mouse skin, 4832
- Stress-activated protein kinase**
acidification and, 2801
activation by ambient particulate matter, lung epithelial cells, 4543
- Stromal cells**
tumor-infiltrating lymphocyte adhesion, 4138
- Suicide gene therapy**
chemically induced mammary tumor, 3529
- Sunscreen**
UVB-induced DNA damage modulation, 2961
- Super synergy**
polyglutamylase role, 3036
- Survival factor**
signaling
chemotherapy and, 801
- Survivin**
antiapoptotic mechanism, 5315
colorectal carcinoma, 5071
expression, gastric carcinoma, 1808
- Synchronous oral carcinoma**
origin, 2003
- T**
- Taiwan**
squamous cell lung cancer
p53 mutations, 328
- TALI/SCL**
expression
cell differentiation and, 562
ectopic, antiapoptotic effects, 2680
- Tamoxifen**
external carcinogen action, 2278
growth effects, breast cancer xenografts, 60
- TARGETIN: see LGD1069**
- Tax**
IL-8 expression induction, 3993

- Taxol:** *see also* **Paclitaxel**
apoptosis
 loop domain, 3202
Bcl-2 phosphorylation
 loop domain, 3202
cell death, 3620
polymer conjugate
 tumor regression, 2404
potency at microtubule minus ends, 1177
- Tcf**
APC/ β -catenin/Tcf pathway
 mutations, colorectal carcinoma, 1130
- TCF17 gene**
expression, testicular tumors, 4598
- ^{99m}Tcnetium**
-labeled P829
 binding properties, 1850
- Telomerase**
activity
 attenuation by hammerhead ribozymes, 5406
 B-cell chronic lymphocytic leukemia, 4918
 brain tumors, 2117
 cervical carcinoma and cervical intraepithelial neoplasia grade III lesions, 3812
 colorectal carcinoma, 4052
 prostate cancer, 619
 expression profile, 622
 leukemia
 properties, 1909
 regulation, development, 4168
 subunits
 expression, cervical cancer, 1558
- Telomerase reverse transcriptase**
human hTERT
 status, cervical lesions, 3812
- Telomere length**
alterations, brain tumors, 2117
B-cell chronic lymphocytic leukemia, 4918
- Temozolomide**
continuous oral, phase I trial, 4363
- TER286**
bone marrow-sparing, 2568
- Testicular tumors**
LKB1 mutations, 2087
TCF17 expression, 4598
- 12-O-Tetradecanoylphorbol-13-acetate**
transepithelial insulin leakiness, 1641
- Thiotepa**
and GST-P1-1-transfected MCF-7 cells, 4616
- Thrombospondin 1**
melanoma proliferation and motility modulation, 3154
- Thymic lymphoma**
truncating *Brca2* mutation, mice, 1338
- Thymidine**
rescue
 dThdPase-moderated, ZD1694 and, *in vitro*, 2737
- Thymidine phosphorylase**
DPD ratio
 capecitabine efficacy correlation, 685
 expression, colon carcinoma, 1551
 thymidine rescue
 ZD1694 and, *in vitro*, 2737
- Thymidylate synthase**
inhibitors
 resistance, comparative genomic hybridization analysis, 5042
 monoclonal antibodies
 epitope mapping, 2606
- Thymosin β -10**
overexpression, thyroid carcinoma, 823
- Thyroid carcinoma**
E-cadherin CpG island methylation, 2063
diagnosis by RT-PCR, 4913
galectin-3, fine-needle aspiration biopsy, 3015
HIP overexpression, 4745
RET rearrangement, 198
thymosin β -10 overexpression, 823
- Thyroid cells**
growth and differentiation
 p53 mutation effects, 2888
 truncated uPA-R expression, 1315
- Thyroid neoplasias**
HMG(Y) protein, detection, 4193
- Tirapazamine**
intracellular metabolism, 2098
- Tissue**
BAG-1 expression, 3116
- Tissue factor**
targeting to tumor vasculature, 4646
- Tissue factor-factor VIIa pathway**
pancreatic carcinoma, 4461
- Tissue inhibitor of metalloproteinase-2**
MMP-2 degradation by plasmin protection, 2957
TNF- α receptor shedding inhibition, colon adenocarcinoma cells, 4001
- Tissue inhibitor of metalloproteinase-3**
invasion inhibition and apoptosis induction, melanoma, 2310
- Tissue-type plasminogen activator**
expression, hepatocellular carcinoma, 2234
- T lymphocytes:** *see also* **Cytotoxic T lymphocytes**
activated
 MUC1 expression, 4079
 adoptive immunotherapy
 p53 targeting, 2601
 CD4+
 MART-1-specific, 5305
 MUC1 priming, 5066
 CD8+
 cancer cell nests, colorectal carcinoma, 3491
 MART-1-specific, 5305
 recruitment and functional maturation, 3376
 CD8+ clones
 self-peptide ligands, 2433
 helper cells
 HPV-16 E7 responses, cervical neoplasia, 1700
 helper TH1 cells
 tumor antigen-reactive CD8+, 1363
 immunity to tyrosinase nonmutated peptide, 296
 leukemia
 apoptosis inhibition by ectopic *TALI/SCL* expression, 2680
 ataxia-telangiectasia and, 2293
 ATM gene and, 2293
 multiple copies in a T-cell malignancy (*MCT-1*) gene
 cell cycle progression, 4233
 proliferation
 IFN- α -expressing tumors and, 5795
 receptor
 chimeric, CD30 targeting, 1116
 renal cell carcinoma-specific CTL usage, 3078
 ζ chain
 expression, oral carcinoma, 5344
- TNP470**
growth and angiogenesis inhibition, hepatoma, 3751
osteolytic bone metastasis inhibition, breast cancer, 462
- Tocopherol**
plasma
 and colorectal adenoma, 661
- Tolyporphin**
photosensitization, 3571
- Tomudex:** *see* **ZD1694**
- Tongue carcinogenesis**
4NQO-induced
 genetic susceptibility, rat, 1660
- Tonsillar squamous cell carcinoma**
pRB-defective
 HPV, 5
- Topotecan lactone**
DNA binding, topo I absence, 3782
- Toxicity**
antibody-dependent cellular cytotoxicity
 B-cell antibodies, 3051
 immunotoxin additivity, 5787
 aspirin, colonic tumor cells *in vitro*, 2772
 cardiotoxicity
 troponin T and, 195
 chemotherapeutics
 modulation by DNA repair, 3965
 chemotherapy
 4-nitrobenzylidene malononitrile protective effects against, 2397
 cytotoxicity
 Bcl-2 modulation by sFv and, 2134
 chlorambucil, B-cell chronic lymphocytic leukemia, 1789
 drug time-course, 5749
 gemcitabine, and nucleoside transporters, 4349
 multilog, mediation by ganciclovir, 3873
 preferential, cytosine deaminase-transduced cells, 2588
 intestinal
 CPT-11-induced, IL-15 protective effects against, 3270
 phototoxicity
 MKT-077, mitochondria, 71
- Toxins**
anti-CD7-saporin immunotoxin
 ADCC additivity, 5787
IL-4
 antitumor activity, glioblastoma, 3649
 recombinant erbB-2 receptor-specific
 pulmonary metastases inhibition, mice, 2661
 recombinant immunotoxins
 tumor accumulation *in vivo*, 968
 staphylococcus enterotoxin A
 antibody conjugate, adoptive immunotherapy, 2838
- TP53**
CDKN2A/ARF pathway inactivation and, 5348
- Trachea**
mucosa
 NNK dosimetry, 1417
- Transcription factors**
AP-1
 inhibition by perillyl alcohol, 711
AP-2
 expression, breast carcinoma, 5466
 cross-linking to MAR DNA by cisplatin, 3004
E2F
 pRb pathway, liver oncogenesis, 123
E2F-1
 chemosensitivity role, 4292
 posttranscriptional regulation, 1646
E2F-4
 mitogenic activity, regulation, 1325
 mutations, colorectal cancer, 594
Ets-2
 transdominant mutant, tumorigenicity and invasion inhibition, 1027
Stat1

- activation by prolactin, 1914
- activation by type I interferons, 1914
- Transfection**
 - lithotripter shock wave, melanoma, 219
- Transforming growth factor**
 - and oncogenes, hepatocarcinogenesis, 3590
- Transforming growth factor α**
 - mRNA stability
 - decrease by *VHL*, 226
 - TGF- α* gene
 - transactivation by HBV preS1, 1813
- Transforming growth factor β**
 - receptor
 - gene alterations, pancreatic and biliary adenocarcinoma, 5329
 - receptor type I
 - mutations, metastatic breast cancer, 4805
 - polymorphism and rare variant, 2727
 - receptor type II
 - gene mutations, ovarian carcinoma, 4227
 - mutation, colon adenoma, 3101
 - mutations, 1986
 - signaling
 - Smad1 role, breast carcinoma, 4752
- Transforming growth factor β 1**
 - Fas-mediated apoptosis induction, glioma, 302
- Transforming growth factor β -stimulated clone 22**
 - salivary gland cancer cells, 549
- Translational research**
 - Seventeenth Bruce F. Cain Memorial Award Lecture, 4211
- Transporter associated with antigen processing (TAP1 and TAP2)**
 - downregulation, breast carcinoma, 737
- Transporter for antigen presentation**
 - downregulation, tumor cells, 3660
- Trichothiodystrophy cells**
 - mutagenesis by nondimer photoproducts, 102
- Trisomy 11**
 - mesoblastic nephroma, 5046
- Triterpenoids**
 - iNOS and COX-2 inhibition, mouse macrophages, 717
- Troglitazone**
 - antitumor effects, prostate carcinoma, 3344
- Troponin T**
 - cardiotoxicity and, 195
- TSC-22: see Transforming growth factor β -stimulated clone 22**
- TSC403**
 - lamps-homologous, characterization, 3499
- TSG101**
 - cell cycle progression effects, 2699
- TSSC3**
 - genomic imprinting, 1052
- Tubulin**
 - polymerization induction by eleutherobin, 1111
- Tumor-associated antigen**
 - DAM gene family, 2969
 - expression, renal cell carcinoma, 4090
 - peptide vaccination, murine leukemia, 1960
 - reactive CD8+ TH1 cells, 1363
 - recombinant vaccinia virus expressing B7 molecules and, 4567
 - retroviral cDNA library, 3519
- Tumor cells: see also specific cells**
 - antigen-processing gene expression decrease, 3660
 - DNA replication inhibition by FAS inhibitors, 4611
 - hypoxic
 - nonproliferating viable, 3547
 - killing by sinusoidal endothelial cells, 1524
 - neuroleukin/phosphohexose isomerase/maturation factor expression, 2667
 - pluripotent, pituitary adenoma, 4715
 - survival
 - modulation by IGF-IR C terminus, 570
- Tumor growth: see also Cell growth**
 - BCH-4556 effects, prostate carcinoma, 3461
 - inhibition
 - AN-238, prostate carcinoma, 4132
 - anti-VEGF/VPF antibody, mouse ascites tumors, 2594
 - cidofovir, hemangioma, 2562
 - IGF-IR blockage, Ewing's sarcoma, 4127
 - muscle cell adenosine, 3181
 - proteasome inhibitor-induced, Burkitt's lymphoma, 4342
 - rMETase, 2582
 - RTP/rit42*, 4439
 - TNP470, hepatoma, 3751
 - modulation by antisense VEGF gene expression, 4185
 - stimulation
 - platelet-type 12-LOX, prostate carcinoma, 4047
 - rhIGF-I, 3021
- Tumorigenesis**
 - inhibition
 - IGF-IR COOH terminus, 2477
 - α 5 integrin/fibronectin interactions, 848
 - neu-induced
 - genetic modulation, 2675
- Tumorigenicity**
 - hsp27 effects, colon carcinoma cells, 5495
 - inhibition by *MMAC1/PTEN*, glioblastoma, 2331
 - sodium ascorbate, male rats, 2557
- Tumor-infiltrating lymphocytes**
 - adhesion to stromal cells, 4138
 - Fas expression, renal cell carcinoma, 2078
- Tumor necrosis factor**
 - mucin
 - combined with TNF-R55, pancreatic cancer gene therapy, 1677
 - receptor
 - 55-kDa, combined with mucin TNF, pancreatic cancer gene therapy, 1677
 - TNF- α and, Mo7e cells, 2217
 - resistance
 - cPLA₂ inactivation by 1,25(OH)₂D₃, 633
- Tumor necrosis factor α**
 - apoptosis
 - susceptibility, breast carcinoma, 4940
 - biotinylated
 - tumor targeting, 3866
 - combined with HSV-tk, gene therapy, 5731
 - gene transfer *in vivo*, 5725
 - limb perfusion
 - melanoma metastasis after, 4880
 - receptor
 - shedding inhibition by TIMP-2, colon adenocarcinoma cells, 4001
 - TNF receptors and, Mo7e cells, 2217
- Tumor peptides**
 - renal cell carcinoma, MALDI-PSD, 5803
- Tumor-protective immunity**
 - cytokine-induced, colon carcinoma metastases, 3918
- Tumors: see also specific sites, types**
 - adriamycin-selected
 - recognition by CTLs, 4790
 - angiogenesis
 - assessment by dynamic MRI, uterine cervical carcinoma, 3598
 - BAG-1 expression, 3116
 - blood vessels
 - lumen, radiation-induced P-selectin localization, 5216
 - endothelium markers
 - vascular endothelial growth factor, 1952
 - heterogeneity
 - in vivo* EPR imaging, 1562
 - hollow fiber
 - blood vessel development, 5263
 - immunology
 - nonclassical MHC class I and, 4682
 - internal
 - XP-C, 4402
 - invasion
 - melatonin effects, MCF-7 breast cancer cells, 4383
 - MAG* expression, 4475
 - malignant
 - centrosome defects, 3974
 - genetic instability, 3974
 - microenvironment
 - IL-2-mediated changes, 1478
 - progression
 - gelatinase A-deficient mice, 1048
 - recombinant immunotoxin accumulation *in vivo*, 968
 - rejection
 - induction by IL-2-IgG fusion protein, 2707
 - scintigraphy
 - radiolabeled somatostatin analogues, 437
 - size
 - angiogenesis inhibition and, 5866
 - targeting
 - biotinylated TNF- α , 3866
 - uridine phosphorylase activity, 5418
 - vascular permeability
 - modulation, 159
 - vasculature
 - tissue factor targeting, 4646
- Tumor suppressor genes: see also Genes; specific genes**
 - chromosome 3p12, renal cell carcinoma, 3533
 - chromosome 18q locus, lung carcinoma, 3700
- Tumor suppressors**
 - differentiation regulators, 4282
 - NES1 role, 4782
- Tumor vaccines**
 - anti-tumor response
 - humoral response and, mice, 5812
- Tyrosinase**
 - nonmutated peptide
 - T-cell immunity, 296
- Tyrosinase-related protein 2**
 - cytotoxic T lymphocyte epitope, 4895

U

- UCN-01: see 7-Hydroxystaurosporine**
- Ulcerative colitis**
 - p16^{INK4a} promoter hypermethylation, 3942
- Ultraviolet B radiation**
 - DNA damage
 - modulation by sunscreen, 2961
 - melanocyte response
 - mediation by cAMP, 47
- Ultraviolet radiation**
 - DNA damage
 - hereditary defective *in vitro* replication, xeroderma pigmentosum, 2445
 - topoisomerase I-DNA complex stimulation, 976
 - metastatic melanoma, transgenic mice, 4061
 - modified adenoviral gene transfer, dendritic cells, 956
 - p53-dependent signaling and DNA replication, fibroblasts, 1993
 - tumorigenesis
 - inhibition by perillyl alcohol, 711

University of California, Los Angeles/Jennifer Jones Simon Foundation Symposium on Prostate Cancer and Epithelial Cell Biology
meeting report, 2895

Upper urinary tract cancers
multifocal, genetic analysis, 5835

Uridine phosphorylase
expression, characterization, and detection, 5418
variant activity, tumors, 5418

Urine
matrix metalloproteinases, 1395

Urokinase-type plasminogen activator
expression, hepatocellular carcinoma, 2234
receptor
expression, hepatocellular carcinoma, 2234
serum levels, ovarian carcinoma, 1843
truncated, thyroid cells, 1315
soluble
cleaved, malignant ovarian cystic fluid, 3294

Uroplakin II
gene expression, transitional cell carcinoma, 1291

Urothelial cancer
multifocal, genetic analysis, 5835

Urothelial tumors
formation
alternative pathways, 1291

Ursodeoxycholic acid
fecal water, colon polyps, 1684

Uterine serous carcinoma
comparative genomic hybridization patterns, 892

V

Vaccination
genetic
gp100, 2509
tumor antigen peptide, murine leukemia, 1960

Vaccines
hydrophobized polysaccharide/HER2 complex, 3385

Vaccinia virus
recombinant
tumor-associated antigen and B7 molecule-expressing, 4567

Vascular endothelial growth factor
antisense
tumor growth modulation, 4185
anti-VEGF/VPF antibody
tumor inhibition, mouse ascites tumors, 2594
drug-induced apoptosis inhibition, hematopoietic cells, 5565
expression
hypoxia and, squamous cell carcinoma, 3765
mouse ascites tumors, 2652
inhibition by scFv antibodies, 3209
receptor-3
lymphatic vessels and Kaposi's sarcoma, 1599

regulation
IGF-I, colon carcinoma, 4008
p53, 2288
progesterin, breast cancer, 392
tumor endothelium marker, 1952

Vascular permeability factor
anti-VEGF/VPF antibody
tumor inhibition, mouse ascites tumors, 2594
expression, mouse ascites tumors, 2652
signaling, mouse mesentery vascular endothelium, 1278

Vasculature
tumor
permeability modulation, 159
tissue factor targeting, 4646

Vasoactive intestinal polypeptide
receptor type-I
regulation by retinoic acid, breast carcinoma, 4845

Vasopressin
receptor expression, small cell carcinoma, 1866

Villous lymphocytes
splenic lymphoma with
chromosome 13q14 deletions, 1736

Vincristine
MRP transport, 5130

Viral vector-targeted antiangiogenic gene therapy, 3362

Vitamin D
receptor haplotypes
prostate carcinoma and, African-Americans, 1620

Vitamin D₃
analog anticancer effects, 3370

Von Hippel-Lindau (VHL) gene
deletions, renal cell carcinoma, 2304
function, renal cell carcinoma spheroids, 4957
sporadic cerebellar hemangioblastoma, 504
TGF- α mRNA stability decrease, 226

v-src
MT1-MMP induction, MDCK cells, 2240

W

WAF1/Cip1
chemoresistance, glioblastoma, 1538

Water
fecal
ursodeoxycholic acid, colon polyps, 1684

Wee1
downregulation by p53, 3231

Weight loss
rhEPO protective effects, 5374

Werner syndrome
phenotype complementation, 5188

Wilms' tumor
familial
19q-linked predisposition, 1387
WT1 gene
exon 5 mutations, 4180

Wistar-Unilever rats
prostate cancer induction, 3282

Workers
benzene-exposed

translocation t(8;21), 2176

Wortmannin
phosphoinositide 3-kinase related kinase inhibition, 4375

X

Xanthine oxidase
combined with respiratory hyperoxia during hyperthermia
oxidative cell injury, 2693

Xenografts
breast carcinoma
EM-800 vs tamoxifen growth effects, nude mice, 60
neuroblastoma
iron chelation, 473
prostate cancer
positron emission tomography, 3009
prostate tumors
drug effects, 2777
solid tumors
radioresponse potentiation by FMdC, 5411

Xeroderma pigmentosum
group C
skin and internal cancers, 4402
p53 mutations, 2449
UV damage
hereditary defective bypass replication, 2445
XPA deficiency
Hprt mutations, internal tissue, 2850
p53 mutations, skin tumors, 641
XPD
targeted disruption, mice, 89

X protein
hepatitis B virus-encoded
transcription activation, 3566

X-rays
p53 induction, 698
P-selectin localization to tumor blood vessel lumen, 5216

XR-75-1 cells
growth
EM-800 vs tamoxifen effects, nude mice, 60

Xyloside
growth inhibition, transformed cells, 1099

Y

YM175
mevalonate inhibition, myeloma cells, 5294

Z

ZD1694
dThdPase-moderated dThd rescue *in vitro*, 2737

Zinc finger
retinoblastoma protein-interacting zinc finger
RIZ1, breast cancer, 4238
TCF17 gene
expression, testicular tumors, 4598

